Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof

ABSTRACT

The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the transporter peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the transporter peptides, and methods of identifying modulators of the transporter peptides.

FIELD OF THE INVENTION

[0001] The present invention is in the field of transporter proteins that are related to the differentation-associated Na-dependent inorganic phosphate cotransporter (a type of neurotransmitter transporter) subfamily, recombinant DNA molecules, and protein production. The present invention specifically provides novel peptides and proteins that effect ligand transport and nucleic acid molecules encoding such peptide and protein molecules, all of which are useful in the development of human therapeutics and diagnostic compositions and methods.

BACKGROUND OF THE INVENTION

[0002] Transporters

[0003] Transporter proteins regulate many different functions of a cell, including cell proliferation, differentiation, and signaling processes, by regulating the flow of molecules such as ions and macromolecules, into and out of cells. Transporters are found in the plasma membranes of virtually every cell in eukaryotic organisms. Transporters mediate a variety of cellular functions including regulation of membrane potentials and absorption and secretion of molecules and ion across cell membranes. When present in intracellular membranes of the Golgi apparatus and endocytic vesicles, transporters, such as chloride channels, also regulate organelle pH. For a review, see Greger, R. (1988) Annu. Rev. Physiol. 50:111-122.

[0004] Transporters are generally classified by structure and the type of mode of action. In addition, transporters are sometimes classified by the molecule type that is transported, for example, sugar transporters, chlorine channels, potassium channels, etc. There may be many classes of channels for transporting a single type of molecule (a detailed review of channel types can be found at Alexander, S. P. H. and J. A. Peters: Receptor and transporter nomenclature supplement. Trends Pharmacol. Sci., Elsevier, pp. 65-68 (1997) and http://www-biology.ucsd.edu/˜msaier/transport/titlepage2.html.

[0005] The following general classification scheme is known in the art and is followed in the present discoveries.

[0006] Channel-type transporters. Transmembrane channel proteins of this class are ubiquitously found in the membranes of all types of organisms from bacteria to higher eukaryotes. Transport systems of this type catalyze facilitated diffusion (by an energy-independent process) by passage through a transmembrane aqueous pore or channel without evidence for a carrier-mediated mechanism. These channel proteins usually consist largely of a-helical spanners, although b-strands may also be present and may even comprise the channel. However, outer membrane porin-type channel proteins are excluded from this class and are instead included in class 9.

[0007] Carrier-type transporters. Transport systems are included in this class if they utilize a carrier-mediated process to catalyze uniport (a single species is transported by facilitated diffusion), antiport (two or more species are transported in opposite directions in a tightly coupled process, not coupled to a direct form of energy other than chemiosmotic energy) and/or symport (two or more species are transported together in the same direction in a tightly coupled process, not coupled to a direct form of energy other than chemiosmotic energy).

[0008] Pyrophosphate bond hydrolysis-driven active transporters. Transport systems are included in this class if they hydrolyze pyrophosphate or the terminal pyrophosphate bond in ATP or another nucleoside triphosphate to drive the active uptake and/or extrusion of a solute or solutes. The transport protein may or may not be transiently phosphorylated, but the substrate is not phosphorylated.

[0009] PEP-dependent, phosphoryl transfer-driven group translocators. Transport systems of the bacterial phosphoenolpyruvate:sugar phosphotransferase system are included in this class. The product of the reaction, derived from extracellular sugar, is a cytoplasmic sugar-phosphate.

[0010] Decarboxylation-driven active transporters. Transport systems that drive solute (e.g., ion) uptake or extrusion by decarboxylation of a cytoplasmic substrate are included in this class.

[0011] Oxidoreduction-driven active transporters. Transport systems that drive transport of a solute (e.g., an ion) energized by the flow of electrons from a reduced substrate to an oxidized substrate are included in this class.

[0012] Light-driven active transporters. Transport systems that utilize light energy to drive transport of a solute (e.g., an ion) are included in this class.

[0013] Mechanically-driven active transporters. Transport systems are included in this class if they drive movement of a cell or organelle by allowing the flow of ions (or other solutes) through the membrane down their electrochemical gradients.

[0014] Outer-membrane porins (of b-structure). These proteins form transmembrane pores or channels that usually allow the energy independent passage of solutes across a membrane. The transmembrane portions of these proteins consist exclusively of b-strands that form a b-barrel. These porin-type proteins are found in the outer membranes of Gram-negative bacteria, mitochondria and eukaryotic plastids.

[0015] Methyltransferase-driven active transporters. A single characterized protein currently falls into this category, the Na+-transporting methyltetrahydromethanopterin:coenzyme M methyltransferase.

[0016] Non-ribosome-synthesized channel-forming peptides or peptide-like molecules. These molecules, usually chains of L- and D-amino acids as well as other small molecular building blocks such as lactate, form oligomeric transmembrane ion channels. Voltage may induce channel formation by promoting assembly of the transmembrane channel. These peptides are often made by bacteria and fungi as agents of biological warfare.

[0017] Non-Proteinaceous Transport Complexes. Ion conducting substances in biological membranes that do not consist of or are not derived from proteins or peptides fall into this category.

[0018] Functionally characterized transporters for which sequence data are lacking. Transporters of particular physiological significance will be included in this category even though a family assignment cannot be made.

[0019] Putative transporters in which no family member is an established transporter. Putative transport protein families are grouped under this number and will either be classified elsewhere when the transport function of a member becomes established, or will be eliminated from the TC classification system if the proposed transport function is disproven. These families include a member or members for which a transport function has been suggested, but evidence for such a function is not yet compelling.

[0020] Auxiliary transport proteins. Proteins that in some way facilitate transport across one or more biological membranes but do not themselves participate directly in transport are included in this class. These proteins always function in conjunction with one or more transport proteins. They may provide a function connected with energy coupling to transport, play a structural role in complex formation or serve a regulatory function.

[0021] Transporters of unknown classification. Transport protein families of unknown classification are grouped under this number and will be classified elsewhere when the transport process and energy coupling mechanism are characterized. These families include at least one member for which a transport function has been established, but either the mode of transport or the energy coupling mechanism is not known.

[0022] Ion channels

[0023] An important type of transporter is the ion channel. Ion channels regulate many different cell proliferation, differentiation, and signaling processes by regulating the flow of ions into and out of cells. Ion channels are found in the plasma membranes of virtually every cell in eukaryotic organisms. Ion channels mediate a variety of cellular functions including regulation of membrane potentials and absorption and secretion of ion across epithelial membranes. When present in intracellular membranes of the Golgi apparatus and endocytic vesicles, ion channels, such as chloride channels, also regulate organelle pH. For a review, see Greger, R. (1988) Annu. Rev. Physiol. 50:111-122.

[0024] Ion channels are generally classified by structure and the type of mode of action. For example, extracellular ligand gated channels (ELGs) are comprised of five polypeptide subunits, with each subunit having 4 membrane spanning domains, and are activated by the binding of an extracellular ligand to the channel. In addition, channels are sometimes classified by the ion type that is transported, for example, chlorine channels, potassium channels, etc. There may be many classes of channels for transporting a single type of ion (a detailed review of channel types can be found at Alexander, S. P. H. and J. A. Peters (1997). Receptor and ion channel nomenclature supplement. Trends Pharmacol. Sci., Elsevier, pp. 65-68 and http://www-biology.ucsd.edu/˜msaier/transport/toc.html.

[0025] There are many types of ion channels based on structure. For example, many ion channels fall within one of the following groups: extracellular ligand-gated channels (ELG), intracellular ligand-gated channels (ILG), inward rectifying channels (INR), intercellular (gap junction) channels, and voltage gated channels (VIC). There are additionally recognized other channel families based on ion-type transported, cellular location and drug sensitivity. Detailed information on each of these, their activity, ligand type, ion type, disease association, drugability, and other information pertinent to the present invention, is well known in the art.

[0026] Extracellular ligand-gated channels, ELGs, are generally comprised of five polypeptide subunits, Unwin, N. (1993), Cell 72: 31-41; Unwin, N. (1995), Nature 373: 37-43; Hucho, F., et al., (1996) J. Neurochem. 66: 1781-1792;-Hucho, F., et al., (1996) Eur. J. Biochem. 239: 539-557; Alexander, S. P. H. and J. A. Peters (1997), Trends Pharmacol. Sci., Elsevier, pp. 4-6; 36-40; 42-44; and Xue, H. (1998) J. Mol. Evol. 47: 323-333. Each subunit has 4 membrane spanning regions: this serves as a means of identifying other members of the ELG family of proteins.. ELG bind a ligand and in response modulate the flow of ions. Examples of ELG include most members of the neurotransmitter-receptor family of proteins, e.g., GABAI receptors. Other members of this family of ion channels include glycine receptors, ryandyne receptors, and ligand gated calcium channels.

[0027] The Voltage-gated Ion Channel (VIC) Superfamily

[0028] Proteins of the VIC family are ion-selective channel proteins found in a wide range of bacteria, archaea and eukaryotes Hille, B. (1992), Chapter 9: Structure of channel proteins; Chapter 20: Evolution and diversity. In: Ionic Channels of Excitable Membranes, 2nd Ed., Sinaur Assoc. Inc., Pubs., Sunderland, Mass.; Sigworth, F. J. (1993), Quart. Rev. Biophys. 27: 1-40; Salkoff, L. and T. Jegla (1995), Neuron 15: 489-492; Alexander, S. P. H. et al., (1997), Trends Pharmacol. Sci., Elsevier, pp. 76-84; Jan, L. Y. et al., (1997), Annu. Rev. Neurosci. 20: 91-123; Doyle, D. A, et al., (1998) Science 280: 69-77; Terlau, H. and W. Stühmer (1998), Naturwissenschaften 85: 437-444. They are often homo- or heterooligomeric structures with several dissimilar subunits (e.g., a1-a2-d-b Ca²⁺ channels, ab₁b₂ Na⁺ channels or (a)₄-b K⁺ channels), but the channel and the primary receptor is usually associated with the a (or a1) subunit. Functionally characterized members are specific for K⁺, Na⁺ or Ca²⁺. The K⁺ channels usually consist of homotetrameric structures with each a-subunit possessing six transmembrane spanners (TMSs). The a1 and a subunits of the Ca²⁺ and Na⁺ channels, respectively, are about four times as large and possess 4 units, each with 6 TMSs separated by a hydrophilic loop, for a total of 24 TMSs. These large channel proteins form heterotetra-unit structures equivalent to the homotetrameric structures of most K⁺ channels. All four units of the Ca²⁺ and Na⁺ channels are homologous to the single unit in the homotetrameric K⁺ channels. Ion flux via the eukaryotic channels is generally controlled by the transmembrane electrical potential (hence the designation, voltage-sensitive) although some are controlled by ligand or receptor binding.

[0029] Several putative K⁺-selective channel proteins of the VIC. family have been identified in prokaryotes. The structure of one of them, the KcsA K⁺ channel of Streptomyces lividans, has been solved to 3.2 Å resolution. The protein possesses four identical subunits, each with two transmembrane helices, arranged in the shape of an inverted teepee or cone. The cone cradles the “selectivity filter” P domain in its outer end. The narrow selectivity filter is only 12 Å long, whereas the remainder of the channel is wider and lined with hydrophobic residues. A large water-filled cavity and helix dipoles stabilize K⁺ in the pore. The selectivity filter has two bound K⁺ ions about 7.5 Å apart from each other. Ion conduction is proposed to result from a balance of electrostatic attractive and repulsive forces.

[0030] In eukaryotes, each VIC family channel type has several subtypes based on pharmacological and electrophysiological data. Thus, there are five types of Ca²⁺ channels (L, N, P, Q and T). There are at least ten types of K⁺channels, each responding in different ways to different stimuli: voltage-sensitive [Ka, Kv, Kvr, Kvs and Ksr], Ca²⁺-sensitive [BK_(Ca), IK_(Ca) and SK_(Ca)] and receptor-coupled [K_(M) and KA_(Ch)]. There are at least six types of Na⁺ channels (I, II, III, μl , H1 and PN3). Tetrameric channels from both prokaryotic and eukaryotic organisms are known in which each a-subunit possesses 2 TMSs rather than 6, and these two TMSs are homologous to TMSs 5 and 6 of the six TMS unit found in the voltage-sensitive channel proteins. KcsA of S. lividans is an example of such a 2 TMS. channel protein. These channels may include the K_(Na) (Na⁺-activated) and K_(Vol) (cell volume-sensitive) K⁺ channels, as well as distantly related channels such as the Tok1 K⁺ channel of yeast, the TWIK-1 inward rectifier K⁺ channel of the mouse and the TREK-1 K⁺ channel of the mouse. Because of insufficient sequence similarity with proteins of the VIC family, inward rectifier K⁺ IRK channels (ATP-regulated; G-protein-activated) which possess a P domain and two flanking TMSs are placed in a distinct family. However, substantial sequence similarity in the P region suggests that they are homologous. The b, g and d subunits of VIC family members, when present, frequently play regulatory roles in channel activation/deactivation.

[0031] The Epithelial Na⁺ Channel (ENaC) Family

[0032] The ENaC family consists of over twenty-four sequenced proteins (Canessa, C. M., et al., (1994), Nature 367: 463-467, Le, T. and M. H. Saier, Jr. (1996), Mol. Membr. Biol. 13: 149-157; Garty, H. and L. G. Palmer (1997), Physiol. Rev. 77: 359-396; Waldmann, R., et al., (1997), Nature 386: 173-177; Darboux, I., et al., (1998), J. Biol. Chem. 273: 9424-9429; Firsov, D., et al., (1998), EMBO J. 17: 344-352; Horisberger, J.-D. (1998). Curr. Opin. Struc. Biol. 10: 443-449). All are from animals with no recognizable homologues in other eukaryotes or bacteria. The vertebrate ENaC proteins from epithelial cells cluster tightly together on the phylogenetic tree: voltage-insensitive ENaC homologues are also found in the brain. Eleven sequenced C. elegans proteins, including the degenerins, are distantly related to the vertebrate proteins as well as to each other. At least some of these proteins form part of a mechano-transducing complex for touch sensitivity. The homologous Helix aspersa (FMRF-amide)-activated Na⁺ channel is the first peptide neurotransmitter-gated ionotropic receptor to be sequenced.

[0033] Protein members of this family all exhibit the same apparent topology, each with N- and C-termini on the inside of the cell, two amphipathic transmembrane spanning segments, and a large extracellular loop. The extracellular domains contain numerous highly conserved cysteine residues. They are proposed to serve a receptor function.

[0034] Mammalian ENaC is important for the maintenance of Na⁺ balance and the regulation of blood pressure. Three homologous ENaC subunits, alpha, beta, and gamma, have been shown to assemble to form the highly Na⁺ -selective channel. The stoichiometry of the three subunits is alpha₂, beta1, gamma1. in a heterotetrameric architecture.

[0035] The Chloride Channel (ClC) Family

[0036] The ClC family is a large family consisting of dozens of sequenced proteins derived from Gram-negative and Gram-positive bacteria, cyanobacteria, archaea, yeast, plants and animals (Steinmeyer, K., et al., (1991), Nature 354: 301-304; Uchida, S., et al., (1993), J. Biol. Chem. 268: 3821-3824; Huang, M. -E., et al., (1994), J. Mol. Biol. 242: 595-598; Kawasaki, M., et al, (1994), Neuron 12: 597-604; Fisher, W. E., et al., (1995), Genomics. 29:598-606; and Foskett, J. K. (1998), Annu. Rev. Physiol. 60:. 689-717). These proteins are essentially ubiquitous, although they are not encoded within genomes of Haemophilus influenzae, Mycoplasma genitalium, and Mycoplasma pneumoniae. Sequenced proteins vary in size from 395 amino acyl residues (M. jannaschii) to 988 residues (man). Several organisms contain multiple ClC family paralogues. For example, Synechocystis has two paralogues, one of 451 residues in length and the other of 899 residues. Arabidopsis thaliana has at least four sequenced paralogues, (775-792 residues), humans also have at least five paralogues (820-988 residues), and C. elegans also has at least five (810-950 residues). There are nine known members in mammals, and mutations in three of the corresponding genes cause human diseases. E. coli, Methanococcus jannaschii and Saccharomyces cerevisiae only have one ClC family member each. With the exception of the larger Synechocystis paralogue, all bacterial proteins are small (395-492 residues) while all eukaryotic proteins are larger (687-988 residues). These proteins exhibit 10-12 putative transmembrane a-helical spanners (TMSs) and appear to be present in the membrane as homodimers. While one member of the family, Torpedo ClC-O, has been reported to have two channels, one per subunit, others are believed to have just one.

[0037] All functionally characterized members of the ClC family transport chloride, some in a voltage-regulated process. These channels serve a variety of physiological functions (cell volume regulation; membrane potential stabilization; signal transduction; transepithelial transport, etc.). Different homologues in humans exhibit differing anion selectivities, i.e., ClC4 and ClC5 share a NO ₃ ⁻>Cl⁻>Br >I⁻ conductance sequence, while ClC3. has an I⁻>Cl⁻ selectivity. The ClC4 and ClC5 channels and others exhibit outward rectifying currents with currents only at voltages more positive than +20 mV.

[0038] Animal Inward Rectifier K⁺ Channel (IRK-C) Family

[0039] IRK channels possess the “minimal channel-forming structure” with only a P domain, characteristic of the channel proteins of the VIC family, and two flanking transmembrane spanners (Shuck, M. E., et al., (1994), J. Biol. Chem. 269: 24261-24270; Ashen, M. D., et al., (1995), Am. J. Physiol. 268: H506-H511; Salkoff, L. and T. Jegla (1995), Neuron 15: 489-492; Aguilar-Bryan, L., et al., (1998), Physiol. Rev. 78: 227-245; Ruknudin, A., et al., (1998), J. Biol. Chem. 273: 14165-14171). They may exist in the membrane as homo- or heterooligomers. They have a greater tendency to let K⁺ flow into the cell than out. Voltage-dependence may be regulated by external K⁺ , by internal Mg²⁺, by internal ATP and/or by G-proteins. The P domains of IRK channels exhibit limited sequence similarity to those of the VIC family, but this sequence similarity is insufficient to establish homology. Inward rectifiers play a role in setting cellular membrane potentials, and the closing of these channels upon depolarization permits the occurrence of long duration action potentials with a plateau phase. Inward rectifiers lack the intrinsic voltage sensing helices found in VIC family channels. In a few cases, those of Kir1.1a and Kir6.2, for example, direct interaction with a member of the ABC superfamily has been proposed to confer unique functional and regulatory properties to the heteromeric complex, including sensitivity to ATP. The SUR1 sulfonylurea receptor (spQO9428) is the ABC protein that regulates the Kir6.2 channel in response to ATP, and CFTR may regulate Kir1.1a. Mutations in SUR1 are the cause of familial persistent hyperinsulinemic hypoglycemia in infancy (PHHI), an autosomal recessive disorder characterized by unregulated insulin secretion in the pancreas.

[0040] ATP-gated Cation Channel (ACC) Family

[0041] Members of the ACC family (also called P2X receptors) respond to ATP, a functional neurotransmitter released by exocytosis from many types of neurons (North, R. A. (1996), Curr. Opin. Cell Biol. 8: 474-483; Soto, F., M. Garcia-Guzman and W. Stühmer (1997), J. Membr. Biol. 160: 91-100). They have been placed into seven groups (P2X₁- P2X₇) based on their pharmacological properties. These channels, which function at neuron-neuron and neuron-smooth muscle junctions, may play roles in the control of blood pressure and pain sensation. They may also function in lymphocyte and platelet physiology. They are found only in animals.

[0042] The proteins of the ACC family are quite similar in sequence (>35% identity), but they possess 380-1000 amino acyl residues per subunit with variability in length localized primarily to the C-terminal domains. They possess two transmembrane spanners, one about 30-50 residues from their N-termini, the other near residues 320-340. The extracellular receptor domains between these two spanners (of about 270 residues) are well conserved with numerous conserved glycyl and cysteyl residues. The hydrophilic C-termini vary in length from 25 to 240 residues. They resemble the topologically similar epithelial Na⁺ channel (ENaC) proteins in possessing (a) N- and C-termini localized intracellularly, (b) two putative transmembrane spanners, (c) a large extracellular loop domain, and (d) many conserved extracellular cysteyl residues. ACC family members are, however, not demonstrably homologous with them. ACC channels are probably hetero- or homomultimers and transport small monovalent cations (Me⁺). Some also transport Ca²⁺; a few also transport small metabolites.

[0043] The Ryanodine-Inositol 1,4,5-triphosphate Receptor Ca²⁺ Channel (RIR-CaC) Family

[0044] Ryanodine (Ry)-sensitive and inositol 1,4,5-triphosphate (IP3)-sensitive Ca²⁺-release channels function in the release of Ca²⁺ from intracellular storage sites in animal cells and thereby regulate various Ca²⁺-dependent physiological processes (Hasan, G. et al., (1992) Development 116: 967-975; Michikawa, T., et al., (1994), J. Biol. Chem. 269: 9184-9189; Tunwell, R. E. A., (1996), Biochem. J. 318: 477-487; Lee, A. G. (1996) Biomembranes, Vol. 6, Transmembrane Receptors and Channels (A. G. Lee, ed.), JAI Press, Denver, Co., pp 291-326; Mikoshiba, K., et al., (1996) J. Biochem. Biomem. 6: 273-289). Ry receptors occur primarily in muscle cell sarcoplasmic reticular (SR) membranes, and IP3 receptors occur primarily in brain cell endoplasmic reticular (ER) membranes where they effect release of Ca²⁺ into the cytoplasm upon activation (opening) of the channel.

[0045] The Ry receptors are activated as a result of the activity of dihydropyridine-sensitive Ca²⁺ channels. The latter are members of the voltage-sensitive ion channel (VIC) family. Dihydropyridine-sensitive channels are present in the T-tubular systems of muscle tissues.

[0046] Ry receptors are homotetrameric complexes with each subunit exhibiting a molecular size of over 500,000 daltons (about 5,000 amino acyl residues). They possess C-terminal domains with six putative transmembrane a -helical spanners (TMSs). Putative pore-forming sequences occur between the fifth and sixth TMSs as suggested for members of the VIC family. The large N-terminal hydrophilic domains and the small C-terminal hydrophilic domains are localized to the cytoplasm. Low resolution 3-dimensional structural data are available. Mammals possess at least three isoforms that probably arose by gene duplication and divergence before divergence of the mammalian species. Homologues are present in humans and Caenorabditis elegans.

[0047] IP₃ receptors resemble Ry receptors in many respects. (1) They are homotetrameric complexes with each subunit exhibiting a molecular size of over 300,000 daltons (about 2,700 amino acyl residues). (2) They possess C-terminal channel domains that are homologous to those of the Ry receptors. (3) The channel domains possess six putative TMSs and a putative channel lining region between TMSs 5 and 6. (4) Both the large N-terminal domains and the smaller C-terminal tails face the cytoplasm. (5) They possess covalently linked carbohydrate on extracytoplasmic loops of the channel domains. (6) They have three currently recognized isoforms (types 1, 2, and 3) in mammals which are subject to differential regulation and have different tissue distributions.

[0048] IP₃ receptors possess three domains: N-terminal IP₃-binding domains, central coupling or regulatory domains and C-terminal channel domains. Channels are activated by IP₃ binding, and like the Ry receptors, the activities of the IP₃ receptor channels are regulated by phosphorylation of the regulatory domains, catalyzed by various protein kinases. They predominate in the endoplasmic reticular membranes of various cell types in the brain but have also been found in the plasma membranes of some nerve cells derived from a variety of tissues.

[0049] The channel domains of the Ry and IP₃ receptors comprise a coherent family that in spite of apparent structural similarities, do not show appreciable sequence similarity of the proteins of the VIC family. The Ry receptors and the IP₃ receptors cluster separately on the RIR-CaC family tree. They both have homologues in Drosophila. Based on the phylogenetic tree for the family, the family probably evolved in the following sequence: (1) A gene duplication event occurred that gave rise to Ry and IP₃ receptors in invertebrates. (2) Vertebrates evolved from invertebrates. (3) The three isoforms of each receptor arose as a result of two distinct gene duplication events. (4) These isoforms were transmitted to mammals before divergence of the mammalian species.

[0050] The Organellar Chloride Channel (O-ClC) Family

[0051] Proteins of the O-ClC family are voltage-sensitive chloride channels found in intracellular membranes but not the plasma membranes of animal cells (Landry, D, et al., (1993), J. Biol. Chem. 268: 14948-14955; Valenzuela, Set al., (1997), J. Biol. Chem. 272: 12575-12582; and Duncan, R. R., et al., (1997), J. Biol. Chem. 272: 23880-23886).

[0052] They are found in human nuclear membranes, and the bovine protein targets to the microsomes, but not the plasma membrane, when expressed in Xenopus laevis oocytes. These proteins are thought to function in the regulation of the membrane potential and in transepithelial ion absorption and secretion in the kidney. They possess two putative transmembrane a-helical spanners (TMSs) with cytoplasmic N- and C-termini and a large luminal loop that may be glycosylated. The bovine protein is 437 amino acyl residues in length and has the two putative TMSs at positions 223-239 and 367-385. The human nuclear protein is much smaller (241. residues). A C. elegans homologue is 260 residues long.

[0053] The Glutamate-gated Ion Channel (GIC) Family of Neurotransmitter Receptors

[0054] Members of the GIC family are heteropentameric complexes in which each of the 5 subunits is of 800-1000 amino acyl residues in length (Nakanishi, N., et al, (1990), Neuron 5: 569-581; Unwin, N. (1993), Cell 72: 31-41; Alexander, S. P. H. and J. A. Peters (1997) Trends Pharmacol. Sci., Elsevier, pp. 36-40). These subunits may span the membrane three or five times as putative a-helices with the N-tertnini (the glutamate-binding domains) localized extracellularly and the C-termini localized cytoplasmically. They may be distantly related to the ligand-gated ion channels, and if so, they may possess substantial b-structure in their transmembrane regions. However, homology between these two families cannot be established on the basis of sequence comparisons alone. The subunits fall into six subfamilies: a, b, g, d, e and z.

[0055] The GIC channels are divided into three types: (1) a-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)-, (2) kainate- and (3) N-methyl-D-aspartate (NMDA)-selective glutamate receptors. Subunits of the AMPA and kainate classes exhibit 35-40% identity with each other while subunits of the NMDA receptors exhibit 22-24% identity with the former subunits. They possess large N-terminal, extracellular glutamate-binding domains that are homologous to the periplasmic glutamine and glutamate receptors of ABC-type uptake permeases of Gram-negative bacteria. All known members of the GIC family are from animals. The different channel (receptor) types exhibit distinct ion selectivities and conductance properties. The NMDA-selective large conductance channels are highly permeable to monovalent cations and Ca²⁺. The AMPA- and kainate-selective-ion channels are permeable primarily to monovalent cations with only low permeability to Ca²⁺.

[0056] The brain-specific Na⁺ -dependent inorganic phosphate transporter (BNPI) belongs to a family of proteins that use the inwardly directed Na+ gradient across the plasma membrane to cotransport inorganic phosphate (Pi). Originally identified as a sequence up-regulated by the exposure of cerebellar granule cells to subtoxic concentrations of N-methyl-D-aspartate, BNPI mediates the Na+-dependent accumulation of Pi in Xenopus oocytes. BNPI has been implicated in adenosine 5′-triphosphate (ATP) production by neurons and protection against excitotoxic injury. However, BNPI is only expressed by glutamatergic neurons, militating against a general metabolic. role in all neuronal populations. In Caenorhabditis elegans, genetic screens for multiple behavioral defects have identified mutants in the BNPI ortholog eat-4, and recent studies indicate a specific role for eat-4 in glutamatergic neurotransmission. The glutamatergic defect in eat-4 mutants appears to be presynaptic, consistent with the localization of BNPI to excitatory nerve terminals. The accumulation of cytoplasmic Pi mediated by BNPI may activate the phosphate-activated glutaminase responsible for biosynthesis of the bulk of glutamate released as a neurotransmitter. However, the family of proteins including BNPI/EAT-4 may have functions in addition to Pi transport.

[0057] BNPI shows sequence similarity to type I but not type II Na+/Pi cotransporters. In contrast to the type II transporters that exhibit robust Na+-dependent Pi uptake, the accumulation of Pi by type I transporters is less striking. Rather, the type I transporter NaPi-1 transports organic anions, including phenol red and penicillin G, with substantially higher apparent affinity than Pi. Human genetic studies have shown that mutations in another protein closely related to BNPI and NaPi-1 account for disorders of sialic acid storage. In these conditions, sialic acid accumulates in lysosomes because of a defect in proton-driven export. Although the sialin protein has not been demonstrated to mediate sialic acid transport, these observations together with the report that NaPi-1. accumulates organic anions with high apparent affinity suggest that BNPI might also transport organic anions. Localization to glutamatergic nerve terminals raises the possibility that it transports glutamate. In addition, BNPI is localized to synaptic vesicles in the brain and to intracellular membranes in transfected cells, suggesting a role for BNPI in the transport of glutamate into synaptic vesicles for regulated exocytotic release.

[0058] Glutamate transport into synaptic vesicles exhibits a number of properties that distinguish it from glutamate uptake by other transport systems. First, in contrast to plasma membrane glutamate uptake, the accumulation of glutamate in synaptic vesicles does not rely on a Na+electrochemical gradient. Consistent with this, glutamate was transported by BNPI in the absence of Na+. Second, vesicular glutamate transport has a substantially lower apparent affinity (Km of ˜1 mM) than the plasma membrane excitatory amino acid transporters (Km of ˜10 to 100 μM). Glutamate transport by BNPI is saturated with a Km of ˜2 mM, in the same range as transport by synaptic vesicles. Third, plasma membrane glutamate transporters recognize both aspartate and glutamate as substrates, whereas vesicular glutamate transport does not recognize aspartate. D-Glutamate partially inhibited the transport of 3H-glutamate, and L-glutamine had no effect, also consistent with prior work. Fourth, low micromolar concentrations of the dye Evans blue inhibited the transport of glutamate into both synaptic vesicles and membranes expressing BNPI.

[0059] For a review associated with the differentation-associated Na-dependent inorganic phosphate cotransporter, see references Bellocchio et al., Science, 289:957-960, 2000, Aihara et al., J. Neurochem. 74: 2622-2625, 2000, Ni et al., J. Neurochem, 66: 2f227-2238, 1996, Takamori et al., Nature 407: 189-194, 2000.

[0060] Transporter proteins, particularly members of the differentation-associated Na-dependent inorganic phosphate cotransporter subfamily, are a major target for drug action and development. Accordingly, it is valuable to the field of pharmaceutical development to identify and characterize previously unknown transport proteins. The present invention advances the state of the art by providing previously unidentified human transport proteins.

SUMMARY OF THE INVENTION

[0061] The present invention is based in part on the identification of amino acid sequences of human transporter peptides and proteins that are related to the differentation-associated Na-dependent inorganic phosphate cotransporter subfamily, as well as allelic variants and other mammalian orthologs thereof. These unique peptide sequences, and nucleic acid sequences that encode these peptides, can be used as models for the development of human therapeutic targets, aid in the identification of therapeutic proteins, and serve as targets for the development of human therapeutic agents that modulate transporter activity in cells and tissues that express the transporter.

DESCRIPTION OF THE FIGURE SHEETS

[0062]FIG. 1 provides the nucleotide sequence of a cDNA molecule or transcript sequence that encodes the transporter protein of the present invention. In addition structure and functional information is provided, such as ATG start, stop and tissue distribution, where available, that allows one to readily determine specific uses of inventions based on this molecular sequence. Experimental data as provided in FIG. 1 indicates expression in the pooled human melanocyte, fetal heart, and pregnant uterus and human leukocytes.

[0063]FIG. 2 provides the predicted amino acid sequence of the transporter of the present invention. In addition structure and functional information such as protein family, function, and modification sites is provided where available, allowing one to readily determine specific uses of inventions based on this molecular sequence.

[0064]FIG. 3 provides genomic sequences that span the gene encoding the transporter protein of the present invention. In addition structure and functional information, such as intron/exon structure, promoter location, etc., is provided where available, allowing one to readily determine specific uses of inventions based on this molecular sequence. 69 SNPs, including 14 indels, have been identified in the gene encoding the transporter protein provided by the present invention and are given in FIG. 3.

DETAILED DESCRIPTION OF THE INVENTION

[0065] General Description

[0066] The present invention is based on the sequencing of the human genome. During the sequencing and assembly of the human genome, analysis of the sequence information revealed previously unidentified fragments of the human genome that encode peptides that share structural and/or sequence homology to protein/peptide/domains identified and characterized within the art as being a transporter protein or part of a transporter protein and are related to the differentation-associated Na-dependent inorganic phosphate cotransporter subfamily. Utilizing these sequences, additional genomic sequences were assembled and transcript and/or CDNA sequences were isolated and characterized. Based on this analysis, the present invention provides amino acid sequences of human transporter peptides and proteins that are related to the differentation-associated Na-dependent inorganic phosphate cotransporter subfamily, nucleic acid sequences in the form of transcript sequences, cDNA sequences and/or genomic sequences that encode these transporter peptides and proteins, nucleic acid variation (allelic information), tissue distribution of expression, and information about the closest art known protein/peptide/domain that has structural or sequence homology to the transporter of the present invention.

[0067] In addition to being previously unknown, the peptides that are provided in the present invention are selected based on their ability to be used for the development of commercially important products and services. Specifically, the present peptides are selected based on homology and/or structural relatedness to known transporter proteins of the differentation-associated Na-dependent inorganic phosphate cotransporter subfamily and the expression pattern observed . Experimental data as provided in FIG. 1. indicates expression in the pooled human melanocyte, fetal heart, and pregnant uterus and human leukocytes. The art has clearly established the commercial importance of members of this family of proteins and proteins that have expression patterns similar to that of the present gene. Some of the more specific features of the peptides of the present invention, and the uses thereof, are described herein, particularly in the Background of the Invention and in the annotation provided in the Figures, and/or are known within the art for each of the known differentation-associated Na-dependent inorganic phosphate cotransporter family or subfamily of transporter proteins.

[0068] Specific Embodiments

[0069] Peptide Molecules

[0070] The present invention provides nucleic acid sequences that encode protein molecules that have been identified as being members of the transporter family of proteins and are related to the differentation-associated Na-dependent inorganic phosphate cotransporter subfamily (protein sequences are provided in FIG. 2, transcript/cDNA sequences are provided in FIG. 1 and genomic sequences are provided in FIG. 3). The peptide sequences provided in FIG. 2, as well as the obvious variants described herein, particularly allelic variants as identified herein and using the information in FIG. 3, will be referred herein as the transporter peptides of the present invention, transporter peptides, or peptides/proteins of the present invention.

[0071] The present invention provides isolated peptide and protein molecules that consist of, consist essentially of, or comprising the amino acid sequences of the transporter peptides disclosed in the FIG. 2, (encoded by the nucleic acid molecule shown in FIG. 1, transcript/cDNA or FIG. 3, genomic sequence), as well as all obvious variants of these peptides that are within the art to make and use. Some of these variants are described in detail below.

[0072] As used herein, a peptide is said to be “isolated” or “purified” when it is substantially free of cellular material or free of chemical precursors or other chemicals. The peptides of the present invention can be purified to homogeneity or other degrees of purity. The level of purification will be based on the intended use. The critical feature is that the preparation allows for the desired function of the peptide, even if in the presence of considerable amounts of other components (the features of an isolated nucleic acid molecule is discussed below).

[0073] In some uses, “substantially free of cellular material” includes preparations of the peptide having less than about 30% (by dry weight) other proteins (i.e., contaminating protein), less than about 20% other proteins, less than about 10% other proteins, or less than about 5% other proteins. When the peptide is recombinantly produced, it can also be substantially free of culture medium, i.e., culture medium represents less than about 20% of the volume of the protein preparation.

[0074] The language “substantially free of chemical precursors or other chemicals” includes preparations of the peptide in which it is separated from chemical precursors or other chemicals that are involved in its synthesis. In one embodiment, the language “substantially free of chemical precursors or other chemicals” includes preparations of the transporter peptide having less than about 30% (by dry weight) chemical precursors or other chemicals, less than about 20% chemical precursors or other chemicals, less than about 10% chemical precursors or other chemicals, or less than about 5% chemical precursors or other chemicals.

[0075] The isolated transporter peptide can be purified from cells that naturally express it, purified from cells that have been altered to express it (recombinant), or synthesized using known protein synthesis methods. Experimental data as provided in FIG. 1 indicates expression in the pooled human melanocyte, fetal heart, and pregnant uterus and human leukocytes. For example, a nucleic acid molecule encoding the transporter peptide is cloned into an expression vector, the expression vector introduced into a host cell and the protein expressed in the host cell. The protein can then be isolated from the cells by an appropriate purification scheme using standard protein purification techniques. Many of these techniques are described in detail below.

[0076] Accordingly, the present invention provides proteins that consist of the amino acid sequences provided in FIG. 2 (SEQ ID NO:2), for example, proteins encoded by the transcript/cDNA nucleic acid sequences shown in FIG. 1 (SEQ ID NO:1) and the genomic sequences provided in FIG. 3 (SEQ ID. NO:3). The amino acid sequence of such a protein is provided in FIG. 2. A protein consists of an amino acid sequence when the amino acid sequence is the final amino acid sequence of the protein.

[0077] The present invention fuirther provides proteins that consist essentially of the amino acid sequences provided in FIG. 2 (SEQ ID NO:2), for example, proteins encoded by the transcript/cDNA nucleic acid sequences shown in FIG. 1 (SEQ ID NO:1) and the genomic sequences provided in FIG. 3. (SEQ ID NO:3). A protein consists essentially of an amino acid sequence when such an amino acid sequence is present with only a few additional amino acid residues, for example from about II to about 100 or so additional residues, typically from 1 to about 20 additional residues in the final protein.

[0078] The present invention further provides proteins that comprise the amino acid sequences provided in FIG. 2 (SEQ ID NO:2), for example, proteins encoded by the transcript/cDNA nucleic acid sequences shown in FIG. 1 (SEQ ID NO:1) and the genomic sequences provided in FIG. 3 (SEQ ID NO:3). A protein comprises an amino acid sequence when the amino acid sequence is at least part of the final amino acid sequence of the protein. In such a fashion, the protein can be only the peptide or have additional amino acid molecules, such as amino acid residues (contiguous encoded sequence) that are naturally associated with it or heterologous amino acid residues/peptide sequences. Such a protein can have a few additional amino acid residues or can comprise several hundred or more additional amino acids. The preferred classes of proteins that are comprised of the transporter peptides of the present invention are the naturally occurring mature proteins. A brief description of how various types of these proteins can be made/isolated is provided below.

[0079] The transporter peptides of the present invention can be attached to heterologous sequences to form chimeric or fusion proteins. Such chimeric and fusion proteins comprise a transporter peptide operatively linked to a heterologous protein having an amino acid sequence not substantially homologous to the transporter peptide. “Operatively linked” indicates that the transporter peptide and the heterologous protein are fused in-frame. The heterologous protein can be fuised to the N-terminus or C-terminus of the transporter peptide.

[0080] In some uses, the fuision protein does not affect the activity of the transporter peptide per se. For example, the fusion protein can include, but is not limited to, enzymatic fusion proteins, for example beta-galactosidase fuisions, yeast two-hybrid GAL fuisions, poly-His fusions, MYC-tagged, HI-tagged and Ig fuisions. Such fusion proteins, particularly poly-His fusions, can facilitate the purificafion of recombinant transporter peptide. In certain host cells (e.g., mammalian host cells), expression and/or secretion of a protein can be increased by using a heterologous signal sequence.

[0081] A chimeric or fusion protein can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different protein sequences are ligated together in-frame in accordance with conventional techniques. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and re-amplified to generate a chimerie.gene sequence .(see Ausubel et al., Current Protocols in Molecular Biology, 1992). Moreover, many expression vectors are conunercially available that already encode a fusion moiety (e.g., a GST protein). A transporter peptide-encoding nucleic acid can be cloned into such an expression vector such that the fuision moiety is linked in-frame to the transporter peptide.

[0082] As mentioned above, the present invention also provides and enables obvious variants of the amino acid sequence of the proteins of the present invention, such as naturally occurring mature forms of the peptide, alielic/sequence variants of the peptides, non-naturally occurring recombinantly derived variants of the peptides, and orthologs and paralogs of the peptides. Such variants can readily be generated using art-known techniques in the fields of recombinant nucleic acid technology and protein biochemistry. It is understood, however, that variants exclude any amino acid sequences disclosed prior to the invention.

[0083] Such variants can readily be identified/made using molecular techniques and the sequence information disclosed herein. Further, such variants can readily be distinguished from other peptides based on sequence and/or structural homology to the transporter peptides of the present invention. The degree of homology/identity present will be based primarily on whether the peptide is a functional variant or non-functional variant, the amount of divergence present in the paralog family and the evolutionary distance between the orthologs.

[0084] To determine the percent identity of two amino acid sequences or two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, at least 30%, 40%, 50%, 60%, 70%, 80%, or 90% or more of a reference sequence is aligned for comparison purposes. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic, acid “identity” is equivalent to amino acid or nucleic acid “homology”). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

[0085] The comparison of sequences and determination of percent identity and similarity between two sequences can be accomplished using a mathematical algorithm. (Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York, 1988; Biocomputing:. Informatics and Genome Projects, Smith, D. W., ed., Academiic Press, New York, 1993; Computer Analysis of Sequence Data, Part 1, Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch (J. Mol. Biol. (48):444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available at http://www.gcg.com), using either a Blossom 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (Devereux, J., et al., Nucleic Acids Res. 12(1):387 (1984)) (available at http://www.gcg.com), using a NWSgapdna CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. In another embodiment, the percent identity between two amino acid or nucleotide sequences is determined using the algorithm of E. Myers and W. Miller (CABIOS, 4:11-17 (1989)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

[0086] The nucleic acid and protein sequences of the present invention can further be used as a “query sequence” to perform a search against sequence databases to, for example, identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. (J. Mol. Biol. 215:403-10 (1990)). BLAST nucleotide searches can be performed with the NBLAST program, score =100, wordlength =12 to obtain nucleotide sequences homologous to the nucleic acid molecules ofthe invention. BLAST protein searches can be performed with the XBLAST program, score =50, wordlength =3 to obtain amino acid sequences homologous to the proteins of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al. (Nucleic Acids Res. 25(17):3389-3402 (1997)). When utilizing BLAST and gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used.

[0087] Full-length pre-processed forms, as well as mature processed forms, of proteins that comprise one of the peptides of the present invention can readily be identified as having complete sequence identity to one of the transporter peptides of the present invention as well as being encoded by the same genetic locus as the transporter peptide provided herein.

[0088] Allelic variants of a transporter peptide can readily be identified as being a human protein having a high degree (significant) of sequence homology/identity to at least a portion of the transporter peptide as well as being encoded by the same genetic locus as the transporter peptide provided herein. Genetic locus can readily be determined based on the genomic information provided in FIG. 3, such as the genomic sequence mapped to the reference human. As indicated by the data presented in FIG. 3, the map position was determined to be on chromosome 12 by ePCR, and confirmed with radiation hybrid mapping. As used herein, two proteins (or a region of the proteins) have significant homology when the amino acid sequences are typically at least about 70-80%, 80-90%, and more typically at least about 90-95% or more homologous. A significantly homologous amino acid sequence, according to the present invention, will be encoded by a nucleic acid sequence that will hybridize to a transporter peptide encoding nucleic acid molecule under stringent conditions as more fully described below.

[0089]FIG. 3 provides information on SNPs that have been identified in a gene encoding the transporter protein of the present invention. 69 SNP variants were found, including 14 indels (indicated by a “−”) and 1 SNPs in exons.

[0090] Paralogs of a transporter peptide can readily be identified as having some degree of significant sequence homology/identity to at least a portion of the transporter peptide, as being encoded by a gene from humans, and as having similar activity or function. Two proteins will typically be considered paralogs when the amino acid sequences are typically at least about 60% or greater, and more typically at least about 70% or greater homology through a given region or domain. Such paralogs will be encoded by a nucleic acid sequence that will hybridize to a transporter peptide encoding nucleic acid molecule under moderate to stringent conditions as more fully described below.

[0091] Orthologs of a transporter peptide can readily be identified as having some degree of significant sequence homology/identity to at least a portion of the transporter peptide as well as being encoded by a gene from another organism. Preferred orthologs will be isolated from mammals, preferably primates, for the development of human therapeutic targets and agents. Such orthologs will be encoded by a nucleic acid sequence that will hybridize to a transporter peptide encoding nucleic acid molecule under moderate to stringent conditions, as more fully described below, depending on the degree of relatedness of the two organisms yielding the proteins.

[0092] Non-naturally occurring variants of the transporter peptides of the present invention can readily be generated using recombinant techniques. Such variants include, but are not limited to deletions, additions and substitutions in the amino acid sequence of the transporter peptide. For example, one class of substitutions are conserved amino acid substitution. Such substitutions are those that substitute a given amino acid in a transporter peptide by another amino acid of like characteristics. Typically seen as conservative substitutions are the replacements, one for another, among the aliphatic amino acids Ala, Val, Leu, and Ile; interchange of the hydroxyl residues Ser and Thr; exchange of the acidic residues Asp and Glu; substitution between the amide residues Asn and Gln; exchange of the basic residues Lys and Arg; and replacements among the aromatic residues Phe and Tyr. Guidance concerning which amino acid changes are likely to be phenotypically silent are found in Bowie et al., Science 247:1306-1310 (1990).

[0093] Variant transporter peptides can be fully functional or can lack function in one or more activities, e.g. ability to bind ligand, ability to transport ligand, ability to mediate signaling, etc. Fully functional variants typically contain only conservative variation or variation in non-critical residues or in non-critical regions. FIG. 2 provides the result of protein analysis and can be used to identify critical domains/regions. Functional variants can also contain substitution of similar amino acids that result in no change or an insignificant change in function. Alternatively, such substitutions may positively or negatively affect function to some degree.

[0094] Non-functional variants typically contain one or more non-conservative amino acid substitutions, deletions, insertions, inversions, or truncation or a substitution, insertion, inversion, or deletion in a critical residue or critical region.

[0095] Amino acids that are essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham et al., Science 244:1081-1085 (1989)), particularly using the results provided in FIG. 2. The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant molecules are then tested for biological activity such as transporter activity or in assays such as an in vitro proliferative activity. Sites that are critical for binding partner/substrate binding can also be determined by structural analysis such as crystallization, nuclear magnetic resonance or photoaffinity labeling (Smith et al., J. Mol Biol. 224:899-904 (1992); de Vos et al. Science 255:306-312 (1992)).

[0096] The present invention fuither provides fragments of the transporter peptides, in addition to proteins and peptides that comprise and consist of such fragments, particularly those comprising the residues identified in FIG. 2. The fragments to which the invention pertains, however, are not to be construed as encompassing fragments that may be disclosed publicly prior to the present invention.

[0097] As used herein, a fragment comprises at least 8, 10, 12, 14, 16, or more contiguous amino acid residues from a transporter peptide. Such fragments can be chosen based on the ability to retain one or more of the biological activities of the transporter peptide or could be chosen for the ability to perform a function, e.g. bind a substrate or act as an immunogen. Particularly important fragments are biologically active fragments, peptides that are, for example, about 8 or more amino acids in length. Such fragments will typically comprise a domain or motif of the transporter peptide, e.g., active site, a transmembrane domain or a substrate-binding domain. Further, possible fragments include, but are not limited to, domain or motif containing fragments, soluble peptide fragments, and fragments containing immunogenic structures. Predicted domains and functional sites are readily identifiable by computer programs well known and readily available to those of skill in the art (e.g., PROSITE analysis). The results of one such analysis are provided in FIG. 2.

[0098] Polypeptides often contain amino acids other than the 20 amino acids commonly referred to as the 20 naturally occurring amino acids. Further, many amino acids, including the terminal amino acids, may be modified by natural processes, such as processing and other post-translational modifications, or by chemical modification techniques well known in the art. Common modifications that occur naturally in transporter peptides are described in basic texts, detailed monographs, and the research literature, and they are well known to those of skill in the art (some of these features are identified in FIG. 2).

[0099] Known modifications include, but are not limited to, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent crosslinks, formation of cystine, formation of pyroglutamate, formylation, gamma carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.

[0100] Such modifications are well known to those of skill in the art and have been described in great detail in the scientific literature. Several particularly common modifications, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation, for instance, are described in most basic texts, such as Proteins — Structure and Molecular Properties, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993). Many detailed reviews are available on this subject, such as by Wold, F., Posttranslational Covalent Modification of Proteins, B. C. Johnson, Ed., Academic Press, New York 1-12 (1983); Seifter et al. (Meth. Enzymol. 182: 626-646 (1990)) and Rattan et al. (Ann. N.Y. Acad. Sci. 663:48-62 (1992)).

[0101] Accordingly, the transporter peptides of the present invention also encompass derivatives or analogs in which a substituted amino acid residue is not one encoded by the genetic code, in which a substituent group is included, in which the mature transporter peptide is fused with another compound, such as a compound to increase the half-life of the transporter peptide (for example, polyethylene glycol), or in which the additional amino acids are fused to the mature transporter-peptide, such as a leader or secretory sequence or a sequence for purification of the mature transporter peptide or a pro-protein sequence.

[0102] Protein/Peptide Uses

[0103] The proteins of the present invention can be used in substantial and specific assays related to the functional information provided in the Figures; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its binding partner or ligand) in biological fluids; and as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state). Where the protein binds or potentially binds to another protein or ligand (such as, for example, in a transporter-effector protein interaction or transporter-ligand interaction), the protein can be used to identify the binding partner/ligand so as to develop. a system to identify inhibitors of the binding interaction. Any or all of these uses are capable of being developed into reagent grade or kit format for commercialization as commercial products.

[0104] Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include “Molecular Cloning: A Laboratory Manual”, 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E. F. Fritsch and T. Maniatis eds., 1989, and “Methods in Enzymology: Guide to Molecular Cloning Techniques”, Academic Press, Berger, S. L. and A. R. Kimmel eds., 1987.

[0105] Substantial chemical and structural homology exists between the differentation-associated Na-dependent inorganic phosphate cotransporter protein described herein and brain-specific Na+-dependent inorganic phosphate transporter (BNPI) (see FIG. 1). As discussed in the background, brain-specific Na+-dependent inorganic phosphate transporter is known in the art to be involved in transporting glutamate into native synaptic vesicles from the brain and it is also a phosphate transporter, presumably at the plasma membrane. Using fluorescence in situ hybridization, the BNPI gene is to be located on th elong arm of 19q13, in close proximity to the late-onset familial Alzheimer disease locus (Ni et al., J. Neurochem, 66: 2f227-2238, 1996), Accordingly, the differentation-associated Na-dependent inorganic phosphate cotransporter protein, and the encoding gene, provided by the present invention is useful for treating, preventing, and/or diagnosing neurotransmitter related disease, brain diseases such as Alzheimer and other disorders associated with this BNPI.

[0106] The potential uses of the peptides of the present invention are based primarily on the source of the protein as well as the class/action of the protein. For example, transporters isolated from humans and their human/mammalian orthologs serve as targets for identifying agents for use in mammalian therapeutic applications, e.g. a human drug, particularly in modulating a biological or pathological response in a cell or tissue that expresses the transporter. Experimental data as provided in FIG. 1 indicates that transporter proteins of the present invention are expressed in the pooled human melanocyte, fetal heart, and pregnant uterus detected by a virtual northern blot. In addition, PCR-based tissue screening panel indicates expression in human leukocytes. A large percentage of pharmaceutical agents are being developed that modulate the activity of transporter proteins, particularly members of the differentation-associated Na-dependent inorganic phosphate cotransporter subfamily (see Background of the Invention). The structural and functional information provided in the Background and Figures provide specific and substantial uses for the molecules of the present invention, particularly in combination with the expression information provided in FIG. 1. Experimental data as provided in FIG. 1 indicates expression in the pooled human melanocyte, fetal heart, and pregnant uterus and human leukocytes. Such uses can readily be determined using the information provided herein, that known in the art and routine experimentation.

[0107] The proteins of the present invention (including variants and fragments that may have been disclosed prior to the present invention) are usefuil for biological assays related to transporters that are related to members of the differentation-associated Na-dependent inorganic phosphate cotransporter subfamily. Such assays involve any of the known transporter functions or activities or properties useful for diagnosis and treatment of transporter-related conditions that are specific for the subfamily of transporters that the one of the present invention belongs to, particularly in cells and tissues that express the transporter. Experimental data as provided in FIG. 1 indicates that transporter proteins of the present invention are expressed in the pooled human melanocyte, fetal heart, and pregnant uterus detected by a virtual northern blot. In addition, PCR-based tissue screening panel indicates expression in human leukocytes.

[0108] The proteins of the present invention are also usefiul in drug screening assays, in cell-based or cell-free systems ((Hodgson, Bio/technology, Sept 10, 1992 (9);973-80). Cell-based systems can be native, i.e., cells that normally express the transporter, as a biopsy or expanded in cell culture. Experimental data as provided in FIG. 1 indicates expression in the pooled human melanocyte, fetal heart, and pregnant uterus and human leukocytes. In an alternate embodiment, cell-based assays involve recombinant host cells expressing the transporter protein.

[0109] The polypeptides can be used to identify compounds that modulate transporter activity of the protein in its natural state or an altered form that causes a specific disease or pathology associated with the transporter. Both the transporters of the present invention and appropriate variants and fragments can be used in high-throughput screens to assay candidate compounds for the ability to bind to the transporter. These compounds can be further screened against a functional transporter to determine the effect of the compound on the transporter activity. Further, these compounds can be tested in animal or invertebrate systems to determine activity/effectiveness. Compounds can be identified that activate (agonist) or inactivate (antagonist) the transporter to a desired degree.

[0110] Further, the proteins of the present invention can be used to screen a compound for the ability to stimulate or inhibit interaction between the transporter protein and a molecule that normally interacts with the transporter protein, e.g. a substrate or a component of the signal pathway that the transporter protein normally interacts (for example, another transporter). Such assays typically include the steps of combining the transporter protein with a candidate compound under conditions that allow the transporter protein, or fragment, to interact with the target molecule, and to detect the formation of a complex between the protein and the target or to detect the biochemical consequence of the interaction with the transporter protein and the target, such as any of the associated effects of signal transduction such as changes in membrane potential, protein phosphorylation, cAMP turnover, and adenylate cyclase activation, etc.

[0111] Candidate compounds include, for example, 1) peptides such as soluble peptides, including Ig-tailed fusion peptides and members of random peptide libraries (see, e.g., Lam et al., Nature 354:82-84 (1991); Houghten et al., Nature 354:84-86 (1991)) and combinatorial chemistry-derived molecular libraries made of D- and/or L- configuration amino acids; 2) phosphopeptides (e.g., members of random and partially degenerate, directed phosphopeptide libraries, see, e.g., Songyang et al., Cell 72:767-778 (1993)); 3) antibodies (e.g., polyclonal, monoclonal, humanized, anti-idiotypic, chimeric, and single chain antibodies as well as Fab, F(ab′)₂, Fab expression library fragments, and epitope-binding fragments of antibodies); and 4) small organic and inorganic molecules (e.g., molecules obtained from combinatorial and natural product libraries).

[0112] One candidate compound is a soluble fragment of the receptor that competes for ligand binding. Other candidate compounds include mutant transporters or appropriate fragments containing mutations that affect transporter function and thus compete for ligand. Accordingly, a fragment that competes for ligand, for example with a higher affinity, or a fragment that binds ligand but does not allow release, is encompassed by the invention.

[0113] The invention further includes other end point assays to identify compounds that modulate (stimulate or inhibit) transporter activity. The assays typically involve an assay of events in the signal transduction pathway that indicate transporter activity. Thus, the transport of a ligand, change in cell membrane potential, activation of a protein, a change in the expression of genes that are up- or down-regulated in response to the transporter protein dependent signal cascade can be assayed.

[0114] Any of the biological or biochemical functions mediated by the transporter can be used as an endpoint assay. These include all of the biochemical or biochemical/biological events described herein, in the references cited herein, incorporated by reference for these endpoint assay targets, and other functions known to those of ordinary skill in the art or that can be readily identified using the information provided in the Figures, particularly FIG. 2. Specifically, a biological function of a cell or tissues that expresses the transporter can be assayed. Experimental data as provided in FIG. 1 indicates that transporter proteins of the present invention are expressed in the pooled human melanocyte, fetal heart, and pregnant uterus detected by a virtual northern blot. In addition, PCR-based tissue screening panel indicates expression in human leukocytes.

[0115] Binding and/or activating compounds can also be screened by using chimeric transporter proteins in which the amino terminal extracellular domain, or parts thereof, the entire transmembrane domain or subregions, such as any of the seven transmembrane segments or any of the intracellular or extracellular loops and the carboxy terminal intracellular domain, or parts thereof, can be replaced by heterologous domains or subregions. For example, a ligand-binding region can be used that interacts with a different ligand then that which is recognized by the native transporter. Accordingly, a different set of signal transduction components is available as an end-point assay for activation. This allows for assays to be performed in other than the specific host cell from which the transporter is derived.

[0116] The proteins of the present invention are also useful in competition binding assays in methods designed to discover compounds that interact with the transporter (e.g. binding partners and/or ligands). Thus, a compound is exposed to a transporter polypeptide under conditions that allow the compound to bind or to otherwise interact with the polypeptide. Soluble transporter polypeptide is also added to the mixture. If the test compound interacts with the soluble transporter polypeptide, it decreases the amount of complex formed or activity from the transporter target. This type of assay is particularly useful in cases in which compounds are sought that interact with specific regions of the transporter. Thus, the soluble polypeptide that ,competes with the target transporter region is designed to contain peptide sequences corresponding to the region of interest.

[0117] To perform cell free drug screening assays, it is sometimes desirable to immobilize either the transporter protein, or fragment, or its target molecule to facilitate separation of complexes from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay.

[0118] Techniques for immobilizing proteins on matrices can be used in the drug screening assays. In one embodiment, a fiusion protein can be provided which adds a domain that allows the protein to be bound to a matrix. For example, glutathione-S-transferase fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, Mo.) or glutathione derivatized microtitre plates, which are then combined with the cell lysates (e.g., ³⁵S-labeled) and the candidate compound, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads are washed to remove any unbound label, and the matrix immobilized and radiolabel determined directly, or in the supernatant after the complexes are dissociated. Alternatively, the complexes can be dissociated from the matrix, separated by SDS-PAGE, and the level of transporter-binding protein found in the bead fraction quantitated from the gel using standard electrophoretic techniques. For example, either the polypeptide or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin using techniques well known in the art. Alternatively, antibodies reactive with the protein but which do not interfere with binding of the protein to its target molecule can be derivatized to the wells of the plate, and the protein trapped in the wells by antibody conjugation. Preparations of a transporter-binding protein and a candidate compound are incubat ed in the transporter protein-presenting wells and the amount of complex trapped in the well can be quantitated. Methods for detecting such complexes, in addition to those described above for the GST-immdbilized complexes, include immunodetection of complexes using antibodies reactive with the transporter protein target molecule, or which are reactive with transporter protein and compete with the target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the target molecule.

[0119] Agents that modulate one of the transporters of the present invention can be identified using one or more of the above assays, alone or in combination. It is generally preferable to use a cell-based or cell free system first and then confirm activity in an animal or other model system. Such model systems are well known in the art and can readily be employed in this context.

[0120] Modulators of transporter protein activity identified according to these drug screening assays can be used to treat a subject with a disorder mediated by the transporter pathway, by treating cells or tissues that express the transporter. Experimental data as provided in FIG. 1 indicates expression in the pooled human melanocyte, fetal heart, and pregnant uterus and human leukocytes. These methods of treatment include the steps of administering a modulator of transporter activity in a pharmaceutical composition to a subject in need of such treatment, the modulator being identified as described herein.

[0121] In yet another aspect of the invention, the transporter proteins can be used as “bait proteins” in a two-hybrid assay or three-hybrid assay (see, e.g., U.S. Pat. No. 5,283,317; Zervos et al. (1993) Cell 72:223-232; Madura et al. (1993) J. Biol. Chem. 268:12046-12054; Bartel et al. (1993) Biotechniques 14:920-924; Iwabuchi et al. (1993) Oncogene 8:1693-1696; 1019 and Brent W094/10300), to identify other proteins, which bind to or interact with the transporter and are involved in transporter activity. Such transporter-binding proteins are also likely to be involved in the propagation of signals by the transporter proteins or transporter targets as, for example, downstream elements of a transporter-mediated signaling pathway. Alternatively, such transporter-binding proteins are likely to be transporter inhibitors.

[0122] The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for a transporter protein is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein (“prey” or “sample”) is fused to a gene that codes for the activation domain of the known transcription factor. If the “bait” and the “prey” proteins are able to interact, in vivo, forming a transporter-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene which encodes the protein which interacts with the transporter protein.

[0123] This invention further pertains to novel agents identified by the above-described screening assays. Accordingly, it is within the scope of this invention to further use an agent identified as described herein in an appropriate animal model. For example, an agent identified as described herein (e.g., a transporter-modulating agent, an antisense transporter nucleic acid molecule, a transporter-specific antibody, or a transporter-binding partner) can be used in an animal or other model to determine the efficacy, toxicity, or side effects of treatment with such an agent. Alternatively, an agent identified as described herein can be used in an animal or other model to, determine the mechanism of action of such an agent. Furthermore, this invention pertains to uses of novel agents identified by the above-described screening assays for treatments as described herein.

[0124] The transporter proteins of the present invention are also useful to provide a target for diagnosing a disease or predisposition to disease mediated by the peptide. Accordingly, the invention provides methods for detecting the presence, or levels of, the protein (or encoding MRNA) in a cell, tissue, or organism. Experimental data as provided in FIG. 1 indicates expression in the pooled human melanocyte, fetal heart, and pregnant uterus and human leukocytes. The method involves contacting a biological sample with a compound capable of interacting with the transporter protein such that the interaction can be detected. Such an assay can be provided in a single detection format or a multi-detection format such as an antibody chip array.

[0125] One agent for detecting a protein in a sample is an antibody capable of selectively binding to protein. A biological sample includes tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject.

[0126] The peptides of the present invention also provide targets for diagnosing active protein activity, disease, or predisposition to disease, in a patient having a variant peptide, particularly activities and conditions that are known for other members of the family of proteins to which the present one belongs. Thus, the peptide can be isolated from a biological sample and assayed for the presence of a genetic mutation that results in aberrant peptide. This includes amino acid substitution, deletion, insertion, rearrangement, (as the result of aberrant splicing events), and inappropriate post-translational modification. Analytic methods include altered electrophoretic mobility, altered tryptic peptide digest, altered transporter activity in cell-based or cell-free assay, alteration in ligand or antibody-binding pattern, altered isoelectric point, direct amino acid sequencing, and any other of the known assay techniques useful for detecting mutations in a protein. Such an assay can be provided in a single detection format or a multi-detection format such as an antibody chip array.

[0127] In vitro techniques for detection of peptide include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence using a detection reagent, such as an antibody or protein binding agent. Alternatively, the peptide can-be detected in vivo in a subject by introducing into the subject a labeled anti-peptide antibody or other types of detection agent. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques. Particularly useful are methods that detect the allelic variant of a peptide expressed in a subject and methods which detect fragments of a peptide in a sample.

[0128] The peptides are also useful in phannacogenomic analysis. Pharmacogenomics deal with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See, e.g., Eichelbaum, M. (Clin. Exp. Phannacol. Physiol. 23(10-11):983-985. (1996)), and Linder, M. W. (Clin. Chem. 43(2):254-266 (1997)). The clinical outcomes of these variations result in severe toxicity of therapeutic drugs in certain individuals or therapeutic failure of drugs in certain individuals as a result of individual variation in metabolism. Thus, the genotype of the individual can determine the way a therapeutic compound acts on the body or the way the body metabolizes the compound. Further, the activity of drug metabolizing enzymes effects both the intensity and duration of drug action. Thus, the pharmacogenomics of the individual permit the selection of effective compounds and effective dosages of such compounds for prophylactic or therapeutic treatment based on the individual's genotype. The discovery of genetic polymorphisms in some drug metabolizing enzymes has explained why some patients do not obtain the expected drug effects, show an exaggerated drug effect, or experience serious toxicity from standard drug dosages. Polymorphisms can be expressed in the phenotype of the extensive metabolizer and the phenotype of the poor metabolizer. Accordingly, genetic polymorphism may lead to allelic protein variants of the transporter protein in which one or more of the transporter funictions in one population is different from those in another population. The peptides thus allow a target to ascertain a genetic predisposition that can affect treatment modality. Thus, in a ligand-based treatment, polymorphism may give rise to amino terminal extracellular domains and/or other ligand-binding regions that are more or less active in ligand binding, and transporter activation. Accordingly, ligand dosage would necessarily be modified to maximize the therapeutic effect within a given population containing a polymorphism. As an alternative to genotyping, specific polymorphic peptides could be identified.

[0129] The peptides are also useful for treating a disorder characterized by an absence of, inappropriate, or unwanted expression of the protein. Experimental data as provided in FIG. 1 indicates expression in the pooled human melanocyte, fetal heart, and pregnant uterus and human leukocytes. Accordingly, methods for treatment include the use of the transporter protein or fragments.

[0130] Antibodies

[0131] The invention also provides antibodies that selectively bind to one of the peptides of the present invention, a protein comprising such a peptide, as well as variants and fragments thereof. As used herein, an antibody selectively binds a target peptide when it binds the target peptide and does not significantly bind to unrelated proteins. An antibody is still considered to selectively bind a peptide even if it also binds to other proteins that are not substantially homologous with the target peptide so long as such proteins share homology with a fragment or domain of the peptide target of the antibody. In this case, it would be understood that antibody binding to the peptide is still selective~despite some degree of cross-reactivity.

[0132] As used herein, an antibody is defined in terms consistent with that recognized within the art: they are multi-subunit proteins produced by a mammalian organism in response to an antigen challenge. The antibodies of the present invention include polyclonal antibodies and monoclonal antibodies, as well as fragments of such antibodies, including, but not limited to, Fab or F(ab′)_(2,) and Fv fragments.

[0133] Many methods are known for generating and/or identifying antibodies to a given target peptide. Several such methods are described by Harlow, Antibodies, Cold Spring Harbor Press, (1989).

[0134] In general, to generate antibodies, an isolated peptide is used as an immunogen and is administered to a mammalian organism, such as a rat, rabbit or mouse. The full-length protein, an antigenic peptide fragment or a fusion protein can be used. Particularly important fragments are those covering functional domains, such as the domains identified in FIG. 2, and domain of sequence homology or divergence amongst the family, such as those that can readily be identified using protein alignment methods and as presented in the Figures.

[0135] Antibodies are preferably prepared from regions or discrete fragments of the transporter proteins. Antibodies can be prepared from any region of the peptide as described herein. However, preferred regions will include those involved in function/activity and/or transporter/binding partner interaction. FIG. 2 can be used to identify particularly important regions while sequence alignment can be used to identify conserved and unique sequence fragments.

[0136] An antigenic fragment will typically comprise at least 8 contiguous amino acid residues. The antigenic peptide can comprise, however, at least 10, 12, 14, 16 or more amino acid residues. Such fragments can be selected on a physical property, such as fragments correspond to regions that are located on the surface of the protein, e.g., hydrophilic regions or can be selected based on sequence uniqueness (see FIG. 2).

[0137] Detection on an antibody of the present invention can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ¹²⁵I, ¹³¹I, ³⁵S or ³H.

[0138] Antibody Uses

[0139] The antibodies can be used to isolate one of the proteins of the present invention by standard techniques, such as affinity chromatography or immunoprecipitation. The antibodies can facilitate the purification of the natural protein from cells and recombinantly produced protein expressed in host cells. In addition, such antibodies are useful to detect the presence of one of the proteins of the present invention in cells or tissues to determine the pattern of expression of the protein among various tissues in an organism and over the course of normal development. Experimental data as provided in FIG. 1 indicates that transporter proteins of the present invention are expressed in the pooled human melanocyte, fetal heart, and pregnant uterus detected by a virtual northern blot. In addition, PCR-based tissue screening panel indicates expression in human leukocytes. Further, such antibodies can be used to detect protein in situ, in vitro, or in a cell lysate or supernatant in order to evaluate the abundance and pattern of expression. Also, such antibodies can be used to assess abnormal tissue distribution or abnormal expression during development or progression of a biological condition. Antibody detection of circulating fragments of the full length protein can be used to identify turnover.

[0140] Further, the antibodies can be used to assess expression in disease states such as in active stages of the disease or in an individual with a predisposition toward disease related to the protein's function. When a disorder is caused by an inappropriate tissue distribution, developmental expression, level of expression of the protein, or expressed/processed form, the antibody can be prepared against the normal protein. Experimental data as provided in FIG. 1 indicates expression in the pooled human melanocyte, fetal heart, and pregnant uterus and human leukocytes. If a disorder is characterized by a specific mutation in the protein, antibodies specific for this mutant protein can be used to assay for the presence of the specific mutant protein.

[0141] The antibodies can also be used to assess normal and aberrant subcellular localization of cells in the various tissues in an organism. Experimental data as provided in FIG. 1 indicates expression in the pooled human melanocyte, fetal heart, and pregnant uterus and human leukocytes. The diagnostic uses can be applied, not only in genetic testing, but also in monitoring a treatment modality. Accordingly, where treatment is ultimately aimed at correcting expression level or the presence of aberrant sequence and aberrant tissue distribution or developmental expression, antibodies directed against the protein or relevant fragments can be used to monitor therapeutic efficacy.

[0142] Additionally, antibodies are useful in pharmacogenomic analysis. Thus, antibodies prepared against polymorphic proteins can be used to identify individuals that require modified treatment modalities. The antibodies are also useful as diagnostic tools as an immunological marker for aberrant protein analyzed by electrophoretic mobility, isoelectric point, tryptic peptide digest, and other physical assays known to those in the art.

[0143] The antibodies are also useful for tissue typing. Experimental data as provided in FIG. 1 indicates expression in the pooled human melanocyte, fetal heart, and pregnant uterus and human leukocytes. Thus, where a specific protein has been correlated with expression in a specific tissue, antibodies that are specific for this protein can be used to identify a tissue type.

[0144] The antibodies are also useful for inhibiting protein function, for example, blocking the binding of the transporter peptide to a binding partner such as a ligand or protein binding partner. These uses can also be applied in a therapeutic context in which treatment involves inhibiting the protein's function. An antibody can be used, for example, to block binding, thus modulating (agonizing or antagonizing) the peptides activity. Antibodies can be prepared against specific fragments containing sites required for function or against intact protein that is associated with a cell or cell membrane. See FIG. 2 for structural information relating to the proteins of the present invention.

[0145] The invention also encompasses kits for using antibodies to detect the presence of a protein in a biological sample. The kit can comprise antibodies such as a labeled or labelable antibody and a compound or agent for detecting protein in a biological sample; means for determining the amount of protein in the sample; means for comparing the amount of protein in the sample with a standard; and instructions for use. Such a kit can be supplied to detect a single protein or epitope or can be configured to detect one of a multitude of epitopes, such as in an antibody detection array. Arrays are described in detail below for nucleic acid arrays and similar methods have been developed for antibody arrays.

[0146] Nucleic Acid Molecules

[0147] The present invention further provides isolated nucleic acid molecules that encode a transporter peptide or protein of the present invention (CDNA, transcript and genomic sequence). Such nucleic acid molecules will consist of, consist essentially of, or comprise a nucleotide sequence that encodes one of the transporter peptides of the present invention, an allelic variant thereof, or an ortholog or paralog thereof.

[0148] As used herein, an “isolated” nucleic acid molecule is one that is separated from other nucleic acid present in the natural source of the nucleic acid. Preferably, an “isolated” nucleic acid is free of sequences that naturally flank the nucleic acid (i.e., sequences located at the 5′ and 3′ ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. However, there can be some flanking nucleotide sequences, for example up to about 5 KB, 4 KB, 3 KB, 2 KB, or 1 KB or less, particularly contiguous peptide encoding sequences and peptide encoding sequences within the same gene but separated by introns in the genomic sequence. The important point is that the nucleic acid is isolated from remote and unimportant flanking sequences such that it can be subjected to the specific manipulations described herein such as recombinant expression, preparation of probes and primers, and other uses specific to the nucleic acid sequences.

[0149] Moreover, an “isolated” nucleic acid molecule, such as a transcript/cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or chemical precursors or other chemicals when chemically synthesized However, the nucleic acid molecule can be fused to other coding or regulatory sequences and still be considered isolated.

[0150] For example, recombinant DNA molecules contained in a vector are considered isolated. Further examples of isolated DNA molecules include recombinant DNA molecules maintained in heterologous host cells or purified (partially or substantially) DNA molecules in solution. Isolated RNA molecules include in vivo or in vitro RNA transcripts of the isolated DNA molecules of the present invention. Isolated nucleic acid molecules according to the present invention further include such molecules produced synthetically.

[0151] Accordingly, the present invention provides nucleic acid molecules that consist of the nucleotide sequence shown in FIG. 1 or 3 (SEQ ID NO: 1, transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in FIG. 2, SEQ ID NO:2. A nucleic acid molecule consists of a nucleotide sequence when the nucleotide sequence is the complete nucleotide sequence of the nucleic acid molecule.

[0152] The present invention fiurther provides nucleic acid molecules that consist essentially of the nucleotide sequence shown in FIG. 1 or 3 (SEQ ID NO:1, transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in FIG. 2, SEQ ID. NO:2. A nucleic acid molecule consists essentially of a nucleotide sequence when such a nucleotide sequence is present with only a few additional nucleic acid residues in the final nucleic acid molecule.

[0153] The present invention flurther provides nucleic acid molecules that comprise the nucleotide sequences shown in FIG. 1 or 3 (SEQ ID NO: 1, transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in FIG. 2, SEQ ID NO:2. A nucleic acid molecule comprises a nucleotide sequence when the nucleotide sequence is at least part of the final nucleotide sequence of the nucleic acid molecule. In such a fashion, the nucleic acid molecule can be only the nucleotide sequence or have additional nucleic acid residues, such as nucleic acid residues that are naturally associated with it or heterologous nucleotide sequences. Such a nucleic acid molecule can have a few additional nucleotides or can comprise several hundred or more additional nucleotides. A brief description of how various types of these nucleic acid molecules can be readily made/isolated is provided below.

[0154] In FIGS. 1 and 3, both coding and non-coding sequences are provided. Because of the source of the present invention, humans genomic sequence (FIG. 3) and cDNA/transcript sequences (FIG. 1), the nucleic acid molecules in the Figures will contain genomic intronic sequences, 5′ and 3′ non-coding sequences, gene regulatory regions and non-coding intergenic sequences. In general such sequence features are either noted in FIGS. 1 and 3 or can readily be identified using computational tools known in the art. As discussed below, some of the non-coding regions, particularly gene regulatory elements such as promoters, are useful for a variety of purposes, e.g. control of heterologous gene expression, target for identifying gene activity modulating compounds, and are particularly claimed as fragments of the genomic sequence provided herein.

[0155] The isolated nucleic acid molecules can encode the mature protein plus additional amino or carboxyl-terminal amino acids, or amino acids interior to the mature peptide (when the mature form has more than one peptide chain, for instance). Such sequences may play a role in processing of a protein from precursor to a mature form, facilitate protein trafficking, prolong or shorten protein half-life or facilitate manipulation of a protein for assay or production, among other things. As generally is the case in situ, the additional amino acids may be processed away from the mature protein by cellular enzymes.

[0156] As mentioned above, the isolated nucleic acid molecules include, but are not limited to, the sequence encoding the transporter peptide alone, the sequence encoding the mature peptide and additional coding sequences, such as a leader or secretory sequence (e.g., a pre-pro or pro-protein sequence), the sequence encoding the mature peptide, with or without the additional coding sequences, plus additional non-coding sequences, for example introns and non-coding 5′ and 3′ sequences such as transcribed but non-translated sequences that play a role in transcription, mRNA processing (including splicing and polyadenylation signals), ribosome binding and stability of MRNA. In addition, the nucleic acid molecule may be fused to a marker sequence encoding, for example, a peptide that facilitates purificafion. Isolated nucleic acid molecules can be in the form of RNA, such as MRNA, or in the form DNA, including cDNA and genomic DNA obtained by cloning or produced by chemical synthetic techniques or by a combination thereof. The nucleic acid, especially DNA, can be double-stranded or single-stranded. Single-stranded nucleic acid can be the coding strand (sense strand) or the non-coding strand (anti-sense strand).

[0157] The invention fturther provides nucleic acid molecules that encode fragments of the peptides of the present invention as well as nucleic acid molecules that encode obvious variants of the transporter proteins of the present invention that are described above. Such nucleic acid molecules may be naturally occurring, such as allelic variants (same locus), paralogs (different locus), and orthologs (different organism), or may be constructed by recombinant DNA methods or by chemical synthesis. Such non-naturally occurring variants may be made by mutagenesis techniques, including those applied to nucleic acid molecules, cells, or organisms. Accordingly, as discussed above, the variants can contain nucleotide substitutions, deletions, inversions and insertions. Variation can occur in either or both the coding and non-coding regions. The variations can produce both conservative and non-conservative amino acid substitutions.

[0158] The present invention further provides non-coding fragments of the nucleic acid molecules provided in FIGS. 1. and 3. Preferred non-coding fragments include, but are not limited to, promoter sequences, enhancer sequences, gene modulating sequences and gene termination sequences. Such fragments are usefuil in controlling heterologous gene expression and in developing screens to identify gene-modulating agents. A promoter can readily be identified as being 5′ to the ATG start site in the genomic sequence provided in FIG. 3.

[0159] A fragment comprises a contiguous nucleotide sequence greater than 12 or more nucleotides. Further, a fragment could at least 30, 40, 50, 100, 250 or 500 nucleotides in length. The length of the fragment will be based on its intended use. For example, the fragment can encode epitope bearing regions of the peptide, or can be useful as DNA probes and primers. Such fragments can be isolated using the known nucleotide sequence to synthesize an oligonucleotide probe. A labeled probe can then be used to screen a cDNA library, genomic DNA library, or MRNA to isolate nucleic acid corresponding to the coding region. Further, primers can be used in PCR reactions to clone specific regions of gene.

[0160] A probe/primer typically comprises substantially a purified oligonucleotide or oligonucleotide pair. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, 20, 25, 40, 50 or more consecutive nucleotides.

[0161] Orthologs, homologs, and allelic variants can be identified using methods well known in the art. As described in the Peptide Section, these variants comprise a nucleotide sequence encoding a peptide that is typically 60-70%, 70-80%, 80-90%, and more typically at least about 90-95% or more homologous to the nucleotide sequence shown in the Figure sheets or a fragment of this sequence. Such nucleic acid molecules can readily be identified as being able to hybridize under moderate to stringent conditions, to the nucleotide sequence shown in the Figure sheets or a fragment of the sequence. Allelic variants can readily be determined by genetic locus of the encoding gene. As indicated by the data presented in FIG. 3, the map position was determined to be on chromosome 12 by ePCR, and confirmed with radiation hybrid mapping.

[0162]FIG. 3 provides information on SNPs that have been identified in a gene encoding the transporter protein of the present invention. 69 SNP variants were found, including 14 indels (indicated by a “−”) and 1 SNPs in exons.

[0163] As used herein, the term “hybridizes under stringent conditions” is intended to describe conditions for hybridization and washing under which nucleotide sequences encoding a peptide at least 60-70% homologous. to each other typically remain hybridized to each other. The conditions can be such that sequences at least about 60%, at least about 70%, or at least about 80% or more homologous to each other typically remain hybridized to each other. Such stringent conditions are known to those skilled in the art and can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. One example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45C., followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50-65C. Examples of moderate to low stringency hybridization conditions are well known in the art.

[0164] Nucleic Acid Molecule Uses

[0165] The nucleic acid molecules of the present invention are useful for probes, primers, chemical intermediates, and in biological assays. The nucleic acid molecules are useful as a hybridization probe for messenger RNA, transcript/cDNA and genomic DNA to isolate full-length cDNA and genomic clones encoding the peptide described in FIG. 2 and to isolate cDNA and genomic clones that correspond to variants (alleles, orthologs, etc.) producing the same or related peptides shown in FIG. 2. 69 SNPs, including 14 indels, have been identified in the gene encoding the transporter protein provided by the present invention and are given in FIG. 3.

[0166] The probe can correspond to any sequence along the entire length of the nucleic acid molecules provided in the Figures. Accordingly, it could be derived from 5′ noncoding regions, the coding region, and 3′ noncoding regions. However, as discussed, fragments are not to be construed as encompassing fragments disclosed prior to the present invention.

[0167] The nucleic acid molecules are also useful as primers for PCR to amplify any given region of a nucleic acid molecule and are useful to synthesize antisense molecules of desired length and sequence.

[0168] The nucleic acid molecules are also useful for constructing recombinant vectors. Such vectors include expression vectors that express a portion of, or all of, the peptide sequences. Vectors also include insertion vectors, used to integrate into another nucleic acid molecule sequence, such as into the cellular genome, to alter in situ expression of a gene and/or gene product. For example, an endogenous coding sequence can-be replaced via homologous recombination with all or part of the coding region containing one or more specifically introduced mutations.

[0169] The nucleic acid molecules are also useful for expressing antigenic portions of the proteins.

[0170] The nucleic acid molecules are also useful as probes for determining the chromosomal positions of the nucleic acid molecules by means of in situ hybridization methods. As indicated by the data presented in FIG. 3, the map position was determined to be on chromosome 12 by ePCR, and confinned with radiation hybrid mapping.

[0171] The nucleic acid molecules are also useful in making vectors containing the gene regulatory regions of the nucleic acid molecules of the present invention.

[0172] The nucleic acid molecules are also useful for designing ribozymes corresponding to all, or a part, of the mRNA produced from the nucleic acid molecules described herein.

[0173] The nucleic acid molecules are also useful for making vectors that express part, or all, of the peptides.

[0174] The nucleic acid molecules are also useful for constructing host cells expressing a part, or all, of the nucleic acid molecules and peptides.

[0175] The nucleic acid molecules are also useful for constructing transgenic animals expressing all, or a part, of the nucleic acid molecules and peptides.

[0176] The nucleic acid molecules are also useful as hybridization probes for determining the presence, level, form and distribution of nucleic acid expression. Experimental data as provided in FIG. 1 indicates that transporter proteins of the present invention are expressed in the pooled human melanocyte, fetal heart, and pregnant uterus detected by a virtual northern blot. In addition, PCR-based tissue screening panel indicates expression in human leukocytes.

[0177] Accordingly, the probes can be used to detect the presence of, or to determine levels of, a specific nucleic acid molecule in cells, tissues, and in organisms. The nucleic acid whose level is determined can be DNA or RNA. Accordingly, probes corresponding to the peptides described herein can be used to assess expression and/or gene copy number in a given cell, tissue, or organism. These uses are relevant for diagnosis of disorders involving an increase or decrease in transporter protein expression relative to normal results.

[0178] In vitro techniques for detection of MRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detecting DNA include Southern hybridizations and in situ hybridization.

[0179] Probes can be used as a part of a diagnostic test kit for identifying cells or tissues that express a transporter protein, such as by measuring a level of a transporter-encoding nucleic acid in a sample of cells from a subject e.g., MRNA or genomic DNA, or deteriining if a transporter gene has been mutated. Experimental data as provided in FIG. 1 indicates that transporter proteins of the present invention are expressed in the pooled human mlelanocyte, fetal heart, and pregnant uterus detected by a virtual northern blot. In addition, PCR-based tissue screening panel indicates expression in human leukocytes.

[0180] Nucleic acid expression assays are useful for drug screening to identify compounds that modulate transporter nucleic acid expression.

[0181] The invention thus provides a method for identifying a compound that can be used to treat a disorder associated with nucleic acid expression of the transporter gene, particularly biological and pathological processes that are mediated by the transporter in cells and tissues that express it. Experimental data as provided in FIG. 1 indicates expression in the pooled human melanocyte, fetal heart, and pregnant uterus and human leukocytes. The method typically includes assaying the ability of the compound to modulate the expression of the transporter nucleic acid and thus identifying a compound that can be used to treat a disorder characterized by undesired transporter nucleic acid expression. The assays can be performed in cell-based and cell-free systems. Cell-based assays include cells naturally expressing the transporter nucleic acid or recombinant cells genetically engineered to express specific nucleic acid sequences.

[0182] The assay for transporter nucleic acid expression can involve direct assay of nucleic acid levels, such as MRNA levels, or on collateral compounds involved in the signal pathway. Further, the expression of genes that are up- or down-regulated in response to the transporter protein signal pathway can also be assayed. In this embodiment the regulatory regions of these genes can be operably linked to a reporter gene such as luciferase.

[0183] Thus, modulators of transporter gene expression can be identified in a method wherein a cell is contacted with a candidate compound and the expression of mRNA determined. The level of expression of transporter mRNA in the presence of the candidate compound is compared to the level of expression of transporter MRNA in the absence of the candidate compound. The candidate compound can then be identified as a modulator of nucleic acid expression based on this comparison and be used, for example to treat a disorder characterized by aberrant nucleic acid expression. When expression of mRNA is statistically significantly greater in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of nucleic acid expression. When nucleic acid expression is statistically significantly less in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of nucleic acid expression.

[0184] The invention further provides methods of treatment, with the nucleic acid as a target, using a compound identified through drug screening as a gene modulator to modulate transporter nucleic acid expression in cells and tissues that express the transporter. Experimental data as provided in FIG. 1 indicates that transporter proteins of the present invention are expressed in the pooled human melanocyte, fetal heart, and pregnant uterus detected by a virtual northern blot. In addition, PCR-based tissue screening panel indicates expression in human leukocytes. Modulation includes both up-regulation (i.e. activation or agonization) or down-regulation (suppression or antagonization) or nucleic acid expression.

[0185] Altematively, a modulator for transporter nucleic acid expression can be a small molecule or drug identified using the screening assays described herein as long as the drug or small molecule inhibits the transporter nucleic acid expression in the cells and tissues that express the protein. Experimental data as provided in FIG. 1. indicates expression in the pooled human melanocyte, fetal heart, and pregnant uterus and human leukocytes.

[0186] The nucleic acid molecules are also useful for monitoring the effectiveness of modulating compounds on the expression or activity of the transporter gene in clinical trials or in a treatment regimen. Thus, the gene expression pattern can serve as a barometer for the continuing effectiveness of treatment with the compound, particularly with compounds to which a patient can develop resistance. The gene expression pattern can also serve as a marker indicative of a physiological response of the affected cells to the compound. Accordingly, such monitoring would allow either increased administration of the compound or the administration of alternative compounds to which the patient has not become resistant. Similarly, if the level of nucleic acid expression falls below a desirable level, administration of the compound could be commensurately decreased.

[0187] The nucleic acid molecules are also useful in diagnostic assays for qualitative changes in transporter nucleic acid expression, and particularly in qualitative changes that lead to pathology. The nucleic acid molecules can be used to detect-mutations in transporter genes and gene expression products such as mRNA. The nucleic acid molecules can be used as hybridization probes to detect naturally occurring genetic mutations in the transporter gene and thereby to determine whether a subject with the mutation is at risk for a disorder caused by the mutation. Mutations include deletion, addition, or substitution of one or more nucleotides in the gene, chromosomal rearrangement, such as inversion or transposition, modification of genomic DNA, such as aberrant methylation patterns or changes in gene copy number, such as amplification. Detection of a mutated form of the transporter gene associated with a dysfunction provides a diagnostic tool for an active disease or susceptibility to disease when the disease results from overexpression, underexpression, or altered expression of a transporter protein.

[0188] Individuals carrying mutations in the transporter gene can be detected at the nucleic acid level by a variety of techniques. FIG. 3 provides information on SNPs that have been identified in a gene encoding the transporter protein of the present invention. 69 SNP variants were found, including 14 indels (indicated by a “−”) and 1 SNPs in exons. As indicated by the data presented in FIG. 3, the map position was determined to be on chromosome 12 by ePCR, and confirmed with radiation hybrid mapping. Genomic DNA can be analyzed directly or can be amplified by using PCR prior to analysis. RNA or CDNA can be used in the same way. In some uses, detection of the mutation involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g. U.S. Pat. Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran et al., Science 241:1077-1080 (1988); and Nakazawa et al., PNAS 91:360-364 (1994)), the latter of which can be particularly useful for detecting point mutations in the gene (see Abravaya et al., Nucleic Acids Res. 23:675-682 (1995)). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers which specifically hybridize to a gene under conditions such that hybridization and amplification of the gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. Deletions and insertions can be detected by a change in size of the amplified product compared to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to normal RNA or antisense DNA sequences.

[0189] Alternatively, mutations in a transporter gene can be directly identified, for example, by alterations in restriction enzyme digestion patterns determined by gel electrophoresis.

[0190] Further, sequence-specific ribozymes (U.S. Pat. No. 5,498,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site. Perfectly matched sequences can be distinguished from mismatched sequences by nuclease cleavage digestion assays or by differences in melting temperature.

[0191] Sequence changes at specific locations can also be assessed by nuclease protection assays such as RNase and S1 protection or the chemical cleavage method. Furthermore, sequence differences between a mutant transporter gene and a wild-type gene can be determined by direct DNA sequencing. A variety of automated sequencing procedures can be utilized when performing the diagnostic assays (Naeve, C. W., (1995) Biotechniques 19:448), including sequencing by mass spectrometry (see, e.g., PCT International Publication No. WO 94/16101; Cohen et al, Adv. Chromatogr. 36:127-162 (1996); and Griffin et al., Appl. Biochem. Biotechnol. 38:147-159 (1993)).

[0192] Other methods for detecting mutations in the gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA duplexes (Myers et al., Science 230:1242 (1985)); Cotton et al., PNAS 85:4397 (1988); Saleeba et al., Meth. EnzymoL 21 7:286-295 (1992)), electrophoretic mobility of mutant and wild type nucleic acid is compared (Orita et al., PNAS 86:2766 (1989); Cotton et al., Mutat. Res. 285:125-144 (1993); and Hayashi et al, Genet. Anal. Tech. Appl. 9:73-79 (1992)), and movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (Myers et al., Nature 313:495- (1985)). Examples of other techniques for detecting point mutations include selective oligonucleotide hybridization, selective amplification, and selective primer extension.

[0193] The nucleic acid molecules are also useful for testing an individual for a genotype that while not necessarily causing the disease, nevertheless affects the treatment modality. Thus, the nucleic acid molecules can be used to study the relationship between an individual's genotype and the individual's response to a compound used for treatment (pharmacogenomic relationship). Accordingly, the nucleic acid molecules described herein can be used to assess the mutation content of the transporter gene in an individual in order to select an appropriate compound or dosage regimen for treatment. FIG. 3 provides information on SNPs that have been identified in a gene encoding the transporter protein of the present invention. 69 SNP variants were found, including 14 indels (indicated by a and 1 SNPs in exons.

[0194] Thus nucleic acid molecules displaying genetic variations that affect treatment provide a diagnostic target that can be used to tailor treatment in an individual. Accordingly, the production of recombinant cells and animals containing these polymorphisms allow effective clinical design of treatment compounds and dosage regimens.

[0195] The nucleic acid molecules are thus useful as antisense constructs to control transporter gene expression in cells, tissues, and organisms. A DNA antisense nucleic acid molecule is designed to be complementary to a region of the gene involved in transcription, preventing transcription and hence production of transporter protein. An antisense RNA or DNA nucleic acid molecule would hybridize to the mRNA and thus block translation of mRNA into transporter protein.

[0196] Alternatively, a class of antisense molecules can be used to inactivate mRNA in order to decrease expression of transporter nucleic acid. Accordingly, these molecules can treat a disorder characterized by abnormal or undesired transporter nucleic acid expression. This technique involves cleavage by means of ribozymes containing nucleotide sequences complementary to one or more regions in the mRNA that attenuate the ability of the mRNA to be translated. Possible regions include coding regions and particularly coding regions corresponding to, the catalytic and other functional activities of the transporter protein, such as ligand binding.

[0197] The nucleic acid molecules also provide vectors for gene therapy in patients containing cells that are aberrant in transporter gene expression. Thus, recombinant cells, which include the patient's cells that have been engineered ex vivo and returned to the patient, are introduced into an individual where the cells produce the desired transporter protein to treat the individual.

[0198] The invention also encompasses kits for detecting the presence of a transporter nucleic acid in a biological sample. Experimental data as provided in FIG. 1. indicates that transporter proteins of the present invention are expressed in the pooled human melanocyte, fetal heart, and pregnant uterus detected by a virtual northern blot. In addition, PCR-based tissue screening panel indicates expression in human leukocytes. For example, the kit can comprise reagents such as a labeled or labelable nucleic acid or agent capable of detecting transporter nucleic acid in a biological sample; means for determining the amount of transporter nucleic acid in the sample; and means for comparing the amount of transporter nucleic acid in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect transporter protein mRNA or DNA.

[0199] Nucleic Acid Arrays

[0200] The present invention further provides nucleic acid detection kits, such as arrays or microarrays of nucleic acid molecules that are based on the sequence information provided in FIGS. 1 and 3 (SEQ ID NOS:1 and 3).

[0201] As used herein “Arrays” or “Microarrays” refers to an array of distinct polynucleotides or oligonucleotides synthesized on a substrate, such as paper, nylon or other type of membrane, filter, chip, glass slide, or any other suitable solid support.. In one embodiment, the microarray is prepared and used according to the methods described in U.S. Pat. No. 5,837,832, Chee et al., PCT application W095/11995 (Chee et al.), Lockhart, D. J. et al. (1996; Nat. Biotech. 14: 1675-1680) and Schena, M. et al. (1996; Proc. Natl. Acad. Sci. 93: 10614-10619), all of which are incorporated herein in their entirety by reference. In other embodiments, such arrays are produced by the methods described by Brown et al., U.S. Pat. No. 5,807,522.

[0202] The microarray or detection kit is preferably composed of a large number of unique, single-stranded nucleic acid sequences, usually either synthetic antisense oligonucleotides or fragments of cDNAs, fixed to a solid support. The oligonucleotides are preferably about 6-60 nucleotides in length, more preferably 15-30 nucleotides in length, and most preferably about 20-25 nucleotides in length. For a certain type of microarray or detection kit, it may be preferable to use oligonucleotides that are only 7-20 nucleotides in length. The microarray or detection kit may contain oligonucleotides that cover-the known 5′, or 3′, sequence, sequential oligonucleotides that cover the full length sequence; or unique oligonucleotides selected from particular areas along the length of the sequence. Polynucleotides used in the microarray or detection kit may be oligonucleotides that are specific to a gene or genes of interest.

[0203] In order to produce oligonucleotides to a known sequence for a microarray or detection kit, the gene(s) of interest (or an ORF identified from the contigs of the present invention) is typically examined using a computer algorithm which starts at the 5′ or at the 3′ end of the nucleotide sequence. Typical algorithms will then identify oligomers of defined length that are unique to the gene, have a GC content within a range suitable for hybridization, and lack predicted secondary structure that may interfere with hybridization. In certain situations it may be appropriate to use pairs of oligonucleotides on a microarray or detection kit. The “pairs” will be identical, except for one nucleotide that preferably is located in the center of the sequence. The second oligonucleotide in the pair (mismatched by one) serves as a control. The number of oligonucleotide pairs may range from two to one million. The oligomers are synthesized at designated areas on a substrate using a light-directed chemical process. The substrate may be paper, nylon or other type of membrane, filter, chip, glass slide or any other suitable solid support.

[0204] In another aspect, an oligonucleotide may be synthesized on the surface of the substrate by using a chemical coupling procedure and an ink jet application apparatus, as described in PCT application W095/251116 (Baldeschweiler et al.) which is incorporated herein in its entirety by reference. In another aspect, a “gridded” array analogous to a dot (or slot) blot may be used to arrange and link cDNA fragments or oligonucleotides to the surface of a substrate using a vacuum system, thermal, UV, mechanical or chemical bonding procedures. An array, such as those described above, may be produced by hand or by using available devices (slot blot or dot blot apparatus), materials (any suitable solid support), and machines (including robotic instruments), and may contain 8, 24, 96, 384, 1536, 6144 or more oligonucleotides, or any other number between two and one million which lends itself to the efficient use of commercially available instrumentation.

[0205] In order to conduct sample analysis using a microarray or detection kit, the RNA or DNA from a biological sample is made into hybridization probes. The mRNA is isolated, and cDNA is produced and used as a template to make antisense RNA (aRNA). The aRNA is amplified in the presence of fluorescent nucleotides, and labeled probes are incubated with the microarray or detection kit so that the probe sequences hybridize to complementary oligonucleotides of the microarray or detection kit. Incubation conditions are adjusted so that hybridization occurs with precise complementary matches or with various degrees of less complementarity. After removal of nonhybridized probes, a scanner is used to determine the levels and patterns of fluorescence. The scanned images are examined to determine degree of complementarity and the relative abundance of each oligonucleotide sequence on the microarray or detection kit. The biological samples may be obtained from any bodily fluids (such as blood, urine, saliva, phlegm, gastric juices, etc.), cultured cells, biopsies, or other tissue preparations. A detection system may be used to measure the absence, presence, and amount of hybridization for all of the distinct sequences simultaneously. This data may be used for large-scale correlation studies on the sequences, expression patterns, mutations, variants, or polymorphisms among samples.

[0206] Using such arrays, the present invention provides methods to identify the expression of the transporter proteins/peptides of the present invention. In detail, such methods comprise incubating a test sample with one or more nucleic acid molecules and assaying for binding of the nucleic acid molecule with components within the test sample. Such assays will typically involve arrays comprising many genes, at least one of which is a gene of the present invention and or alleles of the transporter gene of the present invention. FIG. 3 provides information on SNPs that have been identified in a gene encoding the transporter protein of the present invention. 69 SNP variants were found, including 14 indels (indicated by a “−”) and 1 SNPs in exons.

[0207] Conditions for incubating a nucleic acid molecule with a test sample vary. Incubation conditions depend on the format employed in the assay, the detection methods employed, and the type and nature of the nucleic acid molecule used in the assay. One skilled in the art will recognize that any one of the commonly available hybridization, amplification or array assay formats can readily be adapted to employ the novel fragments of the Human genome disclosed herein. Examples of such assays can be found in Chard, T, An Introduction to Radioimmunoassay and Related Techniques, Elsevier Science Publishers, Amsterdam, The Netherlands (1986); Bullock, G. R. et al, Techniques in Immunocytochemistry, Academic,Press, Orlando, Fla. Vol. 1 (1982), Vol. 2 (1983), Vol. 3 (1985); Tijssen, P., Practice and Theory of Enzyme Immunoassays: Laboratory Techniques in Biochemistry and Molecular Biology, Elsevier Science Publishers, Amsterdam, The Netherlands (1985).

[0208] The test samples of the present invention include cells, protein or membrane extracts of cells. The test sample used in the above-described method will vary based on the assay format, nature of the detection method and the tissues, cells or extracts used as the sample to be assayed. Methods for preparing nucleic acid extracts or of cells are well known in the art and can be readily be adapted in order to obtain a sample that is compatible with the system utilized.

[0209] In another embodiment of the present invention, kits are provided which contain the necessary reagents to carry out the assays of the present invention.

[0210] Specifically, the invention provides a compartmentalized kit to receive, in close confinement, one or more containers which comprises: (a) a first container comprising one of the nucleic acid molecules that can bind to a fragment of the Human genome disclosed herein; and (b) one or more other containers comprising one or more of the following: wash reagents, reagents capable of detecting presence of a bound nucleic acid.

[0211] In detail, a compartmentalized kit includes any kit in which reagents are contained in separate containers. Such containers include small glass containers, plastic containers, strips of plastic, glass or paper, or arraying material such as silica. Such containers allows one to efficiently transfer reagents from one compartment to another compartment such that the samples and reagents are not cross-contaminated, and the agents or solutions of each container can be added in a quantitative fashion from one compartment to another. Such containers will include a container which will accept the test sample, a container which contains the nucleic acid probe, containers which contain wash reagents (such as phosphate buffered saline, Tris-buffers, etc.), and containers which contain the reagents used to detect the bound probe. One skilled in the art will readily recognize that the previously unidentified transporter gene of the present invention can be routinely identified using the sequence information disclosed herein can be readily incorporated into one of the established kit formats which are well known in the art, particularly expression arrays.

[0212] Vectors/host cells

[0213] The invention also provides vectors containing the nucleic acid molecules described herein. The term “vector” refers to a vehicle, preferably a nucleic acid molecule, which can transport the nucleic acid molecules. When the vector is a nucleic acid molecule, the nucleic acid molecules are covalently linked to the vector nucleic acid. With this aspect of the invention, the vector includes a plasmid, single or double stranded phage, a single or double stranded RNA or DNA viral vector, or artificial chromosome, such as a BAC, PAC, YAC, OR MAC.

[0214] A vector can be maintained in the host cell as an extrachromosomal element where it replicates and produces additional copies of the nucleic acid molecules. Alternatively, the vector may integrate into the host cell genome and produce additional copies of the nucleic acid molecules when the host cell replicates.

[0215] The invention provides vectors for the maintenance (cloning vectors) or vectors for expression (expression vectors) of the nucleic acid molecules. The vectors can function in procaryotic or eukaryotic cells or in both (shuttle vectors).

[0216] Expression vectors contain cis-acting regulatory regions that are operably linked in the vector to the nucleic acid molecules such that transcription of the nucleic acid molecules is allowed in a host cell. The nucleic acid molecules can be introduced into the host cell with a separate nucleic acid molecule capable of affecting transcription. Thus, the second nucleic acid molecule may provide a trans-acting factor interacting with the cis-regulatory control region to allow transcription of the nucleic acid molecules from the vector. Alternatively, a trans-acting factor may be supplied by the host cell. Finally, a trans-acting factor can be produced from the vector itself. It is understood, however, that in some embodiments, transcription and/or translation of the nucleic acid molecules can occur in a cell-free system.

[0217] The regulatory sequence to which the nucleic acid molecules described herein can be operably linked include promoters for directing mRNA transcription. These include, but are not limited to, the left promoter from bacteriophage X, the lac, TRP, and TAC promoters from E. coli, the early and late promoters from SV40, the CMV immediate early promoter, the adenovirus early and late promoters, and retrovirus long-terminal repeats.

[0218] In addition to control regions that-promote transcription, expression vectors may also include regions that modulate transcription, such as repressor binding sites and enhancers. Examples include the SV40 enhancer, the cytomegalovirus immediate early enhancer, polyoma enhancer, adenovirus enhancers, and retrovirus LTR enhancers.

[0219] In addition to containing sites for transcription initiation and control, expression vectors can also contain sequences necessary for transcription termination and, in the transcribed region a ribosome binding site for translation. Other regulatory control elements for expression include initiation and termination codons as well as polyadenylation signals. The person of ordinary skill in the art would be aware of the numerous regulatory sequences that are useful in expression vectors. Such regulatory sequences are described, for example, in Sambrook et al., Molecular Cloning: A Laboratory Manual. 2nd. ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1989).

[0220] A variety of expression vectors can be used to express a nucleic acid molecule. Such vectors include chromosomal, episomal, and virus-derived vectors, for example vectors derived from bacterial plasmids, from bacteriophage, from yeast episomes, from yeast chromosomal elements, including yeast artificial chromosomes, from viruses such as baculoviruses, papovaviruses such as SV40, Vaccinia viruses, adenoviruses, poxviruses, pseudorabies viruses, and retroviruses. Vectors may also be derived from combinations of these sources such as those derived from plasmid and bacteriophage genetic elements, e.g. cosmids and phagemids. Appropriate cloning and expression vectors for prokaryotic and eukaryotic hosts are described in Sambrook et al., Molecular Cloning: A Laboratory Manual. 2nd. ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1989).

[0221] The regulatory sequence may provide constitutive expression in one or more host cells (i.e. tissue specific) or may provide for inducible expression in one or more cell types such as by temperature, nutrient additive, or exogenous factor such as a hormone or other ligand. A variety of vectors providing for constitutive and inducible expression in prokaryotic and eukaryotic hosts are well known to those of ordinary skill in the art.

[0222] The nucleic acid molecules can be inserted into the vector nucleic acid by well-known methodology. Generally, the DNA sequence that will ultimately be expressed is joined to an expression vector by cleaving the DNA sequence and the expression vector with one or more restriction enzymes and then ligating the fragments together. Procedures for restriction enzyme digestion and ligation are well known to-those of ordinary skill in the art.

[0223] The vector containing the appropriate nucleic acid molecule can be introduced into an appropriate host cell for propagation or expression using well-known techniques. Bacterial cells include, but are not limited to, E. coli, Streptomyces, and Salmonella typhimurium. Eukaryotic cells include, but are not limited to, yeast, insect cells such as Drosophila, animal cells such as COS and CHO cells, and plant cells.

[0224] As described herein, it may be desirable to express the peptide as a fusion protein. Accordingly, the invention provides fusion vectors that allow for the production of the peptides. Fusion vectors can increase the expression of a recombinant protein, increase the solubility of the recombinant protein, and aid in the purification of the protein by acting for example as a ligand for affinity purification. A proteolytic cleavage site may be introduced at the junction of the fusion moiety so that the desired peptide can ultimately be separated from the fusion moiety. Proteolytic enzymes include, but are not limited to, factor Xa, thrombin, and enterotransporter. Typical fusion expression vectors include pGEX (Smith et al., Gene 67:31-40 (1988)), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein. Examples of suitable inducible non-fusion E. coli expression vectors include pTrc (Amann et al., Gene 69:301-315 (1988)) and pET 1 Id (Studier et al., Gene Expression Technology: Methods in Enzymology 185:60-89 (1990)).

[0225] Recombinant protein expression can be maximized in host bacteria by providing a genetic background wherein the host cell has an impaired capacity to proteolytically cleave the recombinant protein. (Gottesman, S., Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990) 119-128). Alternatively, the sequence of the nucleic acid molecule of interest can be altered to provide preferential codon usage for a specific host cell, for example E. coli. (Wada et al., Nucleic Acids Res. 20:2111-2118 (1992)).

[0226] The nucleic acid molecules can also be expressed by expression vectors that are operative in yeast. Examples of vectors for expression in yeast e.g., S. cerevisiae include pYepSec1 (Baldari, et al., EMBO J. 6:229-234 (1987)), pMFa (Kujan et al., Cell 30:933-943 (1982)), pJRY88. (Schultz et al, Gene 54:113-123. (1987)), and pYES2 (Invitrogen Corporation, San Diego, Calif.).

[0227] The nucleic acid molecules can also be expressed in insect cells using, for example, baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., Sf 9 cells) include the pAc series (Smith et al., Mol. Cell Biol. 3:2156-2165 (1983)) and the pVL series (Lucklow et al., Virology 170:31-39 (1989)).

[0228] In certain embodiments of the invention, the nucleic acid molecules described herein are expressed in mammalian cells using mammalian expression vectors. Examples of mammalian expression vectors include pCDM8 (Seed, B. Nature 329:840(1987)) and pMT2PC (Kaufman et al, EMBO J. 6:187-195 (1987)).

[0229] The expression vectors listed herein are provided by way of example only of the well-known vectors available to those of ordinary skill in the art that would be useful to express the nucleic acid molecules. The person of ordinary skill in the art would be aware of other vectors suitable for maintenance propagation or expression of the nucleic acid molecules described herein. These are found for example in Sambrook, J., Fritsh, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.

[0230] The invention also encompasses vectors in which the nucleic acid sequences described herein are cloned into the vector in reverse orientation, but operably linked to a regulatory sequence that permits transcription of antisense RNA. Thus, an antisense transcript can be produced to all, or to a portion, of the nucleic acid molecule sequences described herein, including both coding and non-coding regions. Expression of this antisense RNA is subject to each of the parameters described above in relation to expression of the sense RNA (regulatory sequences, constitutive or inducible expression, tissue-specific expression).

[0231] The invention also relates to recombinant host cells containing the vectors described herein. Host cells therefore include prokaryotic cells, lower eukaryotic cells such as yeast, other eukaryotic cells such as insect cells, and higher eukaryotic cells such as mammalian cells.

[0232] The recombinant host cells are prepared by introducing the vector constructs described herein into the cells by techniques readily available to the person of ordinary skill in the art. These include, but are not limited to, calcium phosphate transfection, DEAE-dextran-mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, lipofection, and other techniques such as those found in Sambrook, et al. (Molecular Cloning: A Laboratory Manual 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989).

[0233] Host cells can contain more than one vector. Thus, different nucleotide sequences can be introduced on different vectors of the same cell. Similarly, the nucleic acid molecules can be introduced either alone or with other nucleic acid molecules that are not related to the nucleic acid molecules such as those providing trans-acting factors for expression vectors. When more than one vector is introduced into a cell, the vectors can be introduced independently, co-introduced or joined to the nucleic acid molecule vector.

[0234] In the case of bacteriophage and viral vectors, these can be introduced into cells as packaged or encapsulated virus by standard procedures for infection and transduction. Viral vectors can be replication-competent or replication-defective. In the case in which viral replication is defective, replication will occur in host cells providing functions that complement the defects.

[0235] Vectors generally include selectable markers that enable the selection of the subpopulation of cells that contain the recombinant vector constructs. The marker can be contained in the same vector that contains the nucleic acid molecules described herein or may be on a separate vector. Markers include tetracycline or ampicillin-resistance genes for prokaryotic host cells and dihydrofolate reductase or neomycin resistance for eukaryotic host cells. However, any marker that provides selection for a phenotypic trait will be effective.

[0236] While the mature proteins can be produced in bacteria, yeast, mammalian cells, and other cells under the control of the appropriate regulatory sequences, cell-free transcription and translation systems can also be used to produce these proteins using RNA derived from the DNA constructs described herein.

[0237] Where secretion of the peptide is desired, which is difficultAto achieve with multi-transmembrane domain containing proteins such as transporters, appropriate secretion signals are incorporated into the vector. The signal sequence can be endogenous to the peptides or heterologous to these peptides.

[0238] Where the peptide is not secreted into the medium, which is typically the case with transporters, the protein can be isolated from the host cell by standard disruption procedures, including freeze thaw, sonication, mechanical disruption, use of lysing agents and the like. The peptide can then be recovered and purified by well-known purification methods including ammonium sulfate precipitation, acid extraction, anion or cationic exchange chromatography, phosphocellulose chromatography, hydrophobic-interaction chromatography, affinity chromatography, hydroxylapatite chromatography, lectin chromatography, or high performance liquid chromatography.

[0239] It is also understood that depending upon the host cell in recombinant production of the peptides described herein, the peptides can have various glycosylation patterns, depending upon the cell, or maybe non-glycosylated as when produced in bacteria. In addition, the pepfides may include an initial mnodified methionine in some cases as a result of a host-mediated process.

[0240] Uses of Vectors and Host Cells

[0241] The recombinant host cells expressing the peptides described herein have a variety of uses. First, the cells are useful for producing a transporter protein or peptide that can be further purified to produce desired amounts of transporter protein or fragments. Thus, host cells containing expression vectors are useful for peptide production.

[0242] Host cells are also useful for conducting cell-based assays involving the transporter protein or transporter protein fragments, such as those described above as well as other formats known in the art. Thus, a recombinant host cell expressing a native transporter protein is useful for assaying compounds that stimulate or inhibit transporter protein function.

[0243] Host cells are also useful for identifying transporter protein mutants im which these functions are affected. If the mutants naturally occur and give rise to a pathology, host cells containing the mutations are useful to assay compounds that have a desired effect on the mutant transporter protein (for example, stimulating or inhibiting function) which may not be indicated by their effect on the native transporter protein.

[0244] Genetically engineered host cells can be further used to produce non-human transgenic animals. A transgenic animal is preferably a mammal, for example a rodent, such as a rat or mouse, in which oneuor more of the cells of the animal include a transgene. A transgene is exogenous DNA that is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal in one or more cell types or tissues of the transgenic animal. These animals are usefuil for studying the function of a transporter protein and identifying and evaluating modulators of transporter protein activity. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, and amphibians.

[0245] A transgenic animal can be produced by introducing nucleic acid into the male pronuclei of a fertilized oocyte, e.g., by microinjecfion, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. Any of the transporter protein nucleofide sequences can be introduced as a transgene into the genome of a non-human animal, such as a mouse.

[0246] Any of the regulatory or other sequences useful in expression vectors can form part of the transgenic sequence. This includes intronic sequences and polyadenylation signals, if not already included. A tissue-specific regulatory sequence(s) can be operably linked to the transgene to direct expression of the transporter protein to particular cells.

[0247] Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Pat. Nos. 4,736,866 and 4,870,009, both by,Leder et al., U.S. Pat. No. 4,873,191 by Wagner et al. and in Hogan, B., Manipulating the Mouse Embryo, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986). Similar methods are used for production of other transgenic animals. A transgenic-founder animal can be identified based upon the presence of the transgene in its genome and/or expression of transgenic mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic arimals carrying a transgene can further be bred to other transgenic animals carrying other transgenes. A transgenic animal also includes animals in which the entire animal or tissues in the animal have been produced using the homologously recombinant host cells described herein.

[0248] In another embodiment, transgenic non-human animals can be produced which contain selected systems that allow for regulated expression of the transgene.. One example of such a system is the cre/loxP recombinase system of bacteriophage P1. For a description of the cre/loxP recombinase system, see, e.g., Lakso et al. PNAS 89:6232-6236 (1992). Another example of a recombinase system is the FLP recombinase system of S. cerevisiae (O'Gorman et al. Science 251:1351-1355 (1991). If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein is required. Such animals can be provided through the construction of “double” transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

[0249] Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, I. et al. Nature 385:810-813. (1997) and PCT International Publication Nos. WO 97/07668 and WO 97/07669. In brief, a cell, e.g., a somatic cell, from the transgenic animal can be isolated and induced to exit the growth cycle and enter G_(o) phase. The quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyst and then transferred to pseudopregnant female foster animal. The offspring born of this female foster animal will be a clone of the animal from which the cell, e.g., the somatic cell, is isolated.

[0250] Transgenic animals containing recombinant cells that express the peptides described herein are useful to conduct the assays described herein in an in vivo context. Accordingly, the various physiological factors that are present in vivo and that could effect ligand binding, transporter protein activation, and signal transduction, may not be evident from in vitro cell-free or cell-based assays. Accordingly, it is useful to provide non-human transgenic animals to assay in vivo transporter protein fimction, including ligand interaction, the effect of specific mutant transporter proteins on transporter protein function and ligand interaction, and the effect of chimeric transporter proteins. It is also possible to assess the effect of null mutations, that is mutations that substantially or completely eliminate one or more transporter protein functions.

[0251] All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the above-described modes for carrying out the invention which are obvious to those skilled in the field of molecular biology or related fields are intended to be within the scope of the following claims.

1 4 1 1811 DNA Homo sapiens 1 tcagaggtgc ccctcattca aaatgccttt taaagcattt gataccttca aagaaaaaat 60 tctgaaacct gggaaggaag gagtgaagaa cgccgtggga gattctttgg gaattttaca 120 aagaaaaatc gatgggacaa ctgaggaaga agataacatt gagctgaatg aagaaggaag 180 gccggtgcag acgtccaggc caagcccccc actctgcgac tgccactgct gcggcctccc 240 caagcgttac atcattgcta tcatgagtgg gctgggattc tgcatttcct ttgggatccg 300 gtgcaatctt ggagttgcca ttgtggaaat ggtcaacaat agcaccgtat atgttgatgg 360 aaaaccggaa attcagacag cacagtttaa ctgggatcca gaaacagtgg gccttatcca 420 tggatctttt ttctggggct atattatgac acaaattcca ggtggtttca tttcaaacaa 480 gtttgctgct aacagggtct ttggagctgc catcttctta acatcgactc tgaacatgtt 540 tattccctct gcagccagag tgcattacgg atgcgtcatg tgtgtcagaa ttctgcaagg 600 tttagtggag ggtgtgacct acccagcctg ccatgggatg tggagtaagt gggcaccacc 660 tttggagaga agccgactgg ccacaacctc tttttgtggt tcctatgcag gggcagtggt 720 tgccatgccc ctggctgggg tgttggtgca gtacattgga tggtcctctg tcttttatat 780 ttatggcatg tttgggatta tttggtacat gttttggctg ttgcaggcct atgagtgccc 840 agcagctcat ccaacaatat ccaatgagga gaagacctat atagagacaa gcataggaga 900 gggggccaac gtggttagtc taagtaaatt tagtacccca tggaaaagat ttttcacatc 960 tttgccggtt tatgcaatca ttgtggcaaa tttttgcaga agctggacct tttatttgct 1020 cctcataagt cagcctgctt attttgaaga ggtctttgga tttgcaataa gtaaggtggg 1080 tctcttgtca gcagtcccac acatggttat gacaatcgtt gtacctattg gaggacaatt 1140 ggctgattat ttaagaagca gacaaatttt aaccacaact gctgtcagaa aaatcatgaa 1200 ctgtggaggt tttggcatgg aggcaacctt actcctggtg gttggctttt cgcataccaa 1260 aggggtggct atctcctttc tggtacttgc tgtaggattt agtggcttcg ctatttcagg 1320 ttttaatgtc aaccacctgg acattgcccc acgctatgcc agcattctca tggggatctc 1380 aaacggagtg ggaaccctct ctggaatggt ctgtcccctc attgtcggtg caatgaccag 1440 gcacaagacc cgtgaagaat ggcagaatgt gttcctcata gctgccctgg tgcattacag 1500 tggtgtgatc ttctatggga tctttgcttc tggggagaaa caggagtggg ctgacccaga 1560 gaatctctct gaggagaaat gtggaatcat tgaccaggac gaattagctg aggagataga 1620 actcaaccat gagagttttg cgagtcccaa aaagaagatg tcttatggag ccacctccca 1680 gaattgtgaa gtccagaaga aggaatggaa aggacagaga ggagcgaccc ttgatgagga 1740 agagctgaca tcctaccaga atgaagagag aaacttctca actatatcct aatgtctgag 1800 aggcacttct g 1811 2 589 PRT Homo sapiens 2 Met Pro Phe Lys Ala Phe Asp Thr Phe Lys Glu Lys Ile Leu Lys Pro 1 5 10 15 Gly Lys Glu Gly Val Lys Asn Ala Val Gly Asp Ser Leu Gly Ile Leu 20 25 30 Gln Arg Lys Ile Asp Gly Thr Thr Glu Glu Glu Asp Asn Ile Glu Leu 35 40 45 Asn Glu Glu Gly Arg Pro Val Gln Thr Ser Arg Pro Ser Pro Pro Leu 50 55 60 Cys Asp Cys His Cys Cys Gly Leu Pro Lys Arg Tyr Ile Ile Ala Ile 65 70 75 80 Met Ser Gly Leu Gly Phe Cys Ile Ser Phe Gly Ile Arg Cys Asn Leu 85 90 95 Gly Val Ala Ile Val Glu Met Val Asn Asn Ser Thr Val Tyr Val Asp 100 105 110 Gly Lys Pro Glu Ile Gln Thr Ala Gln Phe Asn Trp Asp Pro Glu Thr 115 120 125 Val Gly Leu Ile His Gly Ser Phe Phe Trp Gly Tyr Ile Met Thr Gln 130 135 140 Ile Pro Gly Gly Phe Ile Ser Asn Lys Phe Ala Ala Asn Arg Val Phe 145 150 155 160 Gly Ala Ala Ile Phe Leu Thr Ser Thr Leu Asn Met Phe Ile Pro Ser 165 170 175 Ala Ala Arg Val His Tyr Gly Cys Val Met Cys Val Arg Ile Leu Gln 180 185 190 Gly Leu Val Glu Gly Val Thr Tyr Pro Ala Cys His Gly Met Trp Ser 195 200 205 Lys Trp Ala Pro Pro Leu Glu Arg Ser Arg Leu Ala Thr Thr Ser Phe 210 215 220 Cys Gly Ser Tyr Ala Gly Ala Val Val Ala Met Pro Leu Ala Gly Val 225 230 235 240 Leu Val Gln Tyr Ile Gly Trp Ser Ser Val Phe Tyr Ile Tyr Gly Met 245 250 255 Phe Gly Ile Ile Trp Tyr Met Phe Trp Leu Leu Gln Ala Tyr Glu Cys 260 265 270 Pro Ala Ala His Pro Thr Ile Ser Asn Glu Glu Lys Thr Tyr Ile Glu 275 280 285 Thr Ser Ile Gly Glu Gly Ala Asn Val Val Ser Leu Ser Lys Phe Ser 290 295 300 Thr Pro Trp Lys Arg Phe Phe Thr Ser Leu Pro Val Tyr Ala Ile Ile 305 310 315 320 Val Ala Asn Phe Cys Arg Ser Trp Thr Phe Tyr Leu Leu Leu Ile Ser 325 330 335 Gln Pro Ala Tyr Phe Glu Glu Val Phe Gly Phe Ala Ile Ser Lys Val 340 345 350 Gly Leu Leu Ser Ala Val Pro His Met Val Met Thr Ile Val Val Pro 355 360 365 Ile Gly Gly Gln Leu Ala Asp Tyr Leu Arg Ser Arg Gln Ile Leu Thr 370 375 380 Thr Thr Ala Val Arg Lys Ile Met Asn Cys Gly Gly Phe Gly Met Glu 385 390 395 400 Ala Thr Leu Leu Leu Val Val Gly Phe Ser His Thr Lys Gly Val Ala 405 410 415 Ile Ser Phe Leu Val Leu Ala Val Gly Phe Ser Gly Phe Ala Ile Ser 420 425 430 Gly Phe Asn Val Asn His Leu Asp Ile Ala Pro Arg Tyr Ala Ser Ile 435 440 445 Leu Met Gly Ile Ser Asn Gly Val Gly Thr Leu Ser Gly Met Val Cys 450 455 460 Pro Leu Ile Val Gly Ala Met Thr Arg His Lys Thr Arg Glu Glu Trp 465 470 475 480 Gln Asn Val Phe Leu Ile Ala Ala Leu Val His Tyr Ser Gly Val Ile 485 490 495 Phe Tyr Gly Val Phe Ala Ser Gly Glu Lys Gln Glu Trp Ala Asp Pro 500 505 510 Glu Asn Leu Ser Glu Glu Lys Cys Gly Ile Ile Asp Gln Asp Glu Leu 515 520 525 Ala Glu Glu Ile Glu Leu Asn His Glu Ser Phe Ala Ser Pro Lys Lys 530 535 540 Lys Met Ser Tyr Gly Ala Thr Ser Gln Asn Cys Glu Val Gln Lys Lys 545 550 555 560 Glu Trp Lys Gly Gln Arg Gly Ala Thr Leu Asp Glu Glu Glu Leu Thr 565 570 575 Ser Tyr Gln Asn Glu Glu Arg Asn Phe Ser Thr Ile Ser 580 585 3 66804 DNA Homo sapiens 3 aacctctttt tgtctgagtt tcctgccagt aaaattgggg aaaataagaa gttatttacc 60 acagagtctt gctgggaaga ttgtggtgat acttaaagag tgcttaacac agagccagga 120 ccctagaaag aactcaaaag atattagcaa tatttagcct accaaggatt cagcacggac 180 ttagttgaac ttaattcaaa ttttggataa tttggacagt ggcttgcaga ggatattgac 240 tggtcttgtg gaaatgactc ctggggagcc tgagagccta tagcctatga tttgtcagtc 300 gcatgcagac tggaggattg gaacacagga gcctcaaaga tgaagagttt tttttccacc 360 gcagcagcat ttacagaggc gtcatcctgc tgcccataaa tgtggccaca acttgcagcg 420 tttcagcccc agttcaacaa gtatttaggt aacgcccact ccctgccagg ctctgctagg 480 gcagaggaca ggtgatttgg aggcacagag gagggacatc tcaccttgcc catgcagttt 540 tctagaggat tgatatctta gcatgacctt agaaccccta gaagttaccc agttgaaggg 600 gtgcagagag ttacccaggc agagggcata gcttgagtaa agcccagagg caatagggag 660 cttgctgagt tcagtgaaat gaggatgtgg aaagcagagt gacaagaaga aagacttagg 720 gtcccaggga aaggccttgt gtgccatgat aaagaattgt attgtaaata gtgctgcaat 780 aaacatacgt gtggatgtgt ctttgtagta gaatgattag aatacatgga tacagagagg 840 ggaacatcac acaccggagc tggtcagggg ttggggggca aggagaggga gagcattagg 900 acaaatacct aatgcatgtg gggcttaaaa cctagatgat gggttgatag gtgcagcaaa 960 ccaccatggc acatgtatac ctatgtaaca aacctgcatg ttctgcacat gtatcctgga 1020 acttaaagta aaaaaaaaaa agtccatcta gagggagaaa aggggaaaaa acaaaaataa 1080 ttttatttat cctgaggaca atgaggagtc agtggagagt tctaagcagg ttctagatat 1140 cttccggctc agaaatcttc aattagatgg tcccaaatgg catctacgta tcatactttg 1200 agagagcctg ctctgttgat taggagcaaa taaatgtcct cctggatgta tgtggcctgg 1260 gttttgcatt tgggctactc aaatgcaagt tcctcgtggg accacatcca tgctagtggc 1320 tggctgaaaa acggcttcat gactctcatg aggggaataa aaggcatgga gtggtggctg 1380 tgagcctgtc tgcagggcca gacctcagaa aagcaaaggg ctgtaaatgt ttcataaatt 1440 tctctctggg tgcctgctct ggctgagagc ccattcataa gcccaggcgg ctgaggggca 1500 ggtattgtgc cggttactat agcatcacct tggaaagtct cacttggtga gagcggcagg 1560 cgagctgggg tggggcagga gggggacgcg gctggctgga ggggctggag ctaggccacg 1620 gatactgctg ctggtctcag gactcctggt ggtccggagc tcatgttagc gtccccagct 1680 gcagcccagg gagggagaga ggctgcgctc agtctgagag tggctgcctg agacagctgc 1740 cacaggctgc tgcagagcgt gcagcttttg caagggactg aattcccagc cagacacccc 1800 ttggactctt ttttggaggg gtggggagca gagagaggag ggagttgtct tatcttggaa 1860 gatccgagct gggtttcatc tcctttttga ttttgagtag ttccctccac gagaactgac 1920 ttccaggtgt tcaccaaggg aaacaaggtg gttctcacac tggaaatgag gaaggatgac 1980 agtttttgag actgactgtt aacggctcag aggtgcccct cattcaaaat gccttttaaa 2040 gcatttgata ccttcaaaga aaaaattctg aaacctggga aggaaggagt gaagaacgcc 2100 gtgggagatt ctttgggaat tttacaaagg taaagtttga atgcgaactt tagttccttt 2160 ctgagtagct tcgtattgcc aatgtgtgag agacttggta tcacgttttt aaaaccacac 2220 tttaatgagg agaggatggg tcagattaga tccttctgga gccccttcta gctccagtag 2280 tctatgcctg gaggaaaaac agatgcatga atagtattgg gttgtattag gaaaagatca 2340 agacaaatat gctgtttata tagctggatt agcactttct ggagatgatg atattgcata 2400 tggtatgttt ggcattgaat tagaaaatat ttagggagat aatattttat gttaactcat 2460 tagtaatgac aaatatgcct tgaactgaaa taatttttat gtttttcact gaatccacta 2520 taaatgaaaa ttaaatattt gcaattttta gcttatttaa taaaatacat aaagtggttc 2580 ctgattgtat agtttgcaaa gagaaggata gttacacatt aatttgaagg aagtaactta 2640 aaaaatgtct ttgaagcaga aaatctcaca taattgcagt gggaaaatgt taagtactat 2700 cactgaattg aatgagattt tagtccaaac caaaaagtaa atatttttta aagtaaaata 2760 tattaatgga aggagagttt gctataaatg attgaattaa tgtgacagtt taatttatga 2820 atttttatag acatagtaaa tgccttctca aattatataa atgatttcat aagtggtcct 2880 tatgtgcaag gtaaaatgac tgctttatct ctctgatata aataaatgtg aaaaataact 2940 ttgatacact ttttatttgt ttggatgatt atttctaatc ctggtgagtg aaaatgccat 3000 ctggtgtgtc cttttaactt ttctattatc tcttaaattt aaaaactttt tcatttaaat 3060 gactatttcc aggcaatctg agattcatcc catttcttgt gttttaaaac acatatgctc 3120 ctgtcagtgt taaattttcc catggtatca ctgttaatat taactttcct aataagaaaa 3180 aagagttgga caccttatta ttttagtaat tagaaacaaa aaagcttcaa tcagacctac 3240 actgaattag catgtctaga tgaaaaccta gctcagtgac agcagcataa accagccaaa 3300 tatagaaaaa attacaataa catttttttc agagtgtttt atccttccgt tgagcactcc 3360 ccaggtaacg tcttattgtg ttggcgttca tttgattaga aacgcaaaaa taatttttgc 3420 ataataagca cgatagctta attggcttat tcaagtaatg acaaaggaat ctggcaaagt 3480 caagaataaa aaccataggc cgggcgcagt ggctcacgcc tgtaatccca gcactttggg 3540 aggcggaagt gggaggatcg cttgaggcca gaagttcgag actagcctgg ggaacataga 3600 gagaccatgt ctctacagaa atacaaaaaa ttagccagca tgatggtgca tgcctgtcat 3660 ctcagcttcc caagaagtgg gagtattgct tgagcccaga cattcaaggt tgcagcgagc 3720 caagattgcg tctctgcact ccagctaggg tgacagagtc agactctgtc tcaaaaaata 3780 aaaaaataaa ataaatttaa aaacctatga cgttgggcca tagtcaccat tataaacagc 3840 aaactctgcc ttcatttata aaatatttga tataaaaata cttaggaatt ttcttttcaa 3900 ccttaagttt aattgctttt tgtgaaattt gattgctttt ttcaatagga attattgatc 3960 gaagagccgg ttttgctatg tttgattgga ggagctacat ggagatcttt ttgtttacaa 4020 aattgatttg cttagggata taacaaaatt ggcgattttc caaattgtgt gacctcaacc 4080 agaaattggg ctatgtgtct aggactgttt gaatagtttc ctcagaacaa tagaaaaaca 4140 gctagcacag tactagggac agagaatgca ctaaacaaat gctagatatt gtcatggttg 4200 tcctaattgt agaatggctt tagaaaaaat aaagccaagg tcaaatccct tttttcagtg 4260 atctatagag agaaattatt ggcagaagaa acgaaaacag acattgcttg agcggtgatc 4320 caagttgatc ctcagttcta gtgaggaatt atcaagacca gctctgccac gtgtttggca 4380 ttaatcacag gtgtataagg taattgtatg taaatgaccc tgcccagagc ctggcacata 4440 ctgggcattt ccctctcatt tcactgcttt tcacgtaaaa ccagttgaca gaatcccatg 4500 taaaaaaatc acaaagaact gttttctgtt ttgtaggagc ttttggaagc tagaagcccc 4560 tacattgtaa cttagaaggc aatgtaaatc acagctgtct aataatgttt gaggctgagg 4620 tcatcatcta aatggaattc ttgagatgct ttttaatcac agtgttcctc acagtcaggg 4680 gagtggcaat tgcacaggga agcatttgag agttcgcaca caggcttgat tacagtcagg 4740 catgattagc tttcctggaa aacagtcatt gataagaagc agctgagcaa ttaatcagct 4800 aaaggtaaaa taatatttta gaagtgcagg aagaaagaag atgcactcat ttatagttta 4860 gtattgaatt atatagatga catagaaagc attaaacttg gaaactaatg tccagaaagt 4920 gacatgcaga tttgttcaat ttaaattaca atttatgtgt cctttaattg ttcatgtcta 4980 aaaaacataa cagtgacaaa acagtatctt tcagacactg taaactcatt taattctatt 5040 aaaatcccca tgaagagggg attactataa ttacaacttt tctttttttt gggatagggt 5100 ctcactctgt tgcctaggct ggagtgcagt gatgtgatca tagctcactg cagcctcaaa 5160 ctcctggcct caagccatac tgcctccttg gcctcccaaa gtgctaggat tacaggcatg 5220 agccacagca tctagcaata attttacaga tgagaaaact gaggcacaga gaggttaagt 5280 agcttgccca aggtcacaca gctataaatg gaagagctag gtttcaaacc agatgttcta 5340 tgcccatcat tcttaatcac tacattatgt tacccctgta atcaagtgtc tttcctcttc 5400 ccactcactg tcttgatatt gggccactta tttaggttta gggaggtcta cttggactgc 5460 aatgtagcca gcaacttctg gatctgctgt caagtgtggg ctattctcct aatcagttgc 5520 atctttattg aaggctttct ccaagggagg cttaagggga gtctggtctc cttacaagta 5580 tgtctatctt ccctttaaat gaaactagtc cctgcatcgt gtctgtcttc agcattcagg 5640 agtgtgccag atatgcactt cctgctccat caacaaaggt gagtgtgtta aagcttgctc 5700 tgagatcagg tgatcctggg ttccaactgc tgcaacatcc tttacttccc tgcctgcatg 5760 acctcaggca acttggctgc aatggggtga ctctaggaaa ccaagtcaga tcacatctca 5820 cccctgctca aaactacctc actcagagtt aaagccagtg ccctttcaat ggccttcaag 5880 gacctctgtg atctaggact tttggaaggc tctctgagtt catctgtgac attttcctgc 5940 ctcactctac tctggattca cgggcctcct ggctcttatt agaactcccc cagattcact 6000 cctgtcccgg ctttcgccct gtttcttttg cttaaatgct ttcctcccag atagcctgat 6060 ggctcattcc ctcgctttct tcaagtatgt gctcaaagat ccccactttc ctggccattc 6120 tatttaaaca tgaagctcac ctgccctcct cctcctgccc tcttctctgt ccctctttcc 6180 tgctttactt cacctctgtc ttaggtaggt tccctaaaaa gcacagcctg agacagggat 6240 ttgggtgagc ctagaatgtg atttaatgag ctcttcctga aaaaactggg agggagtaaa 6300 acaagaaggg aaaggagagg ctgggtgtgg tggctcacgc ctataatcct agcattttgg 6360 gagtccgagg caggcagatt gcctgagctc aggagtttga gaccagcctg ggcaacatgg 6420 tgaaacctgt ctctactaaa agacaaaaaa tgagccaggc atagaggcat gtgcctatag 6480 tcgtagctac tcaggaggct gaggcaggag aattgcttga atccgggagg cagaggttgc 6540 agtgagccga gatcacacca ctgcactcca gcctggacga cagagggaga ctccatctcc 6600 aaaaaaaaca aaacaaaaaa aaacagaaag gagaaagagc caagcaagga tgcatgctca 6660 caatgcccag tggccagatc caaaggggaa ggctctggag cacaagcgat gtgctgagtc 6720 cttcctttgg ggcaagtggg gcagcctttt atatctctgc ctcagtcagt catcagctct 6780 gggctgatgg gggtgggtga ggggtttatt tggaggccac tgagcagtgg gaagttctcc 6840 agggttcctc atgccaggac tagaagccca ggcaaggagt caccatggtg gcaagggtca 6900 tgggtcctga tcctcaggag gaaccagaac tgtcacctca tcacgggagc aggaagagat 6960 gtgtttggca ctgaggtggt ccactcggac atctcctgat actgcctggg ctagttttat 7020 ttattttttt attttaattt ttaaaataat agagatgggg gtctcaccat gttgattagg 7080 ctggtcttaa actcctgggc tcaggagatc ttcctgcctt ggcctcccaa gtgctagaat 7140 tacaggcatg agccaccgca ccctgcctag ttttaactgc aaatgggaaa atacagcaac 7200 cgtgacctgc tagcagctct ggaagtagaa gtgtgcttgc ccatcaaggg gaactgggga 7260 gtgtgctatg gtgtctatga cagcccaccc actgcaccgc tcagatcaac ttgcttctca 7320 catgaagttc actccatcca ggtacagctt ctccaagact ctatggttgt aattcctgag 7380 gagccttcca aagaagagtt attaagacag actccaggcc ccactgtgat gactggtccc 7440 tcctctccac ccctttttga tttccctcac ttctgtttgc ttgtctgatg ggttgcccca 7500 gatcttcatc cctgagaggt ctaaatccct ggttaacata acctcaccag gtcatggttg 7560 ctgtatttgc ccactgacag ttaaaaacta gccaaggcag tatcaggaga tgtcccagca 7620 gatcatctgg gtgccaaaca tatttcttcc tgctcccatg atgaagcgac agttctgatt 7680 cctcctgaag attaggatcc atgaccctta tcactgtagt gacttcttac catgtcttct 7740 ggtcttggca cgaggacccc aaagtgactg agcagcagtc gtaaccatat gttgactagg 7800 atttccattg tgttcctaaa tggaagaatt cttccttgtg aatcgggatt tctagctcct 7860 cagagcctaa gctgaagaga tgagatattc ctcaggtggg ttactgggaa tgatggcgag 7920 tggggccact ccttctctca tgccttgttt ctttgacctg tgtgttctgc ccactgggca 7980 cacagcacca tatcataact gttgggtttt ttgtttgttt gtttgggatg gagtcccact 8040 ctgtcgccca ggctggatgc agcggcttga tctcagctca ctgcaacctc tgcctcctgg 8100 gttcaagcaa ttctcctgcc tcagcctcct gaatagtggg attacgggca cccaccacca 8160 tgcccggcta attttgtatt tttagtagag atggggtttc ggtatgttgg tcaggctggt 8220 ttcaaacacc tgacttcaaa tgatccaccc gccttggcct cccaaaatgc tggcgttaca 8280 ggtgcataac tgttgattta tggaatatac tgcatcctgg aagatagcac cttaccctcc 8340 cagggtttca tctccaagct gatgtcgcag ctgcatcttt aagaagcttc ttcagaggcc 8400 aggtgccatg gctcacacct gtaatcccag cactttggga ggccaacgca gatggatcat 8460 ttgaggtcag gagttggaga ccagcctggt caacatggtg aaacatatat tttctactaa 8520 aaatacaaaa aattgccagg cgtggtggtg ggcacctgta atcccaacta ctcaggaggc 8580 tgaggcagga gaattgcttg attaaaccca agggggaaga ggttgcagtg agctgagata 8640 gagccactgc actccagcct gggtgataga acaagattcc atctcaaaaa aaaaaaaaaa 8700 aaaaaaagct tctttagctc tggcaggctg tcagcttctg gatggtgtgg tatatggtgg 8760 ggcttgtgca tcccattgtc atgtgcccac tgctatgcca tcttcaccat aaattgggtg 8820 ttttggtctg aaaaaatgtg atgtgagatc ccatgttgag aaatcagaca ctgaatcctc 8880 agatagtgat gttggctgag acttgtagtc tgaataggca aactcataca tggaatattt 8940 caaccccagt caggatgaat tgctaccctt tccaggatgg aaggggtctg ttacaaacaa 9000 cttctgacca agagactggt ttgtcccctc aggaattgtg ccatctcagg ggctcagcat 9060 tagtcttgtt gctgaccgca gcaggagcta gctcagtcct ggtgagtggg agctccgaca 9120 tagcctccat ccctgctgcc atggttactc tgttcataag tgcactgctc tagcactggg 9180 tggctgagga cggaagctag ctgacatcaa ctggccaagt cagcctgcct atcgtctgtt 9240 ttgtgcctct tccaagtggc atgtgataat gtgcaatcag gagagctcat actaggcatc 9300 cactcataga ttgatccaca tctcttcccc agatcttttt cccagtcctc caatattgct 9360 ttaaatgtcc cctgacctcc agtgaggtca ttcaccactg cctatgagtc catgtatatc 9420 cttacctttg aatgtttctc ttttcataca aaatgtgtgg ccaggagact gctcaaaact 9480 ctgcctattg ggaggctttc cccctcactg tccttcaggg ccatccctgg gtgggctgaa 9540 gtatagcagc agtccatttg caacatgctc taacatacca aattgaccag ctctggacca 9600 aactaagttt tttttcctcc tgtaatttgt tcacaggtgt gagctcatgg agaggcattg 9660 gtatagtaga tataggtcag gtggaaaact ggcccctctg acatgggatt acttgtgtcc 9720 tgtggccctg ctggtgttag attccagatg gaccacttcc gtcttatgat ggacagttgg 9780 acttctcagg tctgatagaa cctagctcct gatgggtcgt tttggctgca tggtctcttg 9840 atattccatg gtcagatgct gtgtctccac caggactcag taacatgcca tgagatgttt 9900 tttgtctgtt gtatatttct ctactataga tgacaaggcc ttgtcccaga atcctaaggc 9960 tctatgctat atttctccta ttgagttttg ccagaaacct catatagtgt cttttcctat 10020 tcagatgact ttagtaccaa gggtatgctg gagaatacag ccctagtggc aagatcaccc 10080 ttattgcagc ctagacttgc tacagaacat tttcttgttt ttggatttca ttaaaaacca 10140 gcagcctttt atgtcatgga ataagtgggt tagaacaata ttcccaagtg ttgaatacac 10200 tgcctcaaaa acccaaagag gtctgccaac cattgtgctt cttccttagt ggcaggaagt 10260 tcaaagcaca ataacttttc cttcactttg aagggaatgt tctggaatgt ctcaaacact 10320 agactcctgt gaacttcgcc cacgtgatgg acctgtgatc tttgtagcaa ttatttctgg 10380 agcacacatg tcttactgag gcatccagag tacttgtcaa ttcttgctcc tgaggtctaa 10440 ataacataat gtcatctatt ggtcataata gatcaatgtg atgttctgca gcaggtccag 10500 aaggtctctc tgactatatt atgagagaga acaatccacg gatatatact gtcattcatc 10560 tcatgtcatt gtgaatttct tagcctcctt tctaatggat atggaaagaa tgcaccagat 10620 caagacaggc aagctatgta catgagttaa gagtgtggta gttccctgtc atccaccgtg 10680 atcccttctt tttttttttt tttttttttt cagggggtag gctggtgaat taccttggga 10740 tccaatgggg gctaccaccc ctgcatcctt taaatctctg aaggtgcaat aatctctgtc 10800 attctgcata atataatact gtttttgatt tatcttctta cacagggatg acagttttaa 10860 ggacttccat ttgacttttt tctattacaa tagcttttat tctacaagtc aaggaaccac 10920 ggaaagcgtt ttccaaatgc taggtgtctc tcttccaatt atacatgtgg gaattataca 10980 tgggggaatg accactggat gggtccatgg acatgaactc actatgagac gatcctgtgc 11040 caggactcca cttattacct gacccttata agccccactc taatggagga agaatagtgc 11100 tataaatctc tgagtatcaa catcaatttg cccctttatc caaaagtctg caaaagatag 11160 aggtatttct ctttcttcag tgtatgttta cccaaattaa tggtggtaga gtcctttggg 11220 gaaggactgt gggcatcatg actgcatttc cttctgtggt gttgcaggtt ccttagtcac 11280 ggaaccttcg gtcttctcct tcagtctttg gattctggcc tagaaactgg gcaagagagt 11340 gtgactttcc actggggtgg ccagcctcag cctactgccc attcatcagc tctttatctt 11400 ttctggtttt atgtatatga agcaataccc ttattggctg cccattttat ttttgttcct 11460 tggagcacca tgttctgtga gtcatctctg agattcctat gggctgattc cctaactgta 11520 gttctgaatt ttctgccctt acctatgatg gttaagtgct cccaatcatc ccaattgcca 11580 ctggttctgg agcagcacct tctactgtga gcctcagcca gaagaggaca gcagcttctg 11640 agcatcagtg gtgcctgtgg ccccatcacc actgcattcc ttattatctt aagagcagga 11700 gtattcctca ggcctcctga gaaatatagt tcgtttgtgg gttttctggt cttatataga 11760 aaatccattc ctgcatagtc atttatttga ggcttttgat ctttctttat aatctgctgt 11820 aacagttccc aacatttctc atttttaaag aaaataagtt aaagagagac cttttaattg 11880 atcaagagtg tgatcaacat taaagatata acaattatgg aattcttata ttccaaataa 11940 tagagatcaa aactttactt aaaggaatag aagatagcca atttaattat cagtaattca 12000 tcgctatgac tggttcaaat tcagcaattt ttataccagg cattaaaaaa tgaaataggc 12060 ttgtaaatta ggtttatata acaatgaagg aaaagagagg atgtagacct ggaccaacca 12120 aaataaggac actcttgtgg ccttaggcat tctctcctgg aatggataat tttttattct 12180 tttatttatt tatttattta tttgagacag ggtctcactc tgtcacctag gctggagtgc 12240 agtggcacaa tcatacctca cggcagcctc aacctcccag gctcaagtga tcctcccacc 12300 tcagcctcct gagtagctga gactacagtt gcgagccacc atgcttggct aatttttaaa 12360 atattctgta gagacgaagg tctcgctatg ttgcctagaa tggtctcgaa ctcctgggct 12420 caagccatcc tcccacctca gcctgccaaa ttgctgggat tacaggcgtg aacccctgtg 12480 cccagctttc aagttatttt ttttaaaagt catggtggcc atatcctgta tctctgtgta 12540 taatgtaata atgactagaa attagtacag aattatattt taaaagtcac caggctactc 12600 tggacatatc tattttgttt aagtttccaa gaaccgtatt agcagtttat caggatcatt 12660 tctcttaagg cctttgccgg gatgttagac cctgtgtcat gggaccatgc cccctttatt 12720 agtttcctag ggctgctgta acaaagtacc acaaactagg tagcttaaaa caacagaaac 12780 ttattctctc acaattctgg agaccagaag tccaaaccca aggtgttggc agggccaagc 12840 tcctcctgaa ggctcttaag gaggcctcat gcttgcctct tgctggctgc tggtagctgc 12900 tgggaatccc aggcgtgcct tggcttgtgg atgcattgct ccaattgctg catttgttgt 12960 cacatggtct tctcccctgg tgtctgtgtc tatgatttca aattcccctc ttcttataag 13020 gacaccagtc atgaaatcaa tctattatga cctcatgtta acttgattac atctgtgaag 13080 actccatttc caaataaggc tacattcaca ggtatcgggg gttagaacat caacatatct 13140 attttggagg acagaattca atctacctcc catattgatg aactctccct tatccaactt 13200 tattacccta ctccctccaa atctagtaca ttcaggatcc attcccgggc atactttcct 13260 gcttcttgat gtaaatgttc atcagattct acgactcctg ctcccagtat cttttcttag 13320 ctcaaaagtg tattttctca tctaaagttt atattctctc cttttacaac ttctcccaag 13380 tacttttaca acaatcaaat tttctaagtg cttcttaaag gttagtaagg cctatagatt 13440 caatacctac agagtaaagc aaccatatta tatattttga catagacaca ctacatatta 13500 acacatagaa ataggctcca cttctgcaag gaaatatgtt gtatcattca aagttcttag 13560 ttgcaatcaa cagaatacac tctagctaaa gtggaatgaa atttcgtaaa gaatgttaag 13620 aattgggctg ggggcaatgg ctcatccctg taatcccagc actttgggag gccaaggcag 13680 ggagaggatc acctgaggtc tggagtttga gaccagcctg gccaacatgg tgaaatccca 13740 tctctactaa aactacaaaa attagccagg catggtggta cgtgcctgta atcccagcta 13800 ctcaggaggc tgaggcagga gaactgcttg aacccaggag gcagacgttg cagtgagccg 13860 aaatcccacc actgcactcc agcctgggca acagagcaag actccatctc aaaaccataa 13920 attaataaaa aataaaagaa tgttaggaat tgttcagact tcctggaagg atcaggtctg 13980 gatgctgtat tctccaggaa aaagcagcag agaacatata ctgctagact gttctggata 14040 aaacacagct gccaccactg cctgcttcta agtgttgatt atattgatga cttgttccag 14100 aaattctgcc acagcagtca cagaggagcc agttgcctct gttgcatttg aaaccatctg 14160 cactgccatt cccctgcatg ctgtatcctc ttcttgttct gtcccgtatc taaatctcat 14220 tcaagtgctt tggatttagc agagtccacc tctcatgcct gcattgtagc tgcaagagag 14280 cctaggaaaa gtaggtgttt tttttgtttt tgtttttgtt gttttttatt ttgttttgtt 14340 tttgctgctc cagcaagatt caaaatatca agaattcatt aagatattgg acagctataa 14400 atgatggttg tctgctacat atgtgtgcta ctagtctaat ttttattttt caacttttga 14460 tacagacatg ggtacaaaac atatttttct aatgtcttga ttttaactac tagaaaagta 14520 acagtgcaag tataacgtta aatggcaact gagctcacta tggaagtgac aatagggagt 14580 ggtggggact gtggtaaatt gagagccaat tgtagccatg acagagtgag agcttgatta 14640 tttcaggtct tcagattttt caaaatgaac aagaaatcca aagttttata tgtttgcttg 14700 tttctgcttt tttgagctat ctcctgatat ttatttattt ttttatttat ttaatacaat 14760 ttttaaaagt agagatgggg gtcttactat gttgcccagg ctggtctcaa actcctggcc 14820 tcaagcaatc ctctcacctt ggcctcccaa agttccagga ttacaggtgt gagccactgt 14880 gctgggcctt ggtttttaaa ctctgtcaat taatctaaat ttatttttta ttttttattt 14940 tttatttttg agatggagtt ttgctcttgt cacccaggct ggagtgcaaa ggcacaatct 15000 cagctcacta caacctctgc ctcctgggtt caggcgattc tcctgcctca gccttctggg 15060 tagctgggat tacaggcatg caccaccatg tccagctaat tttgtattta taatagagat 15120 ggagttttgc catgttggcc aggctggtct tgaactcctg acctcaagtg atctgcatgc 15180 cttggcctac caaagtgctg gggttacagg catgagccac cgtgcccagc caattaatct 15240 aaattctaaa aaaaaaaaaa aaaaaaaaag caaagaccca tacacacatt ataccagata 15300 aacaaaacat ggctatgggc cacatatggc cattgggctt tcagcttgtc atctgtgact 15360 taggctttta aagccataga gactatcttt ttttcctctt gttcatctaa tgatccctgc 15420 tgaggtaaga agcagtgagt ctctgcttaa atggggggat aggaaagggt caaattacca 15480 ggaggaaaca aaaacagcat aggttaatac ctcaaaatct atgaagctgg gctgagtgct 15540 agggattttt ggttcctgac tttctgaaat tataatctac tggaagaggc aaatattaat 15600 ttaaaaatga gagacataga tactggggga gcattgactg ggctggcgtt ggccaggtgc 15660 actttattga gctccttttg aatgtggtgt gctgaaatcc atgctgataa gatcctattt 15720 caaatctcaa actagctctg gggatcgtat tttaaattct ccttcctttc tttaaaattt 15780 accatttatt gattatttat caagtgccag gaattatgct aagcattttg taactcggtc 15840 tcatttaacg ttcacagtag tcccatcttc ctttcataaa tgagggaact caggttgagg 15900 gaagttaggt aatttgctca aggccacata cctaataaat accacagtca gcattgaacc 15960 cagtactgtc tgtctccagg gcatgttctc tgaatcccac tgcaatactc ctccagaacc 16020 tttaaaaaaa agtctctgta ggtaaagcac tcgccattcg tcaggcgctt tctgattagt 16080 tcgtgtggca cactggtagc aataggctgg atagcaaatc tcagttgtgt tctcccttca 16140 ccagctgcag ctggatgatc cttgggcaag ttttttttgt ttgtttgttt tcttttcttt 16200 tgttttgttt tttaagtcag agttctcact ctgtcaccca ggctggagtg cagttcactg 16260 caaccgccac ctcccaggtt caagtgattc tcctgcttca gcctcctgag tagctgggat 16320 tacaggtgct tgccagcaca cccggctaac ttttttgtat ttttagtaga gatgggtttt 16380 caccatgttg gccaggctgg tcttgaactc tgagctcagg tgatccacct gccttggcct 16440 tccaaattgt tgggattaca gccgtgagcc accgtgccca gctgggcaag gttttaaata 16500 ttctgagtgt ctcagtcttc tgagcgtctc agtcttctga gcagtaagat ggggatatct 16560 cctatttgtc aagactattt tgagaattaa gggagataat atatatttta tagaaacctc 16620 gtggagtccc tagagtgtag caagtagtca acgtccttca gttaattttc ttcttccagt 16680 agaatagcaa ctcaaggatc gtgtaaaaga caacatgagc taaatgggac cttttcagag 16740 ggcaaatttg aatgctgtat ttgtttgcta gggctgccac aacaaaatac tacagaatgg 16800 gtggcttaac aaacagaaat ttattttctc acagttctgg aagctagaag tccaagatca 16860 aggtttgatt tctcctgagg cctttgtcct tggcttgcag atattgcctt cttgctatgt 16920 cctcagatgg ctttcctcta tgcatatgca tccctggtgt ctctgtgtgt ccaagtctct 16980 ttttatttat gtattttttt gaaacagggt ctcactctgt cacccagcct ggagtgcagt 17040 ggcgagatca tagttcactg cagtgtccaa ctcctgggct taagtgatcc tctcccctca 17100 gcctcccaag tagctgggac cacaggcatc catgccacca cacctggctc aaatgtcctc 17160 ttcttataag gacattattc atattagatg agggcccacc ctaagggcct catttaacca 17220 taattacgtc cttaagcacc tcatcctaaa tatagccaca tttggtggta ctgggggtta 17280 agacttcaac acatgaattt tgggtcacac atttcagttc ataccaaata cagtgagcaa 17340 gtaaattgat ttaaaaatac tgttttatat atatatttaa ctttagatag gctctctcta 17400 tattgcccat gctggtctcg aactcctggg ctcaagggat cctcctgcct cagcgtccca 17460 aactgctagg attgcaggcg tgagccacca cgcccagcca gtaaatggat ttttaaaata 17520 cgtaaaatta tctgcaagtt ctctcacttt gtgctccaaa tgttgatctt attacctatg 17580 aaacaaaaca aaacaaaacc ttttccgcaa ttagtgggaa catttgaatt gcaaagaaat 17640 agttctttaa gtgcctaagg actagttagc atatcttagg caattagacc cctggggctt 17700 ggatgtttgc tggacaactg tgcctgagaa cagagagcag gcacctccct agtgtgcaga 17760 gggccagcag tctgcagacc gcggctgtct atatttggag aaacaacaat gagaatgtca 17820 ctctagaaag aatgaagatt ctctgatcta aaagaccaac tgcagtcaag cagggaagga 17880 aaacgaaatg ggataaatag ctattatgga taattaaagt cctccaactc ctaagaaatg 17940 agttcgtttt tcttctctta ttcttaaata actttctcgt ctcctcccct ttttataaag 18000 ccttttttct gggcaggatg aatagatcct taaccctgtc tgtaagtgct tcaagccagg 18060 agtgatgtct ggaattgatc caccaattcc attcagttgg acaaggattc attgcttcca 18120 ggcacgatgc tgaacatgga gaataaagat gagttggaaa tggtcctggg atcagggaga 18180 ccttcattca tatatggaca caaatcagtg actttttttt tttttttttt tttttccgag 18240 acagagtctc gctctgtcac ccaggctgga gtgcaatggc accatctcgg ctcactgcaa 18300 cctccgcctc ctaggttcaa gagattctcc tgcctcagcc tcccgagtag ctgggattac 18360 aggtgccagc cactatgccc agctgatttt tgtattttta gtagagacgg ggtttcattc 18420 accatgttgg ttaggctggt ctcgaacccc taatttcagg tgatcctctc gcctcagcct 18480 tccaaagtgc tcagattaca ggcatgagcc actgtgcctg gcccaaatca gtggctattt 18540 acttagcacc tatgctgctg aatgaaaatg actctaactc catgtgagaa gtgttctaac 18600 agaggaatgt ataaaatgcc aaggaaacac cagggatggc agagacccta acgttcaggc 18660 aatgtctatt catttattgg tgataatgtg ttagtctttg tagggtcggc tcatgtatct 18720 ctgtgagata aatatttatt gtacagaaga ggatatgtga gattcagaga ggccaggtta 18780 tttgccccca agtcacacag ctcgcgtatc agtggcagag ctggaaatca aatccaggtt 18840 atctgactgc ccagaagcct ggtgtgttcc atgatacagg gtgagggggt tctgtcttcc 18900 tctgtgagct aggctataca agaaatggcc tgctatttga atgcttttaa aacaaatcaa 18960 atctggtcag gcatagtggt tcacacctat aatcccaaca ctctgggaga ctgagatggg 19020 tggattgctt gaggccagaa gttccacacc agcctggcca acacgctgaa accctgtctc 19080 tactaaaaat acaaaaatta gccgggcgtg gtggcctacg cctgtaatcc cagctactcg 19140 ggaggctgag gcacaagaat tgcttgaacc tgggaggcgg aagttgcagt gagccaagat 19200 tgcgccactg cactccaacc tgggtgacag tgcaagactc cgtctcaaaa aaataaataa 19260 aacaaaacaa atcaaatctg actctgagcc ccctgcctgg gggaagttag atttctgttc 19320 attttgatgc tccccttttg ccacagcaat attatgcaaa ggactcacaa acaactcagg 19380 aggtcctgct aattattgat cctcatttgc tcctgagccc atgatccctt gaagtggtgg 19440 ctcagctgcc actttgggca aagaaaagtg agatcctgtg ctcagacccc tccccacagc 19500 tcctgatatc ccatctccaa ctggagagct gctgtgaggg gctggcttca ggtcagccag 19560 ctgtaggtcc tgcttcttgt ggagcccaca gctccttctt tcagggcttt ccctttgatc 19620 gttactttcc ccttctttct ccccatctcc catactgtat gtcttccctc tggaaagtct 19680 cgggatgtct aagatgacac tgtgcacaca gagggtgctt gtgttggttc aggtcttcca 19740 agaaagcaga taccaagaca ggactcggca catacgagat atggtctcgc tctgttttcc 19800 aggctggagt gcagtggcac aatcacagct cactgcagcc tcaaactctt gagctcaagt 19860 gatcttcctg cctccgcctc ccaaagtact tggattacag gcatgagtta ctacacctgg 19920 ccaagagatt tattgaggga aaatggggaa ggagctggag gaggctgggg gagcattcaa 19980 actgctacct gtgtaggaga gagggaagga agaaaagcta ggtgggaaga ctttcagact 20040 atattacaat actgggacat tttggcatgg ccagtgcaga gtcctagagc cagtcgctgt 20100 cagaggagtc ctgcctctgg caggaaagaa cggcctcaca tccctgcggt gctcagttct 20160 tggcagaata acagcctgtg agaaagaggc gctgtcccca cgccaaatgg gtggttgatt 20220 cagagcacag cagctggggc tgtctgcaat taagcagtgc aaagctccac agcgctttca 20280 gttttcatta gccttcatct aaagcatctg catgtatata gagagcgcta agcttatgac 20340 tggtgacact ttattaatag caatagtgat agtacttacc acttattaat ataaagcact 20400 ttttacgtac caggcactgc cgtgaatcat ttacatgcat caatcattga acaaccctat 20460 gagataccca ttacgattag cccagtttag agatagggat tcttatgggc tgaattgtgt 20520 cttcatatgg atctgcccaa attcattatg gtgaaattct aaccctcagt acctcagaat 20580 atgagtatat ttggagatag ggtctttaaa aaggtaatta aggttaaatg aggtccttac 20640 ggtaggccct aatcgaatat gactgatgtc cttatatgaa gaaaaaattg ggacacacgg 20700 atacatagaa ggaagactat gtgaaggcac agggagaaga gagccatctg caagccaaaa 20760 agaaaggcct cagaagaaac caaggcctgc tgaaacctgg atctcagatt tctggctcta 20820 gaattgtagg aaaatacatt tctgttgttt aggccaccta gtttgtggtg ctttgttaca 20880 gcatccctgg aagactagta gaaggtcaag taacttagcc aaagtcacag agctagcaca 20940 agggagagat agcactgggc atctctcagt ccagagtcca ttctcttccc ctgctcttct 21000 gagtcatgat ggctgcgcaa ggactacaaa gtaacaggta cagatgacaa agtgactcag 21060 gaagatcatt gagaaggagc atggcctggt gtgctgggaa cacacaggaa agtggtccaa 21120 ggaacctaga cagcaaagga gaagggtttc atatcttgcc tctacccact aagggctgtg 21180 tgaccttggc caatttgttc ttgctttctg aactacagtt gtattttgtg tcaaatggga 21240 gtattagatt tcccatgtct cactgagctg tattaatgat caaataagag aattacatga 21300 aagtatctgt agaggagggc agagggagag aactgaattt gcctcataca atattactgt 21360 ggttgttaca tattatcctt gttttagctg ctaggaatat actattatag taatgtgtca 21420 atattagagc atcagttttc tttcttttct tttctttttt ttgagatgga gtctcactct 21480 gttacccagg ctggagtgca gcagtgcaat ctcagctcac tgtaacctct gcctccaagg 21540 ttcaagtgat tctcatgcct cagcctccgg agtagctggg actacaggtg ctcgccacca 21600 tgcctggcta atttttgcat ttttagtaga gacggggttt tgccgtgttg gtcagtctgg 21660 tctcgaactc ctgacctcag gtgatctgcc cacctcagct tctcaaagtg ctgggattac 21720 aggcgtgagc taccacgcca ggcctagagc atcagttttc catcctactt aagttacacg 21780 tatttggttg ccagaaattc atggagacta ctagggcagc ccattataaa gtcctatcat 21840 ccaactgcct ctcagagcta atggcatcaa tgctaagtct agcatcatag actcattaag 21900 tgacggtgag gattaacgta ataaaaatag ctggtatatg ttgcttttta ttatgtggca 21960 agttctgttc taaattacct aagtttgata actcatttat gacaatccta agaacaaccc 22020 tatgaagaag aaactattat aattcctagc ttacagatga agaaactgaa gtccagggag 22080 tttaagtaat taggctaaag tcacacagct gagtaagtgg gcgactcaac attcaaagta 22140 aggtacatga gctcctcagt tggacataga ttggagaagt gaggcatcca agatggcttc 22200 aagatatata tatatatata tttttttttt tttttttttt ttgagacgga gtctcactgt 22260 catgaagact ggaatgcaat gccgctatat cagctcactg cagcctccgc ctcccagatt 22320 caagtgattc tcctgcctca gtctcccgag tagctgggac tacaggcgcg tgccaccacg 22380 gccagctaat ttttgtattt ttagtagaga cggagtttgc catgttggcc aggctggtct 22440 cgaactcctg acctcaggtg atctacctgc cttggcctcc caaagtgctg ggattacagg 22500 cgtgagccac cgcgcccagc ctgatggctt caagattttt gctggagcaa ccaaagtagc 22560 aaaattgtca ttacttatga tgagaataac ttcaggaatt aatttttttt taggggaagt 22620 cagtttggac atgttaagtt taagctgcct tttaggtgtc caaggagatg tcagataagt 22680 ctagttataa agattgggag ctgttagcat atacatggta tctaaagccc agagcctgct 22740 tagatgtcca gagggcatag acagaaagca agagacccga gaatggagtc ctaggcattc 22800 tagtgtatat aggttgaggt aagaaggaat cagctataag agataaaaca gaagaattag 22860 gaggatgacc aagtgttttc ctggaaaaac ataaaatggc caagaaagag aaagtggtca 22920 attgtatcaa atgctgctgc taggttgatt aaatcagatg aggactgaaa atgacctttg 22980 gactgagcca tgaggagggc attgataacc ttaagtaggg cagttttggg ggctcaggtt 23040 gggaatacct ggctggagtg ggtccaggag agaacaggag gagaggaatt gaagacagtc 23100 atttctttct taaaaaaagg aaaatgagaa ataggaggat aactgaaaga gaaaatgtct 23160 tttattttag attctaatat gggaggaata aaagcttatt tataggcaac aggaatgatc 23220 tattatacta gggaggagaa cataatgaat gaagcgtggg ggtggggatt tctggagcaa 23280 tattcgtgag gggataaaag gggacaagat ctagtgtcca gggaaagggg ctggacttag 23340 ctagaagcat ggacaactgc atagacccca tcagtataaa tgcaggccgg caggtaggta 23400 ggtacattgg tagggaaatg gttaggttct tttccaattg ctttaatgtt ctggcacatt 23460 tactaagctt ctactctggg ctcaccggtt gaaattcaaa gctccttccc ttgttctacc 23520 attgcttttc actttgattt caataaaacc cacatcatcc agtaattata gctgcttgta 23580 tatgtgtctt tcttccccat cagcctaaga gctggaagaa ggcagataat atgtcacgtt 23640 gtctattgct ccccaatact tagcccagta cctgagacac agtaggcgct caatatatat 23700 ctgatgaact gaattgaatc cagtgtattt gtttctctat acttgtgccg gaaatttgat 23760 ttccttgagt cataagaacc tgccaaggtg ccgggggcgg tggctcacgc ctgtaatccc 23820 agcactttgg gaggccaagg tgggcggatc acgaggtcag gagatcgaaa ccatcctggc 23880 caacatgttg aaaccccgtc tctactaaaa atacaaaaat tatctgggtg tggtggcgca 23940 tggctgtaat cccagctact caggaagttg aggcaggaga attgcttgag ctagggagtc 24000 agagattgca gtgagccgag aatcgtgcca ctgcactcca gcctggcaac agaccgagat 24060 tccgtcccca aaaaaaaaaa aaaaagaacc tgccaaggtt atctttcata tgaacttgtg 24120 ggcaaatgac ttgtgtttta tccaaactat tgggttaacc attatattag ctatttatca 24180 ctgcatttaa tatttatgaa aacttgcaag ctttaattat ttttaaaaag acttggacct 24240 taagtgggcc atgacagtat cctcagaaag atgacaataa gtaagaggat acaacttcct 24300 ttataattga cagatagggt tccgtttgtc caattacttt ttttttaaaa gaagagataa 24360 attcactgta atgaatgtgc cataattgga atctatagag gtctaccatt tgaataaaag 24420 gtgctggatg atcacctcct tagaggaacc atctaaggag aaaaggatat acaaccaaat 24480 gggtgtgcat tgtgatagaa aatgtccctc tccacctcca cttagtattt tattaagact 24540 tagaaaaatt aggccgggca cagtgcctca cacctataat cccagcactt tgggaggctg 24600 aggcgggcgg atcatctgag tcgggagttt gagaccagcc tgaccaacat ggagaaaccc 24660 cgtctctact gaaaatacaa aaattagcct ggcatggtgg tgcagacctg taatcccagc 24720 tactcaggag gctgatgtga gagaatcgct tgaacctggg aagcagaggt tgcggggagc 24780 cgagatcgtg ccattgcatt ccagcctggg caacgggcaa caaaagcaaa actccgtctc 24840 aaaaaaaaaa aaaaaaaaag acttagaaag gttaaggtca actgtatcag ctgggtcgag 24900 caatgtgaac aaagtctgtc aatgctcttt cagcaggaaa tgcagtatag catattgttt 24960 tagacataga ctctggactt gggcctctat cctacctcaa atgacttagt ttcctcatct 25020 ataaaatgac atgatgacac tgtctacctc atggggttgt tataaaattt aaatgattga 25080 ttgaatgttt ataaaagtcc cacacaatac ccagaacatc agtagtttta gccactataa 25140 cttactttaa taataataat aatatttaat aataataata acttacttta ataataatag 25200 taatacctcc atagtattct actatgggtc ttcctttttg tttttcatct gctggtacct 25260 tttttctttt tgcttagtat actttctttt tcctttaatc ctggctttta ttttctgcct 25320 atcctttttc ccatgtagaa aaatcgatgg gacaactgag gaagaagata acattgagct 25380 gaatgaagaa ggaaggccgg tgcagacgtc caggccaagc cccccactct gcgactgcca 25440 ctgctgcggc ctccccaagc gttacatcat tgctatcatg agtgggctgg gattctgcat 25500 ttcctttggg atccggtgca atcttggagt tgccattgtg gaaatggtca acaatagcac 25560 cgtatatgtt gatggaaaac cggaaattca ggttggtatc agtccatggt ggaagacttt 25620 tctttttgag acagggtctc gctcggtctc ccaggctaga gtacagtggc acgatcttgg 25680 cttactgcag ccccaacctg ccaggttgaa attaacctcc catctcagca tcctcccatt 25740 tcagcatctc agataagtag ctcctcccat ctcagcatct cagcatctca gcatctcagc 25800 atctcagatc agtagctgag actacaatcc tgaggaaact gttgactgca gctgtgtcaa 25860 tactttgctc cttgagagaa agccctgcaa ttccttcagt gatatgacaa aaatggagag 25920 tggctacttg tgctgggcat tgtgcagaat gatggggata gaaaggtgaa tgacctagac 25980 tgagccctgt cctcatggag acaagtaagt gatgacagtt tgagggggta ggtgccacgt 26040 tggaggtaca caggattctt gggctcatag gagagggcac agcccagact tccctattgt 26100 gaacaaattc ccaaagtgat ggctggacca ggcaaagagg gtgtggtgtg gtgggaagaa 26160 gaatgtttga agaaaaaggt actgtgaagg actgtaagaa agagacagag agagagagag 26220 agagagagaa cgtacacatg ctatgtaggt atattttagg aactgaaaca ggagctcatc 26280 atcttttctg tgtcatggac tcctggagat gactaatgaa cctttgccaa agtaatgttt 26340 taagttctta aaataaaaca caaaggatga caaaagaagc caattatatt aaaatataaa 26400 taccaaaaca tttaaaaatc acatttgtga catagaaaca tatgggcttc tttagtagta 26460 catcagtgac aaaatctagt attgggtcta acatttactc tgattttaag ttggaatgta 26520 tgccattgtt ggaaatagtg gccatgactg taatacgatt tgaacatatt tgctatttcc 26580 acgtgggaca cagtcatagg tactagtcat atgacggtgg cttgttgcct acattcataa 26640 tggcagaaaa tgctaaattt tggttaagag tgaaaataaa gatgcatgtt ttcttcccat 26700 ccaagttctc agatgcacag gattccatcc acagactcca ggttgagaac tcccagtgat 26760 tgggtagagc acgttgaggt ggaggcagcg aagtaaatag ggggctgatc atccatagcc 26820 tggtaggcat gtagcaaggg gctgcaagca tggaatgatc acatctgtgc tccagattgt 26880 tcactgcccc attgcagggg gccagattga ggtaagatag gaatggaggc cacagggcca 26940 gttcagaggc catcatagtt ataagcaagg atacttcgaa gtgacttaaa tagtattgtt 27000 ttaggaatca ctggaaacat aaaatctggt ttgctgctta aacgatagac ctagagaagt 27060 actgaggtta tggggtaaaa gaaacaaaca aaaatgtctg cccagtggac accccataaa 27120 tgcatgtttc atcgtactaa actcacacac tgcaatgact catgcagaaa tccgttcatc 27180 tgcagagaga catttaatag ttctctggtc cctccctcta tttgaagaaa catttagatc 27240 acagtttttt gaactagtgt ctgggaaatc actgcactgc aggctgtgcc atgaagaagg 27300 cagtgcgaga cctggagccc atactgtgct gtgtcttatg agactttcca agagggagac 27360 gtggtaggca atattttctg gactgacttg atcatagaat gctctctttc atgccatatc 27420 tattagcatc atctggcaca gtctcctgcc aggcactggt ttgagaaaat ttgatttcaa 27480 tctgtcaaaa gaagtcttta gttggtctgc aagctatttg tttttgcttt tttcaaacca 27540 agagattatt ctgccagagg aaaacagcac catggagatc ctcctaacta gtctctattt 27600 gatgccacag ccaaatctgt cctaaaagga tatcctgtct tttgtggggt gtgggggata 27660 gaggtagaag ggcatatcat gcgtttttaa aataaagaat gatgtatatt agcaaggttt 27720 cagatgtgta tcacatgcat tctttcagcc ttttgtgagc aagaccagct aattaaaact 27780 tgtctgctga ggcccagatc aaaatgagat gctgttttgc atttgtttgt tgcctgaaaa 27840 gatagacctt ggtcaataga gtctgctctg aggcatatgg aaaagacatt ttgattaacc 27900 cgaggaacaa tgctagtgtg cgctctctag tttctacggc tgtgccctct ggagtcttag 27960 agaaactgat taaaatctga aatatggttt aaattttttt cctctggact caggagtagg 28020 aatttagtat cagtaactct agtacagctc taatttatag cagattattt ctcttgtccg 28080 cctagaacaa agcttagata tcaagtgagc atgttcaacc aaatgacaaa tactttgcta 28140 attgtattaa gaaaggctct gaatggctgg tatgtttgtt tggtttttct gttttaaggg 28200 aaaaactaga tatttggcac tgagatatct ttaaatcttt atttcaaaag aaggagagaa 28260 ataagcagta tgaataggta gatctttcaa atatgtggca tatgttctac aaggggtatg 28320 aagagtgatt ttaactaaag cgtgaacact tttttttttt tttgaaacgg gatctctgtt 28380 gcccaggctt tagtgaagtg gtgtgatcat agttcaccgc agccttgacc tcctgggctt 28440 aagtgatcct cccacttcag tttccaagta gctgggtcca caggctcatg ccaccattct 28500 tagctaatta aaaaaaattt tttttagaga tgggatcatg ccatgttgcc caggctgatc 28560 tcaaacccct ggcctcaagg gatcctcctg ccttggtctc ccaaagtgct gggacaagca 28620 tgcaccactg tgcctggccc atattttaaa tttaatagtt atgagttaaa acatgtgaac 28680 tcttagaaaa gtgtttggca tatagtaaga aaataaaatg accgaagttt gagaaacttg 28740 tgattttgtt ttctcattac tctcaggaaa agtccaaagt tcttcccatg gattgtgggc 28800 cctgtaggat tcagagcatg ggctttggaa ctggccagac ctggttttaa tgagctctgg 28860 gaccttgaat aagttgccct tgtgtcctgg tcagagattg ctggttgcga agaaatgtgc 28920 agtgaaactg gctcgagtta aaaggggatt attggggccc ggcatggtgg ctcatgcctg 28980 taatcccagc aatttgggag gccaaggtgg gtggatcacc tgaggtcagg agttctagac 29040 tagcctggcc aacatggtga aaccccatct ctactaaaaa atacaaaaaa tttggccaga 29100 catggtggcg cacacctgta gtaccagcta cttgggaagc tgaggcaaga gaatcctggc 29160 agttggaggt tgtagtgagt cgagatgtgt gagactccat ctaaacaaac aaacaaacaa 29220 acaaaaaatg gtagtgggga ttattgtagg gctgtaagag gatctcgtga aagccaaggg 29280 cagaaagcag gtctgtggtg tatgtgtgca gtctgcaccc aggacgcaga agccagcctg 29340 aggtggggct gaaacccagg ctgtcctcca ccctgaggag ggaagggagt ctttatgtaa 29400 ttctttctga ggccgcagga caggccctgc cagaagtgct gaatggagct ttccctcgtg 29460 ggaactagag aagcctttgc taaggtctcc agcttgcttg ccccacagag tctttcattg 29520 gcttttcttg gagtcagctc cgttttccct ggtccttcat ggactgcttt ctttcctctt 29580 ccctggcttc tcactgccct ccacagtgga agtgccttga gcctttgtct tgctaggaag 29640 ctgatttact tggccctgac tctgtgactc cgtgggactt atttgggttc aagagtgcac 29700 tattgtctaa ctagaatctc tgtgggtttg ggttgctgtc tctctctctc tctctgtgtg 29760 tgtgtgtgtg tgagagagag agagagagag agaaagagaa agagacagag acacagagag 29820 agggagaggc tgactggctg agcctagcct atggctttgc tgtcttaaac attttttttt 29880 tttttttttt ttgagacaga atcttcctct gttgcccagg ctggagtgcg gtgacatgat 29940 ctcagctcac tgcgacctcc acctccccgg ttcaagcgat tctactcctt aggctatcaa 30000 gtagctggga ttacaggtgc atgccacaac gcccagctaa ttttcgtatt ttaaaaatag 30060 agacgaggtt tcaccatgtt ggccaggctg gtcttgaact cctgacttca ggtgatctgt 30120 ccaccccggc ctcccaaagt gctgggatta caggcgtgag ccaccacacc tgactggctt 30180 ggctgtctct actcaggtgt ccagtcagct gtggtagtca gtcggggaga atcccatgtt 30240 gcgggggaag gtgcaatcct ctcagaagtg tgagcagaca ggaactgaca tttctagaag 30300 ttccttgcta accctcattg cccttattgt gaaatgggaa taaaaggact gctttgaaga 30360 tcaaataagc taacctatat taaataccta tattagttcc ctaaggctgc cgtaacatat 30420 taccacaaac ttgatggctt aaaacaatag aaatttattc tctcagagct gtggagaccg 30480 gaagtctaaa tcaaggtgtt ggcagcacct catgccctct gaagactcta gcagagaatc 30540 tttccttgac tcttctagct tctagtggct gcagcagatc ctcggtgtgc gacaatgtca 30600 ctctcatgtc tgcctccatc ttcacgtgga catctttctg cgtgtctcct cttttgtctc 30660 aaatctccat ctgtctttct cctataagga cacttgtcat tgggtttagg gcccagctgg 30720 atagtccaga tatctcattt taagattctt gacattttca catcagcaaa gacttgtttt 30780 ccagataagg tagcatttat aggtcctggg gatttgatgt ggatatcttt tgggggccat 30840 tttttggcct ttcacaatat ctgacacagt gtttggttta ttatagtgat ggtccatata 30900 cagggccatt tttttaaaaa tttataattt taaaaaattt tattgtgata agaatgctta 30960 acatgagagc tactgtttta ataaagtttt tagtgtacaa tacattatgg ttgactctaa 31020 gtacaatgtt gaatagcaga tctctagagc gtgttcattt tgcttgactg aaactttttc 31080 ccattaatta gtaactcctc atttccccct cccccagcac ctgacaacca tcattctact 31140 cttcaagtct atgaatttga ctattttagg tatgtcatgt aggtggaatc atgcagtatt 31200 tgtctttctg tgactggctc atttcactga gtgtaatgtc ctccaggttc atgccagttg 31260 ttacatcttg cagaattttc ttctttataa aagatgaata gtattccatt ggtgtgtata 31320 ccacatttcc tttttttttt ttttgagatg gggtcttact ctgtcaccca ggctggagtg 31380 cagtggcaca atcttggctc actgcaactt ccgcctccca ggttcaagcg attctcctgc 31440 cccagcctcc tgagtagttg ggattacagg catgtgccac catgccaggc taatttttat 31500 atttttagta gagacggggt ttcaccacat tggccaggct ggtctcgaac tcctgacctc 31560 aagtgatcta cccgccttgg gctcccaaag tgctgggatt acaggcatga gccactgcgc 31620 ccagccacat tttctttatt catctgtcaa cgggcattca ggttttttcc acgtcttggc 31680 tattgtgaat aatgcttcag tgaacatggg ggtactaata tctttttgga tcatgatttc 31740 aactcttttg gataaatacc cagaagtggg attgctaagt catacattcg ttctgttttt 31800 aagttttgga ggaacctctg tactgtttcc atggtggctg cacccattcc caccaacagt 31860 atataagggc tttattttct cttcatccgc accaacactt cttgtctttt gtttttgata 31920 atggtcatcc taacaggtat aaagtgacgt cttatggtgg ttttgatttg catttccctg 31980 atggttagtg acattgaccg cctcttcatg tagatattgg ccatttattg gtcttctttg 32040 gagaaatgtc tattcaagtc tttagtccac tattatggtt ttaatgggtc tcaaatgaca 32100 atgaaagtca gttctcagca gcctaggggc tcttcttcat gtattatttc tttcagagat 32160 tgacagaagc actatttccc cagagagaaa ggcatgagaa agggatgttg tgattgacaa 32220 ttagcagctg gttgaagtgg gagttagaga aagggtctag ttctccctct gtcttggatc 32280 ctcaggtaat tctgtggatc tgggcaaaga agtcttgtct ctccttagtg agaaaattaa 32340 gtctctccaa gcaatagaaa gaatatcgtg ttttggggtt aggcagatga gaggttttgt 32400 gtcccctttt ccttgcaaat agttgtatga ccttggacaa gtaaactaat ctctctaagc 32460 cttagtttcc tcatttgcaa ttacctctag gtgttttaaa gattaaagga ggaaatctgt 32520 agaaagcacc ttagtgaaat catattccac ctctgctcaa attttccaat ggttttcatt 32580 tctctttgtt taaaagccag agttccggtg atgtcttaaa gaacccttca tcattgtaac 32640 ctctcttgca ttaacaccta ttctcttcct cctcattcat taccctccag ctgtactgac 32700 atactgcttt tcctctaaca cgcaagacac aaccctacct tgggtccttt gtacttgctg 32760 tttctctgcc tggaaagctc acatctcaaa tgaccatatg acttgctccc ttcctttctt 32820 taggtcttta cttaaaactc atcttctcag tgaagacttc cctggccgtt ctatctaaaa 32880 tttaccccac cacactgcca tccaacactt catattccct tcccttcttt attttttcat 32940 cttattgctg gttaccatct aactctgcct gtaattgttt atcacctgct atctccactg 33000 gcatcttcaa aatggcagga gtcactacag ctgttcactg ctgtacccca gtgcatagaa 33060 ctatgcgtgt tacacaataa acacaaaata cagatttggt gagctgattt gaattaatga 33120 tagctagcta gttccttttt accattgagc ttcaactttc taatccgtaa aatgagaaat 33180 agagagtata ggccaaagtg gcttggactg tgagctccta gaaggcaaag acaatgcttg 33240 tttgagtctg tatttacact gtccagcacc taacattgca ttcaggaagc acaggacgaa 33300 cgttgaacag atgggcggat aaatatgtaa taacttgtga caggaaaata agataagcag 33360 tgatgaaaat ttataaaaca tagtatgttg ataattagga accctcttac tccatatttg 33420 cattttgata tcaaaaagct ttacaaagcc attcatttat tcattcattt ggcgaataca 33480 cacttgtacc ttctatgttc ccaggcgttt gatttaggta ctaagactat aagtcaaaca 33540 ggacatggct gctatcttag agtttcttgg tgccctgtgt gggaaattga catgtggatg 33600 tccattcact gaagacagca ctgtgttggt gccatggctg tgggaccaaa ggtctgtaag 33660 acaagcccaa gaaaaaggga ccagttcaat tttcgggatt caggaagttt cctctgagga 33720 aggaccattt acaatgagtc taaaaagaat gagttacttt acctgggaaa gaatatgagg 33780 aaagggattc cagccctaga gaatcacatt ttcaatggcc taagggttgt ggaaggttgt 33840 gttgttgcta ttgccatcag catagtatca gtaatggctg ctaacattta ttgagtctac 33900 actgtgtgcc agtcactatc ctaatctgtt acatgcaaaa tctctaagca gagagataac 33960 ctactagaaa tattcatgcc atttatcccc acacatccta tggataggta gaatgggctt 34020 tattgtcctc attaagaaat gagagactta agactctaat tctctttgtg ctatcacaaa 34080 actggcatct gaataatgta gtaaataact tagtagcccc ccaaaacccc attttttgtt 34140 ttattcacaa gctattttat tttctcctta gcattcattg ctattttgtg ttttttctct 34200 ctgtgtatat acatatatac acacacatta tatatattat atatatatag agagagacac 34260 acacacatta gatatatgta tttttagaga caggagcttg ctctgtcact cccactggag 34320 tgcagtgtgt gtttgtagct taccttaacc ttgaccaact cctgggttcc agggatcctc 34380 ccatctcaac ctcctgagta gctaggacta caggcacaca ccaccacacc tggctagatt 34440 tgtattatta ttattattat tattattatt actattgaga tggagtctct ctcagtcacc 34500 caggctggag tgtagtggtg tgatcttggc tcactacaac ctctgcctct tgggttcaag 34560 tgattctcct gcctcagcct cccaagtagc tgggattaca ggcgtctgcc accacaccca 34620 gctgattttt atatttttag tagagatggg atttcaccat gttggctagg ctggtctcaa 34680 actcctgacc tcaaatgatc cacccacctc tatctcccaa agtgctggga ttacaggcgt 34740 gagccattgc acctggccta gctggctaga tttttgattt tttgtagaga tggggtctcg 34800 ccacgttgcc caggctggtc ttgagctcct ggcctcaagt aatcctcttg cctaggcctt 34860 ccaaagcatt gggattacag gtgtgagtca ccatgaccat taatataaat acatatatat 34920 ttaaatttgt acataatctc ttattacaag gtgaaatcta tgagagcagg gacttttgtt 34980 tgtttgtttc attttttttt tttgagatgg agtctcactc tgttgcccaa gctggaatgc 35040 agtggtgcaa tctcagctca ctgcaaattc catctcccag gttcatgcca ttctcctgcc 35100 tcagcttcct gagtagctgg gagtacaggt gcccgccacc acgcccggct aatttttttt 35160 gtatttttag tagagatggg gtttcaccgt gttagccagg atggtctgga tctcctgacc 35220 tcgtgatcca cccgcctcag cctcccaaag tgctgggatt acaggtgtga gccaccgcac 35280 ccggccggtt ttgtttttta agatggggtt tcactctgtt gcccaggctg gagtgcattg 35340 gcactatctt ggctcactgc agccttgacc tcctgggctc aagccaggag gctcaagcca 35400 ggctgaggtc ccacctcagc ctcctaaata actgggacta caggcacaca ccactacgcc 35460 tggcccagga cttttgcttg ctgctatccc caagtatgta agatgccctc cataagtatg 35520 tgttaaataa atgaaaaaag aaagacctca tgaggtaatt attgtgtagg ctcattggta 35580 aaaaatggtt gtcagccttt ttctaacaaa cacaactata tctgatttct catttccaga 35640 cagcacagtt taactgggat ccagaaacag tgggccttat ccatggatct tttttctggg 35700 gctatattat gacacaaatt ccaggtggtt tcatttcaaa caagtttgct gctaacaggt 35760 aagataaatt gatataacat gatacaaacc aatgaaatgt ggctttgtac ctataaattc 35820 tgcatagctg gctctcaatt tgggggtgca gaatgaaaaa caggagccat ctggatagat 35880 gcaattcaca gatactgatc ccaaatgacc ctgatcttaa tttattttta tttttatttt 35940 tgagacggtg tctcactctg tcacccaggc tggagtgcag tggtgtgatc ttggctcact 36000 gcaacctctg ccccaccccc tcccccaccc cactcggcat tcaagcaact ctggttcctc 36060 agcctcctga acagttggga ttaaaagtgt gcaccactac acccagctaa cttttgtatt 36120 tttggtagag acgaggtttc accatgttgg ccaggctgat ctcaaactct tgacctcaag 36180 tgatccaccc gccttagcct cccaaagtac tgggattgca ggcgtgtgag acaccagcgc 36240 ccagtcaaga gtttcttttt atttcgtttt tcatccaatt aaatttacct tgcaactctt 36300 caagtgatta tgtggtaaaa agaccaatca actctgagtc aggagaaatg gttcctgccc 36360 cctaactgga tcactgggtg acctctattg agtcactttc cttccctccc tgggcctcag 36420 tttcttcatc tgtgaaatga aacattggac tagattgtat ttcagttccc cttgaccagt 36480 gacattctgt aatcttaggt taatatcacc cagtaccata aaggttttct cagatgagtg 36540 gtgggggctt gcctctagac tgcaagatgt gtctctaatg tccttgagac tctgtagtgg 36600 gtgtttgagc aattaaaagt acccaagaac agagtgagct gtctcaagaa gcagtgagtt 36660 ctctgtcacc ggaggtattc aagcagagga ggatggccac ttgggggaga tgttgtagaa 36720 tgtatcatgt attagaaaag gagtgaacta aatctctcca ggtcgcttcc aattgtattt 36780 cccatatgac tttccataaa tggatttcat gaagtgcatt ccatttttaa aaagtggttt 36840 tttttttcaa attctaaagc acaactcatt agatagttgt gaaaacaata taatgattta 36900 ccaatgagca tttttaaaaa agagagaaat agaagaaaag ataatcaaat agaataaaat 36960 agaaaatatc tgaatgcatt gcacataagg gtaaatattg gtttttgaga cttgtttcag 37020 ttacatttgt atgtatgagt atggactggg ttgcaatata aaatatattt tgtttatggg 37080 ttaaggtaaa aaaattggaa gccactacca taagatctaa ataggaataa gcatatattt 37140 atttaggttc ttgtctaatt tatgtctttt atttattgtt agttatctat tgtattcttt 37200 ttaaaaagtg ataaaatatt ggttgctatg gtttcctggg ttaccgctta cacctcagcc 37260 ttgaaaaaaa atcacacata atctaatttc ccagcacata aaaagagtgg aaacatcatc 37320 aacataagtg agaggggaag aaaatgctgc ttgctctctt ttcccagggc accctgagct 37380 ggccaggaaa tgggagctaa gacaggtaca caacctgtct tgtgcttggc tggtcccagg 37440 acatacaatg cttcttggat agtcagtgtt tctgactctg ggaagcagga aacaacctca 37500 aacatacagt aacagtcaga aaagatcagt cggtggggaa ccaggcagga tggtaggtct 37560 ctagcaagct tacctgaacc tggccaatct ccaacttttc aggacatcat ccaggcagga 37620 catccctgtg ccaccaaaaa tttgttcata gttggtccag gggccagagc ttgggaatca 37680 aagaagccca agagtctagc ttggggtgca ctagacccta acacatctat ttctccaaat 37740 tacaggtgcc agccgccatg cctggctaat tttttgtatt tttagtagag atggggttca 37800 ccatgttggc caggctggtc tcaaactcct gacctcaggt gatccaccca cctcagcctc 37860 ccaaagtgct gggattacag gtacgatctt tccacaggga tttccacagg gatctttcat 37920 gaactgttag gtttgtttct ggtgcttagc tgaagtagca catccatcag cagacctgcc 37980 gaataacaca atgctttggt cccccagggt ctttggagct gccatcttct taacatcgac 38040 tctgaacatg tttattccct ctgcagccag agtgcattac ggatgcgtca tgtgtgtcag 38100 aattctgcaa ggtttagtgg aggtaggaga tactttcctt acagtttttg atattgctag 38160 agacagcgca gtcctttaga aaattcacct tctgaagaaa atccccttta ctcagttttt 38220 ttctatattt tcttcctttt cctgctgttt ccattctctg gtaatggcta aaattgcaag 38280 aattttaatt aaaatgcctt gtgtgatttt acatttatga acaataaagt acccttgcat 38340 aatgatctta gagataatct aacctgaccc tcttcatttt aatagatagt gtaactgaag 38400 cccaaatcta cagttcacat agcagaggct cattccacta aaacaattta agtggattca 38460 ttaataaatc tgtacatttt caagggtgta gtctgatgca gagatttaat tcaatgaagg 38520 aggcagcatg atatggagcc agaaggtaaa tattttggac tttacaggcc ttacagtgtc 38580 tgttgcatct actcaaccct gctgttatag tgcaaaagca gccagagaca atatggaaac 38640 aaatgggcat ggctacgttc caattaaaca ttttacaaac tgaaatttga acttcatatg 38700 attgttgtgt gccattaaat attactcttc ttttgatttt ttttctcacc attttaaaat 38760 gtaaaaaaga ttcttagctt gtgggctata caaaaacaga tggtgaacca attggcccat 38820 agtttgccaa ccctcgatat acagcaatgt ttcccaaaca cagtcattca cctctgacct 38880 tcgccagttt gttatgccca tgtacaactt gtactattat ttgcctattg ttttccccta 38940 gatcgactca tttaaaacaa aaaacaaaag atacctatta ctctaagcaa taccatcttt 39000 gaaatcatgg gtttgatgtg ttagttacat cttttccttt tttttttttt tttttttgag 39060 atagagtctc gctctgtagc ccaggctgaa gtgcggtggc atgatctcgg cccgttgcaa 39120 catctgcctc ccaggttcaa gcgattctcc tgcctcagcc tcctgagtag ctgggactac 39180 aggtgccagt taccacaccc ggctaatttt ttgtattttt agtagagatg gggttttacc 39240 atgttggcca ggctggtctt gaactcctga cctcaggtga tccgcccacc tcagcctccc 39300 aaaatgctgg gattacaggt gttagccacc acacccagcc actagttaca tctttttcaa 39360 agcatacata tatatagtag aattatatat aaatttaatt atatatagat taattataac 39420 atatatacta gtgtatatat gtatatataa tatatacata tatagtatat atataatata 39480 tatagtgtat atatatactg tatcatatat agtgtatgta tataatatac atacactagt 39540 atatatatta taattaaaaa tgtaagttgt tatatcattt caaatccaac tctagtccca 39600 ctagagggac atatatgaca ctttgggatg tacccgtgta gtggaaagaa cacgatatta 39660 gcatccatga agactaaatt ttagtcactt aacagccctg agtctcaggt tctgtatctt 39720 gaaatgagtg gatggaccaa ctgattgtgg aaggctcttc ctacactgat agtctatgat 39780 aatatgaaat ataaatataa agaccttttc ccccatctcc taccatgctt acatgtgaag 39840 tgtatttgaa tttcagcatc tgtactgtga gtcaaaatag ctcaatcatg ctgtttagtg 39900 tctgttttag tccatttggg cttctacaga ataccataaa ctaggtaggt tataaacaaa 39960 agaatttttt tttttttttt tgagacagag tctcactgtg tcaccgaggc tggaggcagt 40020 ggtgtgatct cagctcactg caacctctgc ctcccaggtt caagcgattc ttctgcttca 40080 gcctcctgca tagctgggat aacaggcaca tgccactgca cccggctaat ttttgtattt 40140 ttggtagaga taggattttg ccatgttggc caggctggtc tcgaactcct gacttaggtg 40200 atccgcccac ctcggcctcc caaactgttg ggattacaag cataagccac tgtgcctggc 40260 cttttttttt tttcagtctc gctctgttgc ccaggctgaa gtgcagtggt gcaatctcag 40320 ctcactgcaa tctctgcctc ctgggttcag gcgattcttg tgcctcagcc tcccaagtag 40380 ttgggattac aggcatgcac caccatgccc aactagtttt tgtattttta gtagagatgg 40440 ggtttcatca cgttggctag gctggtcttg aactcctggc ttcaagtgat ccacccacct 40500 cggcctctca aagtgctggg actacaggcg tgagccaccg ctcctggcct agaaatgtat 40560 ttcttacagt tctggaggct gaggagtcaa agatcaaggt gctggcagat cggtgacttg 40620 ggagagctag cttcctggtt cataaacaac taccttctct ttgtctgccc atggcagaac 40680 ggatgaggga gctctctgga gtttctttta caaggcacta atctcattca tgagggctac 40740 acccttatta cttagtcact tcccaaaggt ccatctccaa ataccatcac attgggaatt 40800 aggttttaac ataggaattt ggtggggaca caaacattca acctacaaca gtgtctgtaa 40860 attgggcttt tatattgtag cctgtgtgaa gaagcagcat ccatatttta aacacaagca 40920 gaaactacag tcaaatcaac taatctattt tcaactcttc tgccagggtg tgacctaccc 40980 agcctgccat gggatgtgga gtaagtgggc accacctttg gagagaagcc gactggccac 41040 aacctctttt tgtggtgggt atattagaat cgtaacaaat tttatttatg aatgcttttt 41100 ttgggttcat gcagtggctc acgcctgtaa tctcagcact ttagggaggc cgaggcagga 41160 ggatccctgg agcccaggag ttcgagatca gcctggacaa tatagtgaca cttcgtcttt 41220 aaaaaaaaaa aaaaaaatta gccgagcatg gaggtgtgtg cctgggatcc tagctactag 41280 ggaggctgag gcaggaggac tgcttgagcc tgggaggttg aggctgcatt aagctatgat 41340 ggccacagca ctccagcctg agtgacagag tgagaccttg tatctaaaaa gaaaaaagaa 41400 aaaagaaatg gaatgctttt ttggcttcaa gcaactgaaa accctactaa gggccttaaa 41460 atgagtctat ttattttata taacagaatt ctaaaggtga gtggtggcta gtgttggttc 41520 tgctgctcaa aaatccatcc agggcctagg catgttctga ctttctactc tgctatcctc 41580 agacatagct ttttatttac ttctgtgctt attccatctg tccctttcat caggaaaaca 41640 aaagctttcc caaagccccc taccaacctt ccactttaat ttctttggcc ctaactgtat 41700 catatgcttt actaaatgca gaggaggcta ggcaagcaga tgcctagctt caccagcctc 41760 ttcaggagtg aaggggaagg gagaaagggt tggaagtggt tgttggatta gccaacaaat 41820 gacatttgct aaggacaaaa gtggaaagat gggatcatca agcatcccac gcctcttctt 41880 tttatatgaa actaaagttc agtgacttgc ccaagatcat ggagctagaa caagacctga 41940 actgttgatc tggaactttc cttacttcac gctcctacca tgtacacatt gtcatataga 42000 aatgtaaatt aatttttgtc attatatccc agataataag aagtagagac catccatctt 42060 atctgaaagt aaatgagtag cccccaagta gtatgtgact ttaattcctg catctccaaa 42120 cttcaccttg ctgaggttgc catctccaag ctacccctgt gggacaggcc tctctaggtg 42180 tggctgggtc cctaggaatc aatcaacaac agaacaacaa cagcacatgc cgctgccatc 42240 aacacagtgg taaatgtgtc gggggaaggg gcccatgaag gtaaaagtac cttagaccag 42300 ccaggcatgg tggctcacac ctgtaatccc agcactttgg gaggctgagg tggaggattg 42360 cttgagccta ggagtttgag accaacctgg gcaacatggt gaaaccccat ctctaccaaa 42420 aatacaaaaa attagctggg tgcggtggct catgtctgtg gtcccagcta ctcaggaggc 42480 caaggtggga ggatcgcttg agcccggagg tggaggttgc agtgagccga gatcacacca 42540 ttgtactcca gcctgggtga cagaggaaga ccccgtctca aaaaaaaaaa aaagtacctt 42600 agaccacaaa agtcacagtg tggcctaggc agtgtgaatt acagcttagg tctgtctgat 42660 tttcaaacta gcacactttt cctaagatat tcttctttgc taaagggaga aagatagctt 42720 tctatttatt tctgcatatg ttttaatttt cctcttcctg ctggcctttt acctccttga 42780 aataataata aagtaatcct gagaatgtgg tgtgaggtat tcaccgctat gcctactttg 42840 tgcctcgttg ggaattgcat gctcagctga gatgtcttta catattcagt gtctcttgtc 42900 cttagaaacc atctccatcc gctcatttgc agtttaagca tctccatccc tactactgtg 42960 cttataccaa ctctagaaga ggataagact caccccagct ggccttgtgg cttgttagat 43020 ccttgacctt actttctttg gatggtttat ttgtaagacc tttcattttg atttgccagc 43080 aaaatgagca tgactagcag ccactcccca ttcttagtgt gtttttatag ccctaaaagg 43140 gctgatttaa gaaatggttt gactctcaag gaaagttacc tgatcaagga cacaggcctc 43200 attacatgtc ccagctaagg tgtggccttg gtttcaaaga acagccaaag gaaaatgtgg 43260 aagaaggaaa cccaggcttg gagtgtataa attcttaatc tcaaaagata ttggagttag 43320 aagggattct agaaaacatc cagtgatatg gtttggctct gtcgccaccc aaatctcatc 43380 ttgtagctcc cataattccc atgtgttatg ggagggacct ggtgggaatt gattgaatca 43440 tgggggtggg tctttcccat gcttttctcg tggtagtgaa tgggtctcat gagatctgat 43500 ggttttaaaa acgggagttt ctctgcacaa gctctctctt tgcttgccgc catccacgta 43560 agatgtgact tgctcttcta tgccttccgc catgattgtg aggcctcccc cgccacgtgg 43620 aactgtgagt ccaattaaac ctctttcttt tgtaaattgc tcacacttgg gtttgtcttt 43680 atcagcagca tgaaatcaga ctaatacatc cagttacaac ccattgtttt atagttgagg 43740 aaactgaggc tgagggagga aaaaagattt aaattcttac agctagtgag ggccgaaccg 43800 ggggctcttt ctcaccccca gttctgttct tccttctttg cataccattc aacaatcatc 43860 tgaggcccag gggactgagc tgcagtctgc tccccagggc agtctgggag cagctggggg 43920 cagctgcagt aagggctgag tgccctgttg tttgctcaag gggctgtgtc taataggaac 43980 tgacattgga gaatgtctaa aaggatgagg aagatttttt ctgatagaaa agaagggtag 44040 tttaggtcac attgtgtatt agtctgtttt cacataacta taaagaacca cctgagactg 44100 ggtaatttat aaaagaaaga ggtttaatca actcacagtt ctgcatggct ggggaggcct 44160 caaggaactt acaatcacgg caggaggcaa aaggggaggc aaggcacatc ttacatggtg 44220 gcaggagaga gagagagaga gtgaagggga aggtgccaca cttttaaacc atcagatctc 44280 atgagatctc actcactatc gtaagaacag cacgggggaa atccgccccc atgacccagt 44340 cacctcccac caggttcttc cctcaacaca tggggattac aatttgagat gcaatttggg 44400 tagggacaca gagccaagcc atatcacatt gtaaagtttc cccaatgata gaatgctttt 44460 tactatgtaa ggggaattat taggtgcttt tgagtgaagg aggcatgact gaatgattaa 44520 ataagagtaa gggctttggg gttccacaga cctgggctcc tgtcctgtga cttgtcactt 44580 ctacctgtgt gacctcaggc aatctgcctc ccctcctcca gcctggcttt ctccttataa 44640 aatgggggtc atattggtac ttaccttgtc aggttgaagg agagttaaac aaagtcatag 44700 gtacagtata cttagcatgg tactaggcac ccagaaagca ctcagtgcat cttagttggt 44760 ggggttattc tctacctgcc cctgtcccag gcattctttt gcattaccta aaccagactc 44820 acccacccca cctcccaggg tatttggcct ggggacaaag gccaccctat ctccacgcac 44880 agcagaatga gacctgcagc ccattttcaa cacatgcctg gagtgctcac cttattggtt 44940 tgaggagccc tgagattgtt ttttgagtgt gttgtcattc tgtacatgat aatagcggta 45000 atagctggca tttgtgtaac ccattatagc ttacaaagca tcttcacata catagtttat 45060 ttgaatctca aaacaacccc ttgagatgga tatttcattc ccatcttatc tctgaggaaa 45120 atgagtctct tgacttcctc gggtgtcatg atgttcagat tccagatctc aggctgggcc 45180 tttcaccgag ggtcaggctc accttggaaa gatgtgattt aatctatttc tctggaagat 45240 ccccaacctc ccatttccta aagatcttcc ttagcatcaa attctgggat atagaatttc 45300 ctttcaccac tcactttttc tgaagcaaga gttttttcat tcacagccca gggggagttt 45360 cagagagtaa cttctccttt cagctaataa ctcccaataa tgggaggtca cagggctcat 45420 ctttccctac cagacgtcca gaggatagca gaggtcagct cactgcctct agtcacaatt 45480 atcttgtcta gacaagataa acattcacac acaggtaagc atttgcaagg ttaagtttta 45540 caaagtaaga aatacatgta aaaatgtacc cattcaggag ctgaatggag acagcagccc 45600 tcttgccatc tggaatttaa ttgttcaccc ctcacctttt tttttttttt tttttttgat 45660 acagtcactc tgtcacccag gctggagtgc agtggtgaga tcttggctca ctgcaacctc 45720 cgcctcacgg gttcaagcaa ttcccgtgcc tcagccgccc aagtagctgg gattacaggc 45780 acgcgccacc atgccaggct aattttttgt atttttagta gagatggggt tttgctatgt 45840 tgaccaggct ggtcttgaac tcctggcctc aagtgatctg tccacctcag cctcccaaag 45900 tgttaggatt acaggtgtga gccaccgtgc ctggcaaccc tctccttttt ttttttaatc 45960 aagactttaa aaatcatgat cttttaaata attcaatgtc cctcatttaa agatctggat 46020 gagaatcctc ccagtcctcc taagcaaatt ttgtatgttc ctttgcttgc tctttttagc 46080 ttccaatatt gcgcctggtt gaattttcaa aatttctctt agattttttt catcttctga 46140 ttccattctc tcatgtaatt ccaaactgtg atgctggagc aatctttgtc taaatcctgt 46200 gtggtctctg gatgaagtta aagggcatct tggtgacctt cctctcctgg aagccctgtt 46260 ctgtggcaca ctgggagttt gcctgtctct gcacggaggc agtctgattc ctgctcagtt 46320 tgattaattc ctgactttac catatgaatt ctaaatgagc tgaaaaggct tgcatgatga 46380 ttggtcagat tccctcaatc ttttcttgtt ccaggttcct atgcaggggc agtggttgcc 46440 atgcccctgg ctggggtgtt ggtgcagtac attggatggt cctctgtctt ttatatttat 46500 ggtgagtgat ttgacttcac aagttcacat gtgactcata gagatggtat tttactgcat 46560 atgggtttgg ctcagagttc attacatcaa aatagagatt actaaaacaa gtttattgta 46620 taaatggaat actttatcta tgatttgatt aatatttata ttaaagttga cctaaaaaaa 46680 taagtagaac attgtctttc tttaaatacc agttaacaag aggaacgtca acaaaatact 46740 tacccctagc tgaacatact gccatttgga aatattgtaa agatcctttt gtagttcata 46800 aatgtgataa ttgggtgttc acgtgcatgt atgagatgtc tgagtccctc aaaccttgtt 46860 acaacattgg tacattaccc attttacctg aaaaaaatat atatggtaaa aattgaaaaa 46920 tttagaaacg gaagaaaatg agaccatata acccagcctt ttctttttta actgcaggca 46980 tgtttgggat tatttggtac atgttttggc tgttgcaggc ctatgagtgc ccagcagctc 47040 atccaacaat atccaatgag gagaagacct atatagagac aagcatagga gagggggcca 47100 acgtggttag tctaagtgta agtataaaaa gtcagatgaa gacttacctt ttttcataag 47160 tgattgtgtt gccttcttac agaaaaaatg tcaatatctt tactaaaaat atcatggtat 47220 ttttactccc tagaaattta gtaccccatg gaaaagattt ttcacatctt tgccggttta 47280 tgcaatcatt gtggcaaatt tttgcagaag ctggaccttt tatttgctcc tcataagtca 47340 gcctgcttat tttgaagagg tctttggatt tgcaataagt aaggtaaaca cacagatgct 47400 ccaaatattt ttgaacttta aatctcttga ttctacagag aataactttg tatgataaaa 47460 taattaaatt gctgatcata attcataaca gttctgtgac acctaatagc ctggctgtca 47520 gacaagttat acattctatg catagtatgc atagctgttt aatttcttct tagcaaggat 47580 cagagccgta ttaagctgct ttaaagattt atgttgtacc caatcttaga gtgtttttga 47640 agctagctca aggacggcat attaggcaag gataaaaaga tttgagggtg tgggttttct 47700 ttttttcctg taagctactc agtgagtagc agtaagaacc ttaccattca ttttgcagaa 47760 caccccttct ccataatggt ggctatagca gtaacaatca ttgcttgcaa tgggttagaa 47820 agaacctctt tctgccaggc gtggtggctc acgcctataa tcccagcatt ttgggaagcc 47880 aaggctggcg gatcacctga ggttaggacc agcctgacca acatggcaaa accctgcctc 47940 tactaaaaat acaaaaatta gctgggcgta gtgatgcaca cctgtgatcc tagttactca 48000 ggaggctgag acaggagaat cacttgaacc caggaggcag aggttgcagt gaggcgagat 48060 tgcaccactg cactccagcc tgggcaacag agcaagactc tgtctaaaaa aaaaaaagaa 48120 gaagaaaaaa taaacagaaa aaaaagaaag aacctctttc aatgctccca gacattatca 48180 tcaagccaat tgtgttttag ggaggaaggg tgtggatagt gaatcatcaa ccatcatcat 48240 aagataaacc tctttcctac aagggaaaga acagcagccg agcaaacaca aatgtctgcc 48300 tagctacaga tactgtcaga agtgaccatg gaagagctgg cataatcatg aaatggtggc 48360 tgtcatcagt catcagtgct cactgggtgc caagtgcttt atctcccatg tgccatgccc 48420 tctgtgatga ataaaagtca tcgctgccct caaggagctt ccaatctggt agaggacaca 48480 gataggtcta aaatcattcg ctcattcatc atttatttat tatgaaattc aggcctaccc 48540 agctcccaca taattagatg cttaaatttg gtggtggtag gtaggggggc tgtggagtgg 48600 aggtgggcaa gggaattagg gaggcccctc tctcagaaat aatgacaaac tgcttactgt 48660 ttctttccct tccaggtggg tctcttgtca gcagtcccac acatggttat gacaatcgtt 48720 gtacctattg gaggacaatt ggctgattat ttaagaagca gacaaatttt aaccacaact 48780 gctgtcagaa aaatcatgaa ctgtggaggt actgtggatt tcatagatgg cttaggcagc 48840 ttttgtagaa ttagggtaaa ctgaactgca gagcatatat taagaagtga catttagtca 48900 ttggagtgga tcttaaagac ctctaagtct gtccctcagc agacacttga gtgttgtcca 48960 tcacagtgct gccaagaggt catccagctg ggacctttcc atacatcctt ccacatttat 49020 tgtttgctta tgtagtttat tcccttctct gcttaccttt ctacctatcc atatgttttg 49080 gtaagaaaca gaagaaaagt agtctttcct cctagcctat gcttgtgcat gggacacaca 49140 cacacacaca cacacacaca cacacacaca ccattttctt tcttgatttt atttagctcc 49200 tgctttatgt tttaattttg taaagacaaa gtgaatgtta ggtgatttcc caaaagaggt 49260 aggcgaaagt aattgtgaac ccctacaatg ttcatgagtg ctttttaaaa aactcatctt 49320 ttttgtttag cttttaaaat taacatttat tgaatgcttt ctgtgccaga cactaagcta 49380 aatcttctac atacattatt ttatttaatc ttcataacca ccatgtggag caggtactat 49440 tactatatgc aatttgcaat gaggaaacag aggtaaaata aagggacttg ctcaagtagc 49500 agatccctgc aaggtatcag gtaggccgga gcctaccgcc aaagctctta gtttgcggct 49560 acccctctgg aggactagtc aggatgagcg agcaggaggt agaggatagc gccacctatg 49620 ggcaagagct cacaactgtg atattaagtt gaaagggacg gattgcgtat gctctgacag 49680 atagctaggt ctggcacatt tagaagtgaa gactataccg agggacacag gagcaggcat 49740 gatctgatcc catagcattt cgggaagaaa gcctaagagt ctgttggcac ctgttctccc 49800 agttccttga ctgctggtcc caggcaggga tgtgtgggcc tgaccttagc ttgaactttc 49860 ttgtagagga ctgagggtta gcggatatag gcctgctatc tggtgggcag gaggtgaagc 49920 tctgggacat tgcattcaag tcctctccaa gagagctgta gcagctagaa taatgcccat 49980 gtcctaatcc tcagaagctg tgaatatgtt tccttacatg tcaaaaggga ctttgcaggt 50040 gggattaaat tgaggttctt gagatgggag tttatcctgc attatctagg tgggcccaat 50100 ataatcacaa taatccttat aaaaggagga aggagggtca gagtcagaaa agaagatgtg 50160 atggtggagg caagagtcag agtgatgcag ccacaaacca aggaatgcaa gcagacccta 50220 gaagctggag aagacaagaa gagattccgc catagcacct ctagaaggaa tgcaactctg 50280 taggctgctg ccttgacttt agccctgtac cattttggat ttttggcctc cagaactgta 50340 caatagtgca gagagtattt tagaggtgac atctaatcat tggaatagat cttaaagacc 50400 cctaagtcta tccctcagca gatacttgat atttgtgttg ttttgagcca ctgagtttgt 50460 ggtaatttat tacagcagca aatgaaaact aacacagcgg taggcagggt gcagtggctc 50520 actcctgcaa tcctagcact ttgggaggtt gaggcgggca gaccacttga gctcaggagt 50580 tcgaaatcag tcagggcaat agtgagaact tttctctatt aaaaaataaa acatttataa 50640 aatgaaaact aatacagtag ccaaagcctc acccttctaa tgataaaatt ctgctccagc 50700 tgaacagccc tcacccaagc cctgaacata tctttctgtc tctgactttg cccactccct 50760 ttctctttcc ctgtgagttc tcaccttcac ctctcaatcc agtcctctct atacatccag 50820 ctcaattctt ctcctcttat gtttccttaa agccatgcca ttctccagtg atccctctga 50880 atatgtccac atggctagat tggcaactca tcatgtggtg ccttattgca gctctctcag 50940 gaaaagattt taggcagagg gaatagtatg tgcaatgacc ctggggcagg caggaatgtg 51000 gcctgtgtga gaatagaagg aaggggagtc agaatggctg agtgacggga gacgggatcg 51060 ggatgttttt ctagggtcag atcatggcag gccttgtcgg cgtatgcaga gcttgggttt 51120 tatttgaagt acattgagat gcagatgatt taaagcacgg aatggatatg atctcatttt 51180 tttttttttt tgagacagag tctcgctctg ttacccaggc tggagtgcag tggtgcaatc 51240 tcagctcact gcaacctccg cctcttgggt tcaagtgatt ctcctgcctc agcttcctga 51300 gtagctggga ttacaggcat gggccaccat gcctggctaa tcttttgtat ttttgtagag 51360 acagggtttc actatattgg ccaggctggt ctcaaactcc tgacctcaag taatccgccc 51420 gcctcggcct tccaaagtgc tgggattaca ggcatgagcc acctcgcctg gccttgctta 51480 tttattttta atctggggaa ttatgcaggg tacaagagta aaagaaggga gaccaggtag 51540 gaggtgattt cagttgtcct gtctagagaa gatggtggct tagacaaatg aggtggcaat 51600 ggagatggag agaggggggt caatttctaa attctcagag ccaacagttc tcatctttaa 51660 attacataat aatatttact tcagaggata gttatgagag ttaaatgata caacgtatga 51720 atgcacctag tgcggtgttc aacctataaa aagttctcaa caaatgttaa tgctgctttt 51780 tttctcctat gttcaagaca caaaaaacac agaagttttt caaagagttc tttaacaaat 51840 atctgtgatt gtatttcctt tggacaaaaa aatgtacttc taaactggca actttaaata 51900 agtttctgga ttttaaacac tatttgcaca acctcttcta aacccagatg cattggatat 51960 tcttgagcat attttgtggg aatgtcttgt tcctatttaa ttctgcccca gtacctctgc 52020 tgtttctcca taattggtgg tgattatgtt atgttgtggt gatgagaact ttcaaagatg 52080 tttaattgct aacaaagtgc ctgttgagag gaaatagttt tttttctgca gaaactagaa 52140 ggcatatgtg gaatctttct gcctcatctc ccatctttaa aaaatacctc ttcacatggc 52200 ttttcatgtt catatatata tatatttttt ttgtttgttt gttttgtttt gttttgtttt 52260 tgagatggag tctcgctctg tcacccaggc tggagtgcag tggcgtgatc tcagctcact 52320 gcaagttccg cctcccaggt tcacaccatt ctcctgcctc agcctcccga gtagctggga 52380 ctacaggcac ccgccaccac acccggctaa ttttttgtat tttttagtag aggcggggtt 52440 tcaccgtgtt agccagggta gtctcgatct cctgaccttg tgatccaccc acctcggcct 52500 cccaaagtgc tgggattaca ggcatgagcc accgtgcccg gccattcttt tatattttga 52560 catagtagga ccagtgagtt atatatagaa aataaaattt ttaaaaagac cataatggtc 52620 ccactttttc tgcttaaata cagagatgct agagcagaga taactacatg aaaacaaagt 52680 tttgtgccat cagtgaagaa tgcaggttga tttggaaatg atgaagcact ggtatgatct 52740 tccagagaat tttggttggc tttttggttt cctactaaga aatatagaag gcatttctca 52800 tctgagaagg atcacacata tcttggagcc tgtcatcttt tatttccata gattttaata 52860 tgccattaaa atcatttaaa gcaaaacaga tcacttaaga catgatgttc aattcattct 52920 gaatcagggt ctacgtctat gatgcttaaa gacagatgcc aaattcttgt cctgccccct 52980 ctatagaaca tgcaaagtgt aactgaggtc aaaaattcta ttctggctga atcagttgca 53040 agtgtgaact tcagattatt ttaatatgaa ataaaatatt tcttaggcct ttaagtccta 53100 gttttgtttt tcttgtcaac tctaaatagg ttcaatttta aggatctcct gattacccct 53160 aaagttgaaa ttttatcctt aagctcctga aacatgcagc cctgtctcta gtattttaac 53220 tgtcagtaga aaccatttag gctcttaaat gctttttttt ccactggcaa tctgctattt 53280 ggccaaaatt ttttttctta cagatgaact gatgtatcat ttgtaagttt tattctttat 53340 acaatgtcat cattctaatt ctttggggga attgactttc tgcatgcttc tgttcagagt 53400 gtaaaaataa aagaagtttc agccagatgc cttgttattt aggataggca cttctaagac 53460 acatatagtt agtatatgaa acactagcta tttttcccta tgtgtagtct taaatgttga 53520 aacaaaatta agaacaagta gcaatgatat aaagcctata gttttaaaag taagacttcc 53580 ctaattacat ttcatcctct ttagaagcca tttaaaacaa ttattagttc ttgcccttct 53640 ttatagtagt gttgaagaaa taggttcaaa aaggtaaata ttaataactt aaccatcatt 53700 tacggtaagt acttcagctt gtgaatctta ttttcttctt tctgggtccc atttcctttc 53760 ctttgcatta attcattaaa cgttatgtat gtatgtatgt atgtatgtat gtatgtatgt 53820 atgtatgtat gtatttagag acagagtctc actctgttgc ccaggctgga gtgcagtggt 53880 gcaatcttgg ctcactgcaa cctccacctc ccggtttcaa gtgattctcc cgcctcagcc 53940 tcctgagtag ctgggattac aggcacatgc aaccatgcct ggctaacttt catatgttta 54000 gtagagaagg ggttttgcca tgttgcccag gctggtcttg aactcctgac gtcaggtgat 54060 ccgcctgcct cgtcctccca aagagctgga attataggtg tgcaccacca tgcctggcca 54120 aacgttattt attgagtgca tactacatgc tagacagact ctgtgttaaa tatacagttt 54180 tgtgggagag gcagaaacac aaatgaaaag ttacaaagca atattgaaaa gttctataaa 54240 atgatgagaa ggtgatgtca gcttcattgg ttgagggtag ggagagggtt gttagggaag 54300 ctttctagag gaggcactat ttaatctgga ctttaaaaat agtaagattt atccagaaaa 54360 agagaaaatg atgagagaag agtatcccag gtaaagaaac aatgtgtgaa aatatgtaca 54420 ggcatgagat agtattgtgt ggttagaaaa cagctaatag aggagtatgt ctgtggcaca 54480 gagggctatc cacagaatgg gggcagtaag caaagagatg agggctggaa gaagatgaaa 54540 ctggaacagc aggaggtatt cattatagaa cactatactc atgatatgga gctcatgaca 54600 aacacgttaa gcacaggagc aaataatgag gtgtgtggct tagaaagaca gtggtattga 54660 gaatgcatca gaggaggacg agttgggaag actaccaaag tggcttattg tggctgagca 54720 tggtggctta ggcctgtaat cccagcactt tgggaggcca aggcaggcag atcacctgag 54780 gtcagaagtt ggagaccagc ctggccaaca tggggaaacc cggcctctac taaaaataca 54840 aaaattagac tgggcgtggt ggctcacgcc tgtaatccca gcactttggg aggctgaggt 54900 gggtggatca cgaggtcagg agactgagac catcctggct aacacggtga aaccccatct 54960 ctactaaata tataaacaat tagctgggca tggtggtggg tgcctatagt cccagctact 55020 caggaggctg aggcaggaga agggcacgaa cccgggaggc agagcttgca gtgagccaag 55080 atcgcgctgc tgccctccag cctgggtgac agagcaggac tccatctcaa aaaaaaaaaa 55140 aagttagccg ggcgtggtgg tggactataa tcccagcgac gggggaggct gagtcaggag 55200 aaccacttgc acccgggagg cagaggttgt aatgagctga gattgcacca ctgcactcca 55260 gtctgggtga cagagcacga ctccatctca aacaaaagaa gaaaaaaagg tggcttattg 55320 cagttttcct ggtaagaggt cacggggcct ggaactaaag cagtgacagg ggaggggaaa 55380 gtggcagttg cactggacag atgtttccga ggccaaacct gcagatttgt atatgaaagc 55440 tcaggcagga ggagaagtcc aaggtagttc tgaagtttct gcatcggact tctggctatc 55500 atttgttgag ctgtgcccat gtgccacact cagtacctca tataccaatt tcatttactt 55560 ttccgatacc tcacaaggct gtggtactat ctccagcttt tggatgagga atctaagagg 55620 tgtagtaact tgttcaaggt cacaaaatta gtgattttga agtggaaagt gaacccatac 55680 cagtttgact ctaaagattg ggttctaaac acagaatatg gaagattaat ttagaggaga 55740 agaaagcacg tggtggcgat ggtttggtga tggtttgctt gtttgtttag gagtaaaaaa 55800 ataggggaag aggccagggg tggtggctca tgcctgtaat cccagcactt tgggaggctg 55860 aagtgggcgg accacctgag gtcaggagtg gccagcctgg ccaacatggt gaaaccagcc 55920 tggccaacat ggtgaaaccc caactctact aaaaatacaa aattagctgg gcgtggtagc 55980 acatgcccat aatcccagct acttgggagg ctgaggcagg agaatcattt gaacttggga 56040 ggcagaagtt gcagtgagcc aagatcatgc cgttgcactc cagcctgggt gataagagca 56100 agactctgtc tcaaagaaaa aataaataaa taaataaata aaaatagggg atgagagaat 56160 tgatttgggc atgttgcctt tgaggtactg tagaacaatt gtgtggagat gtctggaatc 56220 agcagacagt ctccaaatga agcaccacta attgtctctt ccccctccta aggcactcta 56280 tatacttgga aatgatattt atatcatttt tctgtctgtt gtcagctgaa cttttttttc 56340 gggtgagaag gaacttcttc ataatttcct cattcttttt attttttatt gtgctagact 56400 cacttattct gaatgaaagg aacagaaagt acttttgttc tgcaatattt tctgtgcaaa 56460 attctcatgt attgtttgtt tttttttttt ttaagaggcc tgagagcttg gtgaactttg 56520 aaatagaaaa attttgactt ttgctttaca aggggtgaag tgctgttttt gtttgtttct 56580 ttgtttgttt ttgtttcaga tatttgctac agttttctgg ttgcttttgg caataaatat 56640 tagagtgttg tcattttact tttaagggaa aggccataac tagtcaaagg ggaatcatta 56700 ccacagttat atagtagagt tttagtattt aacaatggca gggacagcta cccatgaagc 56760 aactaataat taacatccct catctcagga gcatcattgg aacctattgg gaccgtgtgg 56820 tgttcaaggt gcaccgcgat aatgttagaa agtttgtgaa cacccaggga atattagcaa 56880 agtcatgtag tcatgaaagt cctgggtggc attgtaagca ctgtaccaga atgtaggtct 56940 gtggaggaac agaaaaccaa acactgcatt tccccactca taagtgggag atgaacaatg 57000 agaacacatg gatacaggga ggggatcatc acacactggg gcctgctagg gggcaagggg 57060 agggacagca ttagggcaaa tacctaatgc atgtggggcc caaaacctag atgatgggtt 57120 gataggtgga gcaaaccatc atggcacatg tatacctatg taataaacct gcacattctg 57180 cacatgtatc cctgaactta aatcccagaa cttcaagtaa agttaaaaaa aaaaaaaaaa 57240 aaacttaaat tccagaactt aaagtaaaaa aaaaacatag acacaaacaa aataaactta 57300 ggtctgtgga attataggtt agttcttatt tgataaataa atgaacttgg gttgaccgat 57360 atgaaaatga catttttttc ccttgctgtt tccatttgca ggttttggca tggaggcaac 57420 cttactcctg gtggttggct tttcgcatac caaaggggtg gctatctcct ttctggtact 57480 tgctgtagga tttagtggct tcgctatttc aggtaatgtg tcctttgggt ttccagatct 57540 tgactataga ttcaacaagt cccaggaaga aggaaggaca aggatattgt agcaccttct 57600 ttcagtagcc agtccattct cagagagcag gaccaccgtc cagagaatgt gatctagtgg 57660 gggtgatttt gtaagatcac tgagaactgg gcttgggagc tcagttaagg tggaattttt 57720 cctacttact ttgttacggg aaaagacaca aagtgcagat gacccttctg agacacgagc 57780 agaggcccaa gcatatgtcc tgggtgaagt ggactttcat actttagcac catgtcaccc 57840 tacctgacag aggctcctgt gactttttca agcctcgccc tcttgctaga gaactgcgag 57900 tgtcattaca gtcataggat cagaagtttt tttaagagtg aaaaccttct ttagattttt 57960 gtctactcca ttgctttcat tttccaaaca agaaaatgcg ggtccataga ggggaagtga 58020 ctttctgaac agggtaaaga ataatgacaa tgatgatgtg agctagcgat gaccaagcac 58080 agattctgtg ccagggaata ttccatgaga tctgcatata ttaagccctg tctctctcac 58140 aactaccctg ctgggtatca gtgctattac ggtccccatt ttacaggagc agaaaccagt 58200 ctactatatg tgagagaaag gccagagtgc aatcatatca gaagcttcct atgcaaaact 58260 gggtcaaaga gtgaaattta gttgtttgtc tatctttaaa acatcgtaat aagaatatgg 58320 ttactggccg ggtgcgctgg cttacgcgtg taatcgcagc actttgggag accgagacga 58380 atggatcact tgagcccagg agttcaagac cagcctgggc aacatggcaa aaccccatct 58440 ctacaaaaaa tacaaaaagt tagctaagtg taatggcgca cacctgcagt cccagttagt 58500 caggaggttg aggtgagagg atggcttgag cctgggagtt ggaggttgcg gtgagctgag 58560 ttcgtgccac tgcattccag cctggatgac aaagcgagac cccttctcaa gaaaaaaata 58620 aataaataaa ataaaaataa aaaatggtta cttaaagaaa atttcacata tattgtatat 58680 atatcataac attgtgaagc aagtagtagt atatcactat gctactgggt ttttcactat 58740 tttactaaag ctcagaaaaa tttgatactt tcttaatatc acacagttag tggcaaagga 58800 aggatgacag aacagttctg cctggcccaa aggccgtgct ccttccatta ttccaggttg 58860 ccttaaatat caaacagtgt tagtgtccca gaatagaaaa atatggaacc tctggtctaa 58920 actgccctaa gacaggggct tgtatctttc aaaataaata gagttgatga ataaattaga 58980 aaataaagta aaagtctaaa ttaaaagtaa cttgcagcta agtaatttgg tttagagatg 59040 catagacctg ggtttgaggc cctctttact atttactatt tataaaataa aaaatttgct 59100 aaattatgaa aactctcaag cttcagtttt ctcatctaga gattggagag atgaaacagc 59160 aacctcatag ggttgttggg aggataaact tagataattc atgtatttcc ccgcacttct 59220 tgtgggctgg gcattattct tagcactggg gatattgcag tgaataaatg aaagtgtcca 59280 tccccataaa gtttacattc tagtggaaat acttattcaa ataaaaacct tagctgtatt 59340 tatttgaagt ccttagcaca gtgccagatg cataacaaaa ttaatgagtg ttcaccatta 59400 ttgttctatt agtacacaca ccagcccagt gcctctcaaa gtgttatgtg aaatcaccat 59460 aagatatttc agaatgcaga ttctgatttg gtagctctag ggtggagcct gagattctgc 59520 agttttagca agttccccag agctgctgct gctgcagggc agtccacact ttgagtagca 59580 agggcagagc aatcacgatt tgcttccagt aggaagcgga ggaacgcctt cccttgataa 59640 ctttgtgatg caaaagagat ccatatcctg ttcccagaga tactgaaatg ttcaagttca 59700 tattgcttcc tttcccccga ttgccaatta agtcacaatc tgaaggagag aaacccaata 59760 ctccaaatca cataaactgc ttttttgttt tccttttttt ttagacaggg tctcttgcct 59820 tgtgcagtgt ctcatgacta taatcccagc actttgggag gccgaggcag atggatcacc 59880 tgagatccag gagttcgaga ccaacctggc caacatggtg aaaccgcatg tctactaaaa 59940 atacaaaaac tagttggttg tggtggtatg tgcctgtagt cccagctact ggggaggctg 60000 aggttgcagt gagccaagat tgcaccactg cactccagcc tgggtgacaa agagagattc 60060 tgtctcaaaa aaaaaaaaaa aatagacagg gtctcgctct gacacacagg ctggtgtgca 60120 gtggcatgat cgcggatcat tgcagcctct acctcccatg ctcaactgat tctcctgcct 60180 cagcctcctg agtagctggg gctacaggca tgtgccacca cttccagata tatatatatt 60240 ttttcgagac agggtctcac gatgttgccc aagctggtct cgaactcctg gcctcaagtg 60300 attctcctgc cttggcctct caaagtattg agattacagg catgagccac cacacctggc 60360 cttcttgcca ctttttaaac atgatttcat ttaatcctca ttgcaacctt gatgagaaag 60420 gtattgctat attcacttta ttggtgggga aaccaaagtg tggtttaact tgccgagtga 60480 agtggctggg agtgtggaat aaaggtctgt tggtcccagc aatgacactg tgggagggat 60540 tgcagccaca ggggcaataa ttcctcagaa tctactgtct gccaactttt aaaggaataa 60600 acatagatgt cagggaagac tgactggcac aatttaggag ctgattatag acaagactgc 60660 tgagatagat gaagttaaaa ataggcaaga gatgagtgat gcctgttttg ggaaatgtcc 60720 tatacagaag atagattctc tcagtttatg tgtaattttt ttatctgcta taaaaatcta 60780 tcaatatctc aatttctcag tgattttccc ccctccccaa atgtcaggat tgtgcagcta 60840 gaaacctaaa tggcttttcc cacattatct ttagctgaat gcagatgccc aggctttgta 60900 tcagagcata atactcaaca atcatattaa ttgcttctta tctctggatt cttttctaat 60960 aaagtgttta tcacattcaa atccatggta agattaatga acttgcagct gttttatatt 61020 ctgatcattt ggcacattga cctgaaagat aaggtatgtt tattattacc aaaaagtttt 61080 ctcaaaattt ctccctgaag ggaagtagga aagacaacca accagtgtgc cagattagaa 61140 caaaaaaatg ttttaagtcc tattttcagt tttttttttt gcacagaata gagaaataaa 61200 aagcaaagca aaggaagaca aaaagatgaa taaagcctac aaccccttgc tataatttca 61260 gtagctgaag ctggtaatta atttagcaac tatttattga gtgactacaa tgtgccaggc 61320 actttgctag ttcaggggag atggtggtaa acaagacgga tggctaacca cctgtaaaga 61380 gcatgcatgt tggtttacac gtctatgcac catgtagtta acatacatta tttaacttaa 61440 ttcctacatc aattttataa gaatcattat cccgttatgt agatgaaact aaggttcagg 61500 aagtttaaat ccttggtcta ggcttgcatc tcaactaagc tgccagaact gaggtctgtc 61560 tgatttgaac atgcacccct gcaatatatt gacaaagtca gatctcagct cgctgtaacc 61620 tccaactcct gggttcaagt gattctcctg tctcagcctc ccaagtagct gggattacag 61680 gcatgtgcca ccatgcctgg ctaatttttg tatttttagt agaggtgagg ttttgccatg 61740 ttggccaggc tggtcttgaa cttctgacct caggtgatcc acccgcctca gcctcccaaa 61800 gtgctgagat tataggcgtg agcaaccatg cccggccagc agcattatct tttgatagaa 61860 gacctcaaag agagggagtt actttgcaat ggcagcagaa ggtagcagta gtagtagtgg 61920 tagttagcat agctttgata tttgccaagg gcttcacata cctatttccc ctgagtctct 61980 atcacagcac ctctgtgaag tgaatagtaa tattatcctc atattggaga tgaagaaaca 62040 aaggccccca aattacttgt ttacatagta gaaataagat tcaagtccag atttacagac 62100 tccaaatcaa gtaggtgtgt gaaagtgttt cataaattac agaaggttct cccaatgttt 62160 gtgcaaatgt ttcattaaaa agcacccttt tcattgtgtg aaaatgtggc catgtggcca 62220 ataaagtagg cttacccttg gctgcctttt aagagtaagt caggggtagg agtgggaata 62280 ttataaagca aggtttggtc tagtcatact gtatgtgatt gtatgattat ttactctgaa 62340 taaatgtgat tcaggcttta ggcttttcaa tattgtgcca aacaccgtat tttggaattc 62400 agaacctaca aggtagagat gccataattc tctttataga gagagccctt gatagatatc 62460 cataatcaat tccagcattg tctaccagtg ctgctttgtg cagacacagc ctcttgaacc 62520 cagtcctctt ggtctggaaa ctagtcatat actagaggaa accaaacaga ttggtaaagg 62580 ctggggcaac tgagtatttt ccaaagcata tttgaaattc tgttcttgac tctgattttg 62640 aggttttggc ttcactgtag gttttaatgt caaccacctg gacattgccc cacgctatgc 62700 cagcattctc atggggatct caaacggagt gggaaccctc tctggaatgg tctgtcccct 62760 cattgtcggt gcaatgacca ggcacaaggt aaaggtctcc tttgtggcta tgggttacaa 62820 tatcagagga ctggagctct acacaaactt gagatttcaa ggctctactg cagtctgtaa 62880 atgtgtatgt ccttgacctt gactgagtca gctgaacttc tttttttttt cttccttctt 62940 ctgattttca aatcattgct tatcaatggc accaaggcta gttgttgttt tgttctatgt 63000 tttctcaatt gaggaataat agtctgggga gaggggatgg gccatagaaa ctgtttagag 63060 acccaaagaa gaaactgagg cagtcaactt gggataaatg agttactgaa gattgttttc 63120 tcattctcag tgattaaacc ttatagccta tttccatcca ttgcttagca tgtttcagca 63180 taaaaagatg agtgctattc tacttccttg ttaagaataa aataaacagg acattgataa 63240 cctacccagt tgttactgag cctttgtgaa tttagacaag ggtggatggt agaggcagat 63300 ccatccagag ttcaaccaca gcccacatga tttctttatc tttgtcactg aaacgtctca 63360 agatgctgct ttctgcaaat aagaattctt tgataccatg ggattttttt cccccatcta 63420 ttttcttagt tggattgcct attacaaata taacttcaga agtttttgca gcttcctgca 63480 gaagaaagtg tgagataaat tttcttactt tttgacagaa aaggtaggat tttataggca 63540 gagaattcat gttttccatc tctgttcatg aaatgatagg attgataacc tgactattaa 63600 atccaagata tcttccccca accttagaca caaattccca ttattttttg acatactttt 63660 ttttacactg aaaatattat aaagttcttg tcagtcaagg gtgagaactt taatggctca 63720 aatattgtta tgtatccaac aacaagcaag aaggagactt ctgatattta aaacggtggg 63780 ttcctaaaac aattttaatt tagctgacta tgtgaaggga aaccccattt gagtattcaa 63840 aaagctatgc aatggtgctg caggtattaa tatttgtata tgttgtttat tttaaaatgt 63900 attttcttgt aatcccagca ctttgggagg ccaaggcggg tggatcatga ggtcaggaga 63960 tcgagaccat cctggctaac acagtgaaac cccgcctcta ctaaaaatac aaaaaattag 64020 ccaggcgtgg tggcgggcac ctgtagtccc agctactcag aggctgaggc aggagaatgg 64080 tgtgaaccca ggaggcggag cttgcagtga gccgagatcg cgccactgca ctctagcctg 64140 ggtgacagag cgagactcca tctcaaaaaa aaaaaaaaga attttctaaa ttaaaaaaat 64200 acgtatttat tgttttgtct aactttcata ttcattgttg tcttaacttt cattttttaa 64260 gtttttcttt taaatttggt ttgaatcccg gatggtgctt ctgacacacg tcctcccgcc 64320 caaggagcct ctagagcatc gccttccaaa tgggcaggtg ctttttcaca gtggaggcct 64380 ccaggacata ctggtaatct ctagttttag ttaaaacatt aattggcact ttatttcctt 64440 atttagaccc gtgaagaatg gcagaatgtg ttcctcatag ctgccctggt gcattacagt 64500 ggtgtgatct tctatggggt ctttgcttct ggggagaaac aggagtgggc tgacccagag 64560 aatctctctg aggagaaatg tggaatcatt gaccaggacg aattagctga ggagatagaa 64620 ctcaaccatg agagttttgc gagtcccaaa aagaagatgt cttatggagc cacctcccag 64680 aattgtgaag tccagaagaa ggaatggaaa ggacagagag gagcgaccct tgatgaggaa 64740 gagctgacat cctaccagaa tgaagagaga aacttctcaa ctatatccta atgtctgaga 64800 ggcacttctg tcttctcctt actttagaaa cagaaagtat ccatacctat tgcctttctt 64860 gtagcccagc ttgccagagg tccaaatatt gggaggggag aagatctaac cagcaacagg 64920 gaaaagagaa atattatctt tcaatgacat gtataggtaa ggagctgcgc tcagttgata 64980 acatagttga taatacatat tttttgaatt gacagttgac ccttctctca aagagctaaa 65040 cttattcaga aaggaatgac tagaagaaaa aggagacaat accatgttgt tcaaagaaac 65100 attgaaggaa attgggatgt ttggccagaa ggaatgtaaa cagtagtagt agctgccacc 65160 acatctctag ggtagccatg cagaggaggg cttcatattc ccaataaacc ccacgttgtg 65220 gcaggtgctt tataaacact cttatttaat ctccacacct ttatgacaca catttcttat 65280 ccccatttta caaccaaggc atctaaagca acaagaaatg aacttgccca aggtcatctg 65340 ccagggtcag tgctgagact gttgaagctc tcaataggtg gcagttttag ggaagatttc 65400 cattcagtgt agggaagaca tttgtaataa tgaaaactga aaatggagta attgtgagta 65460 actcaccact ttagcaggtg ttggggaagg gaaacatttg ggttgatgag gcagagggga 65520 ttcaaatgtg tgagaggcta gattcaaaga ccctcagtgt tctatgttat ctgaagagtc 65580 aaatggtttt gtgactccat agtttttaaa gtaataaggg tcaaagacta catcagagat 65640 tcaaataggt ttttaaagaa aagctaagca agagagccaa atttttagaa atctgatggt 65700 caaaatagct gaaagcagta aacaagagat tggctattaa atttcaactt tccataatat 65760 taagaatgta gctaaatgat gtcccaaact acttacaaac ttttaagaca tttaataatt 65820 taagaagtag gttcatgtgt tttcttaggt aaagttcttc tgaaagaatt ttctattttt 65880 aaaaaatgta tctctttagc cttttctgct ggagattata ttaggaagtt tcatcagatt 65940 gtataaaatt atgattttgt atcaaaagta ttcatgatga ctctatttgg aatgatattc 66000 agggaaatca caataatata gcagtagtta tacagagaaa tactacaatg aaaacatttg 66060 gggcaattag acctacagtt actgttgaaa aattcacctt tgattgcata aggcaattac 66120 atggatactt ttagatatat ttaaaatttt aacattggca tctaaagtgt tatttgaaaa 66180 taaaattatt ttcctgttca ttgattttaa acattttatt cctactttca gaagaaaaat 66240 ataatacgga aaaaattata gatttacttg tagcttatta ttgtaaagtg gttttttttt 66300 tttttttttt ttttctaatt tctcccacat gtatttctgg tccccagtga tactagctga 66360 gttgtagtgt attttataaa tggaataatc ttggggaaaa attgcgattc ttcattaaat 66420 aatattcttt atgtcactag catacaattt atgttagtag acatctttaa atctctttaa 66480 tgagtgaatc catgcaagcc ccataaaaca gttcctagca tgcagaaaat gcccacgtaa 66540 atagctgtca tcatcattat cttttaacat tttgggggac tttccagttg aaaagaaaac 66600 atgctatgtc atttttatcc attatccctg gaacttattg tgaaagttgt gctgttttct 66660 aagtaaaata aaaaataaaa aattagcaat ttatgatagc cagtgtttta ttttgtgtgt 66720 gtgttagtaa agtcaaataa ttgtatttta aaaactcacg ataatcctta aggtagtatt 66780 gtatattgtg acacaaagtt gtat 66804 4 578 PRT Rattus norvegicus 4 Glu Ser Val Lys Gln Arg Ile Leu Ala Pro Gly Lys Glu Gly Ile Lys 1 5 10 15 Asn Phe Ala Gly Lys Ser Leu Gly Gln Ile Tyr Arg Val Leu Glu Lys 20 25 30 Lys Gln Asp Asn Arg Glu Thr Ile Glu Leu Thr Glu Asp Gly Lys Pro 35 40 45 Leu Glu Val Pro Glu Lys Lys Ala Pro Leu Cys Asp Cys Thr Cys Phe 50 55 60 Gly Leu Pro Arg Arg Tyr Ile Ile Ala Ile Met Ser Gly Leu Gly Phe 65 70 75 80 Cys Ile Ser Phe Gly Ile Arg Cys Asn Leu Gly Val Ala Ile Val Asp 85 90 95 Met Val Asn Asn Ser Thr Ile His Arg Gly Gly Lys Val Ile Lys Glu 100 105 110 Lys Ala Lys Phe Asn Trp Asp Pro Glu Thr Val Gly Met Ile His Gly 115 120 125 Ser Phe Phe Trp Gly Tyr Ile Ile Thr Gln Ile Pro Gly Gly Tyr Ile 130 135 140 Ala Ser Arg Leu Ala Ala Asn Arg Val Phe Gly Ala Ala Ile Leu Leu 145 150 155 160 Thr Ser Thr Leu Asn Met Leu Ile Pro Ser Ala Ala Arg Val His Tyr 165 170 175 Gly Cys Val Ile Phe Val Arg Ile Leu Gln Gly Leu Val Glu Gly Val 180 185 190 Thr Tyr Pro Ala Cys His Gly Ile Trp Ser Lys Trp Ala Pro Pro Leu 195 200 205 Glu Arg Ser Arg Leu Ala Thr Thr Ser Phe Cys Gly Ser Tyr Ala Gly 210 215 220 Ala Val Ile Ala Met Pro Leu Ala Gly Ile Leu Val Gln Tyr Thr Gly 225 230 235 240 Trp Ser Ser Val Phe Tyr Val Tyr Gly Ser Phe Gly Met Val Trp Tyr 245 250 255 Met Phe Trp Leu Leu Val Ser Tyr Glu Ser Pro Ala Lys His Pro Thr 260 265 270 Ile Thr Asp Glu Glu Arg Arg Tyr Ile Glu Glu Ser Ile Gly Glu Ser 275 280 285 Ala Asn Leu Leu Gly Ala Met Glu Lys Phe Lys Thr Pro Trp Arg Lys 290 295 300 Phe Phe Thr Ser Met Pro Val Tyr Ala Ile Ile Val Ala Asn Phe Cys 305 310 315 320 Arg Ser Trp Thr Phe Tyr Leu Leu Leu Ile Ser Gln Pro Ala Tyr Phe 325 330 335 Glu Glu Val Phe Gly Phe Glu Ile Ser Lys Val Gly Met Leu Ser Ala 340 345 350 Val Pro His Leu Val Met Thr Ile Ile Val Pro Ile Gly Gly Gln Ile 355 360 365 Ala Asp Phe Leu Arg Ser Lys Gln Ile Leu Ser Thr Thr Thr Val Arg 370 375 380 Lys Ile Met Asn Cys Gly Gly Phe Gly Met Glu Ala Thr Leu Leu Leu 385 390 395 400 Val Val Gly Tyr Ser His Thr Arg Gly Val Ala Ile Ser Phe Leu Val 405 410 415 Leu Ala Val Gly Phe Ser Gly Phe Ala Ile Ser Gly Phe Asn Val Asn 420 425 430 His Leu Asp Ile Ala Pro Arg Tyr Ala Ser Ile Leu Met Gly Ile Ser 435 440 445 Asn Gly Val Gly Thr Leu Ser Gly Met Val Cys Pro Ile Ile Val Gly 450 455 460 Ala Met Thr Lys Asn Lys Ser Arg Glu Glu Trp Gln Tyr Val Phe Leu 465 470 475 480 Ile Ala Ala Leu Val His Tyr Gly Gly Val Ile Phe Tyr Ala Leu Phe 485 490 495 Ala Ser Gly Glu Lys Gln Pro Trp Ala Asp Pro Glu Glu Thr Ser Glu 500 505 510 Glu Lys Cys Gly Phe Ile His Glu Asp Glu Leu Asp Glu Glu Thr Gly 515 520 525 Asp Ile Thr Gln Asn Tyr Ile Asn Tyr Gly Thr Thr Lys Ser Tyr Gly 530 535 540 Ala Thr Ser Gln Glu Asn Gly Gly Trp Pro Asn Gly Trp Glu Lys Lys 545 550 555 560 Glu Glu Phe Val Gln Glu Ser Ala Gln Asp Ala Tyr Ser Tyr Lys Asp 565 570 575 Arg Asp 

That which is claimed is:
 1. An isolated peptide consisting of an amino acid sequence selected from the group consisting of: (a) an amino acid sequence shown in SEQ ID NO:2; (b) an amino acid sequence of an allelic variant of an amino acid sequence shown in SEQ ID NO:2, wherein said allelic variant is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3; (c) an amino acid sequence of an ortholog of an amino acid sequence shown in SEQ ID NO:2, wherein said ortholog is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3; and (d) a fragment of an amino acid sequence shown in SEQ ID NO:2, wherein said fragment comprises at least 10 contiguous amino acids.
 2. An isolated peptide comprising an amino acid sequence selected from the group consisting of: (a) an amino acid sequence shown in SEQ ID NO:2; (b) an amino acid sequence of an allelic variant of an amino acid sequence shown in SEQ ID NO:2, wherein said allelic variant is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1or 3; (c) an amino acid sequence of an ortholog of an amino acid sequence shown in SEQ ID NO:2, wherein said ortholog is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3; and (d) a fragment of an amino acid sequence shown in SEQ ID NO:2, wherein said fragment comprises at least 10 contiguous amino acids.
 3. An isolated antibody that selectively binds to a peptide of claim
 2. 4. An isolated nucleic acid molecule consisting of a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence that encodes an amino acid sequence shown in SEQ ID NO:2; (b) a nucleotide sequence that encodes of an allelic variant of an amino acid sequence shown in SEQ ID NO:2, wherein said nucleotide sequence hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or3; (c) a nucleotide sequence that encodes an ortholog of an amino acid sequence shown in SEQ ID NO:2, wherein said nucleotide sequence hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or3; (d) a nucleotide sequence that encodes a fragment of an amino acid sequence shown in SEQ ID NO:2, wherein said fragment comprises at least 10 contiguous amino acids; and (e) a nucleotide sequence that is the complement of a nucleotide sequence of (a)-(d).
 5. An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence that encodes an amino acid sequence shown in SEQ ID NO:2; (b) a nucleotide sequence that encodes of an allelic variant of an amino acid sequence shown in SEQ ID NO:2, wherein said nucleotide sequence hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or3; (c) a nucleotide sequence that encodes an ortholog of an amino acid sequence shown in SEQ ID NO:2, wherein said nucleotide sequence hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3; (d) a nucleotide sequence that encodes a fragment of an amino acid sequence shown in SEQ ID NO:2, wherein said fragment comprises at least 10 contiguous amino acids; and (e) a nucleotide sequence that is the complement of a nucleotide sequence of (a)-(d).
 6. A gene chip comprising a nucleic acid molecule of claim
 5. 7. A transgenic non-human animal comprising a nucleic acid molecule of claim
 5. 8. A nucleic acid vector comprising a nucleic acid molecule of claim
 5. 9. A host cell containing the vector of claim
 8. 10. A method for producing any of the peptides of claim 1 comprising introducing a nucleotide sequence encoding any of the amino acid sequences in (a)-(d) into a host cell, and culturing the host cell under conditions in which the peptides are expressed from the nucleotide sequence.
 11. A method for producing any of the peptides of claim 2 comprising introducing a nucleotide sequence encoding any of the amino acid sequences in (a)-(d) into a host cell, and culturing the host cell under conditions in which the peptides are expressed from the nucleotide sequence.
 12. A method for detecting the presence of any of the peptides of claim 2 in a sample, said method comprising contacting said sample with a detection agent that specifically allows detection of the presence of the peptide in the sample and then detecting the presence of the peptide.
 13. A method for detecting the presence of a nucleic acid molecule of claim 5 in a sample, said method comprising contacting the sample with an oligonucleotide that hybridizes to said nucleic acid molecule under stringent conditions and determining whether the oligonucleotide binds to said nucleic acid molecule in the sample.
 14. A method for identifying a modulator of a peptide of claim 2, said method comprising contacting said peptide with an agent and deternnning if said agent has modulated the function or activity of said peptide.
 15. The method of claim 14, wherein said agent is administered to a host cell comprising an expression vector that expresses said peptide.
 16. A method for identifying an agent that binds to any of the peptides of claim 2, said method comprising contacting the peptide with an agent and assaying the contacted mixture to determine whether a complex is formed with the agent bound to the peptide.
 17. A pharmaceutical composition comprising an agent identified by the method of claim 16 and a pharmaceutically acceptable carrier therefor.
 18. A method for treating a disease or condition mediated by a human transporter protein,,said method comprising administering to a patient a pharmaceutically effective amount of an agent identified by the method of claim
 16. 19. A method for identifying a modulator of the expression of a peptide of claim 2, said method comprising contacting a cell expressing said peptide with an agent, and determining if said agent has modulated the expression of said peptide.
 20. An isolated human transporter peptide having an arnino acid sequence that shares at least 70% homology with an amino acid sequence shown in SEQ ID NO:2.
 21. A peptide according to claim 20 that shares at least 90 percent homology with an amino acid sequence shown in SEQ ID NO:2.
 22. An isolated nucleic acid molecule encoding a human transporter peptide, said nucleic acid molecule sharing at least 80 percent homology with a nucleic acid molecule shown in SEQ ID NOS:1 or
 3. 23. A nucleic acid molecule according to claim 22 that shares at least 90 percent homology with a nucleic acid molecule shown in SEQ ID NOS:1 or
 3. 